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ABSTRACT
Ovarian cancer is the 7th leading cause of cancer related death and the 5th most
commonly diagnosed cancer among women. Primarily diagnosed in stage III or stage IV,
aggressive treatment is necessary and involves surgical debulking and administration of
systemic chemotherapeutics. Unfortunately, these strategies fall short in effectively
treating ovarian cancer and many patients experience local disease recurrence,
development of multidrug resistant tumors, regional or distant metastatic events, or a
combination of the three. As such, there is a significant need for additional treatment
options and methods of delivery to improve therapeutic efficacy and disease survivability.
RNA interference (RNAi) is a type of gene therapy that can cause specific
knockdown of genes that are responsible for cancer cell survival, migration, invasion, and
a host of other oncogenic pathways. RNAi, induced by delivery of short interfering RNA
(siRNA), can cause therapeutic effects by eliminating the ability of cancer cells to translate
oncogenes into the proteins required for oncogenic functioning. However, significant
barriers to delivery including instability in physiological conditions, inefficient cell uptake,
and degradation via endosomal entrapment and lysosomal trafficking, severely reduce the
efficacy of RNAi-based therapeutics. Without a robust delivery vehicle, siRNAs cannot
avoid these barriers, will be rapidly degraded, and rendered completely ineffective.
Peptide-based delivery systems have shown promise as siRNA carriers and can
deliver siRNA cargo intracellularly. Fusogenic peptides, cell penetrating peptides, and
targeting peptides can all be used as systems to complex with and deliver siRNA cargo.
This work developed a tandem peptide system, comprised of fusogenic and targeting
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peptide regions, to efficiently complex with siRNAs specific for the CSNK2A1 gene, guide
delivery to ovarian cancer cells, and encourage endosomal breakdown and escape of
siRNAs into the cytosol. The two peptide regions are specifically designed to implement
active targeting of an overexpressed cell receptor in ovarian cancer, the luteinizinghormone-releasing-hormone receptor, as well as cause endosomal membrane fusion and
destabilization through pH-responsive conformation shifts in the fusogenic amino acid
sequence. This action would result in release of CSNK2A1-targeted siRNAs and
consequential knockdown of the CSNK2A1 gene, resulting in reduced cancer cell ability to
proliferate, migrate, and recolonize after treatment.
With this work, we show the potential for this novel peptide biomaterial to be an
effective carrier of siRNA cargo by effectively avoiding barriers to RNAi therapy and
nanoparticle delivery systems. Development of the amphipathic fusogenic peptide and
tandem targeting-fusogenic sequences were both explored in vitro with further support for
the fusogenic peptide being examined using an in vivo xenograft mouse model. Exhibiting
effective delivery of bioactive siRNAs, the fusogenic peptide successfully reduced
expression of CSNK2A1 mRNA and CK2α protein, causing significantly reduced ovarian
cancer cell migration, colonization, and tumor volume in a mouse model. The tandem
peptide enhanced ovarian cancer cell uptake and specifically targeted the luteinizinghormone-releasing-hormone receptor. Future work will include fusogenic applications in
3D tumor spheroids, targeting-fusogenic peptide linker variations, and examining the
tandem peptide in vivo to assess active targeting in a clinically relevant tumor location.
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CHAPTER 1 – LITERATURE REVIEW
Peptide-Based Delivery of Therapeutics in Cancer Treatment
Timothy Samec, Jessica Boulos, Serena Gilmore, Anthony Hazelton, Angela AlexanderBryant*
Clemson University, Department of Bioengineering, Clemson, SC
This report has been submitted to Materials Today - BIO for publication review.

Abstract: Current delivery strategies for cancer therapeutics commonly cause significant
systemic side effects due to required high doses of therapeutic, inefficient cell uptake of
drug, and poor cell selectivity. Nanoparticle delivery systems, more specifically, peptidebased delivery systems have shown the ability to alleviate these issues and can significantly
enhance therapeutic loading, delivery, and cancer targetability. Peptide systems can be
tailor-made for specific cancer applications and this review presents the current status of
the three peptide variants commonly used in cancer therapeutic delivery: fusogenic, cell
penetrating, and targeting peptides. Peptide nanoparticle design, characteristics, and
applications will be discussed. Finally, peptide applications in the clinical space will be
featured in the concluding section.
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1.1 Introduction
Cancer is one of the leading causes of death globally and the second leading cause
of death in the United States.1 Current cancer treatment regimens can often cause
significant adverse side effects and fall short in effectively eliminating advanced disease.2
Low therapeutic targeting ability, insufficient cellular uptake, and development of
multidrug resistance are among the current treatment limitations.3 These limitations can
result in decreased efficacy and increased likelihood of metastatic disease. Numerous
research endeavors have been initiated to improve personalized therapeutics that address
the challenges of cancer treatment, including rapid growth, distant metastatic spread,
dysregulation of oncogenes, and development of treatment resistance.4Exploiting some of
these inherent characteristics of cancer to increase treatment efficacy and circumvent offtarget adverse effects are key to developing better therapeutics and therapeutic delivery
systems. 4
Because of the diverse functions that peptides offer, this nonviral carrier has rapidly
gained exposure and popularity as a prospective delivery vehicle. Peptide-conjugated and
peptide-based delivery systems are commonly comprised of peptides derived from viral
proteins, which assist viruses in delivering their genome into host cells and are known to
have high delivery efficiency 5, or synthetic peptides that have been designed to optimize
delivery properties including efficient cargo complexation, cell targeting, degradation
avoidance, and controlled cargo release.6–11 Combinations of the 20 naturally occurring
amino acids provide a spectrum of characteristics, including vehicle conformation, charge,
polarity, and hydrophobicity, all of which are vital to ensuring efficient drug loading and
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delivery to cancer tissue.

6,12

These delivery systems have been used to target tumor

microenvironments, enhance cellular uptake, disrupt lysosomal degradation pathways, and
assist in controlled and sustained release of therapeutics. 4–6,13 Additionally, the release of
therapeutic cargo can be initiated by internal and external stimuli including pH, enzyme
activity, redox potential, thermal shifts, and light.11,14–16 Due to their versatility, these
peptides, either natural or synthetic, contain specific biochemical properties that have been
utilized in three areas of classification: fusogenic, cell penetrating, and targeting peptides
that have been implemented in several in vitro and in vivo applications as delivery systems
for cancer therapy and as therapeutic modalities (peptide vaccines) in clinical trials.17–20
Through the addition of functional peptides, nanoparticle delivery systems can become
well-suited for systemic delivery with minimal immune response and efficient cargo
loading.21 Additionally, exploiting overexpressed cell surface receptors has been a focus in
developing peptide-modified delivery systems for patient- and cell-specific medicine to
reduce adverse systemic reactions.21 Nanoparticle-based delivery systems primarily
comprised of lipids and polymers have been well-studied and show promise for use in
clinical models and personalized medicine. 22 Barriers to implementing majority lipid and
polymer-based systems include particle aggregation, cytotoxicity, reduced efficacy at low
doses, and low cell specificity. 22–24 Fortunately, many of these issues can be addressed
through addition of natural or synthetically-derived peptide systems. 22
While peptides have been used extensively as complementary portions of
nanoparticle delivery systems 25,26, using peptides directly as delivery systems has several
advantages. Peptides yield a low immunogenic response because of their small size and
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ability to be tailor-made with minimal surface charge densities to minimize opsonization,
avoiding downstream phagocytotic destruction when complexed with nanoparticles (NPs).
27,28

Additionally, peptide-based systems, can accumulate quickly in the tumor

microenvironment (TME) due to their size and utilization of the enhanced-permeability
and retention (EPR) effect. Peptides can also be designed to avoid clearance via the
reticuloendothelial system (RES), by containing hydrophilic residues that pull in water to
shield the peptide from opsonization, and have enhanced tissue targeting capabilities. 8,29
However, the basis of the peptide design and incorporation within a delivery system
determines whether these advantageous properties can be exploited.
This review discusses peptide delivery systems and highlights applications of
fusogenic, cell penetrating, and targeting peptides as delivery systems for cancer therapy.
Peptide systems and peptide-conjugated nanoparticles (NP) will be discussed as carriers
for chemo and gene therapeutics individually and as combination approaches.
Characteristics of each subtype will be discussed as well as current research that
exemplifies the advantages and disadvantages of each. Having a complete understanding
of the benefits and pitfalls of each peptide subtype can assist in designing peptides as
complementary components or direct delivery systems. Several efforts have been
successful in identifying optimal peptide formulations to advance these systems to clinical
trials, with some achieving phase III completion. 30 Special focus will be given to past and
current clinical trials exploring peptide-based systems.
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1.2 Fusogenic Peptides
A major barrier to nanocarrier-mediated delivery of therapeutics is their lack of
endosomal escape, which causes degradation of both the delivery system and its therapeutic
cargo. When a molecule is unable to readily pass through the cell membrane via diffusion,
endocytosis allows uptake of the molecule into the cell. Through endocytosis, the cell
internalizes a molecule by vesicle formation, and the molecule is sorted into the endosome,
where it is recycled or trafficked to lysosomes for degradation. 31 Once in the endosome,
molecules often lack the ability to escape into the cytoplasm where they can perform their
desired function. Use of fusogenic peptides in delivery systems combats this issue by
allowing cargo to escape from the endosome. Fusogenic peptides release their cargo
through the fusion process. This process begins with the membrane and peptide in close
proximity followed by formation and expansion of an aqueous pore for a completed fusion
reaction.

32

Within this process, the transition states typically consist of non-bilayer

phospholipids and curved monolayers, both of which are unfavorable for membrane
interaction due to electrostatic and steric barriers. 33 Therefore, fusogenic peptides fulfill
the need to facilitate endosomal escape through a variety of mechanisms.

1.2.1 Characteristics of fusogenic peptides and mechanisms of membrane disruption
Though there are many fusogenic peptides, all share common characteristics that
enable their functional ability for endosomal escape. A fusogenic sequence is typically 1320 residues in length and is critical for the fusion process to be anchored into the membrane.
34

The fusion sequence is typically hydrophobic in nature and located at the N-terminus of
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the peptide sequence. 35,36 Typically, a mutation within this segment leads to a complete
loss of fusogenic function 36, but specific residue additions at this location have been shown
to increase fusogenicity. 37 The primary structure of the fusogenic peptide sequence is
amphiphilic in nature, enabling the peptide to maintain a high affinity for lipid bilayers.
Additionally, when forming amphiphilic helices, these sequences can create a
hydrophobicity gradient, which plays a role in the peptide’s endosomal escape ability
through accelerating fusion. 38
Fusogenic peptides are pH dependent, membrane disrupting peptides. At a
physiological pH, fusogenic peptides are inactive, but become protonated and undergo
activation in an acidic environment similar to that of an endosome. 39 At an acidic pH, most
fusogenic peptides undergo a conformational change to an α-helix secondary structure to
fuse with and disrupt the endosomal membrane to allow for endosomal escape. 36,40 The
“spring-loaded” nature of the conformational change of peptides usually happens in two
major steps. 40 First, fusion peptides are released from the native complex to refold into
long helical bundles, thus projecting the N terminus toward the target membrane. 40 Next,
the peptides form a six-helix bundle, composed of N terminal helices and antiparallel C
terminal helices. 40 This typical post-fusion structure forces the peptide and membrane into
close proximity and anchors the peptide into the membrane through the fusion peptide and
transmembrane area.

41

These secondary structures are required for endosomal escape

because the insertion of amide groups into membranes is unfavorable unless the amide
groups are hydrogen bonded through protonation. 42
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After fusogenic peptides initiate their secondary structure at an acidic pH, they
utilize a variety of techniques to facilitate endosomal escape. Fusogenic peptides can cause
curvature modulation through lowering of the bilayer hexagonal phase transition
temperature to promote negative curvature.

34

This increase in negative curvature of

contacting monolayers can form an intermediate membrane state in the process of fusion.
43

Another method is to disrupt the membrane through peptide helix insertion into the target

endosomal membrane during the fusion process to perturb the regular packing of lipids. 35
The hydrophobic characteristics of a fusogenic sequence allow for membrane disruption in
two ways. For two bilayers to merge, each monolayer must rupture and reform;
hydrophobic peptides have the ability to lower membrane rupture tension, which is
important for acceleration of fusion.44 Hydrophobic peptides also form a hydrophobic
gradient along the helical axis; the gradient determines the angle of insertion. Attenuated
Total Reflectance-Fourier Transform Infrared experiments determined that the peptide
inserts at an oblique angle to properly disrupt the target membrane. 45 Finally, through the
energy associated with their conformational change, fusogenic peptides have the energy to
drive the fusion process by lowering the activation energy for the unfavorable
intermediates within the process. 45
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Figure 1.1 Depiction of fusogenic peptides (FPs) delivering bioactive siRNAs
through pH-sensitive endosomal escape.
Taken up through endocytosis, FPs undergo a conformational change to adopt a helical
secondary structure under acidic conditions within the endosome, resulting in fusion and
disruption of the membrane to allow the release of complexed cargo into the cytosol for
subsequent incorporation with RNAi machinery. Created with BioRender.com.
Once the fusion process is complete, the membrane of the endosome has been disturbed,
and the contents are released into the cytosol. Figure 1 illustrates the process of a fusogenic
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peptide nanoparticle carrying siRNA cargo into a cell and causing endosomal escape,
releasing the therapeutic cargo to achieve RNA interference (RNAi).

1.2.2 Subtypes of fusogenic peptides
Three common subtypes of fusogenic peptides exist due to variations in the secondary
structure formed at acidic pH and are illustrated in figure 2. The conformational structure
of a peptide can be evaluated by using circular dichroism, X-ray, or nuclear magnetic
resonance. Most fusogenic peptides form an α-helix structure to promote endosomal
escape. The most studied fusion protein is the glycoprotein hemagglutinin (HA) of the
influenza virus. HA2, a synthetic peptide derived from HA, changes conformation to form
an α-helix at the endosome’s acidic pH and inserts itself into the membrane. 6 HA2 has
functioned as an endolytic moiety on CPP and targeting peptide systems to deliver proteins
into cancer cells , with Liou et al highlighting delivery into A549 adenocarcinoma alveolar
epithelial cells. 46 Furthermore, HA2 conjugated to the TAT CPP exhibited higher cellular
uptake and endosomal destruction capabilities in HeLa, HEK, 10T1/2, and HepG2 cells
compared to CPP formulations Transportan, R8, penetratin, and TAT alone.

47

The

polypeptide structure T22-GFP-H6, with internal HA2 conjugation to form T22-GFPHA2-H6, targeting the CXC chemokine receptor 4 highlights the enhanced ability of
endosomal lysis and delivery of GFP to HeLa cells, but also that these effects were
concomitant with reduced targeting efficacy. 48,49 Though a desired delivery effect was
achieved, the importance of peptide system design considerations, specifically when
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conjugated in tandem, should not be overlooked as interactions between the peptide regions
can cause reduced efficacy of each peptide’s specific role.
Though α-helices are the primary known structure of FPs, they can also form β-sheets
upon conformational change for membrane insertion through sequence editing or
truncation and has been observed using lipid membrane interactions, Fourier-transformed
infrared analysis, and solid-state nuclear magnetic resonance spectroscopy. 53–56 Shown in
the gp41 fusion domain of HIV, interactions of amphipathic repeats between individual FP
can adopt an anti-parallel structure, specifically when containing glycine residues, causing
whole-sheet insertion of the FP supramolecular structure into the endosomal membrane.
54–57

A third subtype of fusogenic peptides are known as internal fusogenic peptides, and

do not form singular secondary structures. 58,59 Example of internal fusogenic peptides are
the Ebola and sarcoma virus peptide, containing subunits that respond to pH decrease
through oligomerization, causing membrane fusion with evidence of α-helix structures, βsheet conformations, and internal loop structures, shown by nuclear magnetic resonance
imaging, circular dichroism, lipid mixing resonance, delivery of genetically modified virus
expressing GFP at different pH. 51,52,60,61
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Figure 1.2 Fusogenic peptides can undergo three different conformations to cause
endosomal membrane interactions.
α-helices (A-D) 50 are the main structure formation upon protonation in an acidic
environment and can exhibit time and pH-dependent fusion depth. Internal loop (E-H)
51,52
and β-sheet (I-K) structures have also been noted as major players in fusogenicity,
dependent on the internal amino acid sequence, and have been highlighted in viruses
including ebola, sarcoma, and HIV. Further information and permission related to panel
A-D
should
be
directed
to
ACS
and
can
be
accessed
at
https://pubs.acs.org/doi/10.1021/jp409412g.
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1.2.3 Therapeutic Applications
Fusogenic peptide systems have shown great success in delivering gene and
chemotherapies both in vitro and in vivo. Shown in table 1, most FPs have been
implemented as conjugated moieties to other peptide or nanoparticle formulations. The
exact number of currently discovered and utilized FPs is not entirely known. Still,
continued derivations of natural viral fusion sequences, including dINF-7 and HA2, have
almost endless permutations to evaluate optimum amphipathic qualities and endosomal
membrane fusion ability. With each new FP evaluated, the window for clinical therapeutic
applications grows wider through delivery of chemotherapies, immunotherapies, and gene
therapies.
Table 1.1 Fusogenic peptides conjugated to other nanoparticles or used
alone for therapeutic delivery.
Peptide

Sequence

GALA

WEAALAEALAEALAEHLAE
ALAEALEALAA

KALA

WEAKLAKALAKALAKHLAK
ALAKALKACEA

599

GLFEAIEGFIENGWEGMIDG
WYGGGGRRRRRRRRRK

HA2

GDIMGEWGNEIFGAIAGFLG

INF7

GLFEAIEGFIENGWEGMIDG
WYGC
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Application
GALA complexed to a hepatitis B
surface antigen bionanocapsule and
was delivered to SKBR3 breast and
HeLa cervical carcinoma cells 62
A polyelectrolyte complex micelle
displaying KALA delivered siRNA in
breast cancer cells 63
Chimeric peptide enhanced siCIP2A
bioactivity in CAL27 oral squamous
cell carcinomas in vitro and in vivo 64,65
HA2 complexed with TAT protein
transduction domain enhanced
internalization and endosomal escape
in 3T3 fibroblasts, COS7 kidney cells,
and CHO-K ovarian cells 66
Encapsulated within a liposome system
and delivered to CV1 kidney cells,
INF7 enhances endosomal escape
capabilities 67

H5WYG

GLFHAIAHFIHGGWHGLIHG
WYG

EALA

AALAEALAEALAEALAEALA
EALAAAAGGC

SFP

FEAALAEALAEALA

ccX31

Undisclosed

Conjugated to polyethylene glycol
(PEG)-tetraacrylate (PEG-TA), pHdependent endosomal membrane
interaction was analyzed in a549 nonsmall lung carcinoma and HeLa
cervical carcinoma cells 68
Conjugation to a folate-PEG-PE
liposome caused folate receptor
mediated endocytosis and endosomal
escape in KB cervical cancer cells 69
Novel synthetic fusogenic peptide
compared to functionality of viral
fusogenic peptides analyzed via
circular dichroism, hemolysis, and lipid
mixing 70
Triple stranded coiled coil formation
enhances lipid mixing for membrane
destabilization 33

One example of a gene therapy application for fusogenic peptides is in delivery of
small interfering RNA (siRNA) to induce RNA interference (RNAi). RNAi is a gene
regulatory mechanism that targets messenger RNA to induce sequence-specific
suppression of gene expression that was originally observed as a natural process for gene
regulation and defense against viruses and other foreign genetic material. 71,72 Due to the
large size and negative charge of siRNA, it lacks the ability to readily interact with the cell
membrane for uptake.
Fusogenic peptides can protect siRNA from degradation, facilitate transport into
the endothelium, promote cellular uptake, and release siRNA into the cytosol.
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This

application is especially promising for cancer treatment to mediate cytosolic delivery of
bioactive siRNAs for targeting and silencing oncogenes. In one study, an influenzaderived fusogenic peptide, diINF-7, was evaluated for delivery of EGFR-siRNA into
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human epidermoid carcinoma cells. Electrostatic complexation of the diINF-7 peptide to
EGFR-siRNA particles resulted in increased knockdown of EGFR in comparison to siRNA
delivered alone, confirming the functionality of the fusogenic peptide. 73
The GALA peptide, a synthetic derivation of the amphipathic influenza virus
peptide, HA2, mimics the fusogenic properties of the virus-derived peptide through pHresponsive conformational change, allowing insertion of the peptide into the endosomal
membrane. 74 GALA was complexed to a bionanocapsule consisting of a hepatitis B surface
antigen and a lipid bilayer. The complex was delivered to HER2-positive SKBR3 human
breast carcinoma cells and HER2-negative HeLa human cervical carcinoma cells
containing the green, fluorescent cargo calcein.

62

Cells treated with the GALA-

functionalized nanoparticle displayed enhanced cytoplasmic localization of green
fluorescence in comparison to non-GALA NPs, indicating release of the fluorescent cargo
from the endosomes into the cytosol. The non-GALA NPs displayed colocalized
fluorescence, demonstrating endosomal entrapment. 75
Another application of fusogenic peptides is conjugation to other nanoparticles to
improve efficacy of delivery systems., shGALA, a shortened form of the GALA peptide,
was conjugated to liposomal delivery system PEG-MEND, designed for siRNA delivery.
76

Cellular uptake studies comparing delivery of PEG-MEND to shGALA-conjugated

PEG-MEND (shGALA-MEND) demonstrated that uptake efficiency of both liposomal
systems into HT1080 fibrosarcoma cells was approximately 100%. 76 However, further
studies revealed that only the shGALA-MEND delivery system allowed release of siRNA
from the endosome into the cytosol. 77 Endosomal escape of siRNA was confirmed through
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RT-qPCR, revealing increased gene silencing mediated by the shGALA-MEND liposomes
compared to PEG-MEND. 74
Fusogenic peptides could be highly beneficial for therapeutic delivery systems due
to the peptides’ versatility in design and application. Inclusion of FPs into other
nanoparticle systems have consistently shown enhanced cellular uptake efficacy and
endolytic activity, with few drawbacks. The amphipathic nature of FPs reduce cytotoxicity,
enhance membrane affinity, and can assist in therapeutic loading. 78 Additionally, because
of these common peptide properties such as amphiphilic nature and location of the insertion
sequence, fusogenic peptides enhance endosomal escape to effectively deliver and release
therapeutic cargos. FPs do create the opportunity for efficient release of therapeutics into
the cell but can reduce cell targetability and cell uptake prior to endosomal encapsulation
without being delivered at high quantities. 48

1.3 Cell Penetrating Peptides
In addition to endosomal escape, efficient internalization of cargo at therapeutically
effective concentrations is another major barrier to drug delivery. Limitations to
nanoparticle-cargo cell uptake can be attributed to particle size, charge distribution, and
net neutrality or negativity. 79 Though fusogenic peptides can cause increases in cell uptake,
their amphipathic nature can reduce net charge and limit membrane interaction. Cell
penetrating peptides (CPP), a well-studied peptide subtype, play a major role in increasing
cellular uptake of nanoparticle delivery systems and can also influence endosomal escape.
Physiochemical properties, including charge density, degree of hydrophobicity, and CPP
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concentration, create interactions with the cell membrane and activation of cellular
internalization. The known methods of cellular internalization using CPP-conjugated NPs
and CPP complexes include inverted micelle internalization, direct translocation via
membrane pore formation, and endocytotic mechanisms, such as micropinocytosis,
clathrin-mediated, and caveolae-mediated endocytosis, illustrated in figure 3. 7,80 Although
each of these mechanisms have been demonstrated to play a role in CPP delivery,
pinocytosis and clathrin-mediated endocytosis are the primary routes of internalization. 81

1.3.1 Characteristics of CPPs for internalization and endosome escape
CPPs are commonly less than 40 amino acids long and are often cationic or
amphipathic in nature. 30,81 With these size and charge qualities, small therapeutic cargo,
including

siRNAs,

miRNAs,

oligonucleotides,

and

low-molecular

weight

chemotherapeutics, can traverse the cell membrane upon electrostatic interaction or
through hydrophobic-hydrophobic/hydrophilic-hydrophilic internal interactions with
CPPs, resulting in a net positive charge allowing for cell membrane interaction. 82 Many
CPPs can be designed from naturally occurring viral proteins that have the ability to
efficiently complex with cargos. The first CPP was derived from the human
immunodeficiency virus (HIV).

83,84

The transactivator of transcription (TAT) protein

domain is a major player in HIV-gene expression, has been chemically synthesized, and
comprehensively characterized to describe its interaction with the cell membrane.

83

Synthetic variants of TAT, led to significant advances in particle-based systems and has
seen substantially increasing uses over years of drug delivery research.
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13,82–88

CPP

sequences form specific secondary structures containing high cell membrane affinity;
however, structures formed depend on total peptide charge and helical properties. 30,81,83
Increased peptide helical content has been shown to increase cellular uptake through
aromatic tryptophan inclusions, while higher overall peptide charge can induce rapid
oligonucleotide complexation and interaction with the negatively charged cell membrane.
30,81,89

Figure 1.3 Cell penetrating peptides (CPPs) can be utilized to deliver siRNA and
other cargo through electrostatic interactions with the positively charged amino
acid residues.
CPPs are primarily internalized via endocytotic mechanisms, including
micropinocytosis, clathrin-mediated, and caveolae-mediated endocytosis. Under acidic
conditions in the endosome, some CPPs are protonated and can induce an influx of water
and chloride ions into the endosome, resulting in increased internal pressure and eventual
endocytotic rupture and release of siRNA or other therapeutics, allowing for subsequent
RNAi activity.
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Varying characteristics of CPP designs, including the charge density and amino
acid chain length, can affect the method and extent of cellular uptake. 90 Antennapedia, a
homeoprotein identified in Drosophila 89,91, R9, a nona-arginine CPP sequence, and TAT
were investigated to determine their route on internalization; none showed evidence of a
single, isolated pathway.

89

Macropinocytosis, clathrin-mediated endocytosis, and

caveolae-mediated endocytosis were all observed. 89 However, the results revealed that
endocytosis of the peptides was concentration dependent, with R9 and TAT requiring
micromolar concentrations for rapid endocytosis and distribution. 89 R9 and TAT were also
able to directly translocate into the cytoplasm of HeLa cells. 89,90 Another CPP, R8, an octoarginine sequence, was delivered in CHO cells, and single-molecule spectroscopy was used
to examine the system diffusion coefficient and residence time of the peptide within the
cellular membrane. 92 Similar to other CPPs, R8 exhibited heterogeneous uptake behavior
with evidence of active endocytotic mechanisms and the capacity to translocate the cell
membrane when delivered after CHO cell treatment with cytochalasin D, an actin filament
disruptor. 92 Solid-state nuclear magnetic resonance (NMR) paramagnetic relaxation of
penetratin was able to show direct insertion into single- and double-membrane Mn2+
vesicles at depths dependent on the concentration of peptide delivered, driven by cationicanionic interactions. 85,90 The ability of CPPs to use multiple routes of uptake can be
advantageous for delivery of therapeutic cargo when concentration of delivered cargos is
variable, spatially limited, or delivered to receptor-inhibited cells. 85,89,92
Inclusion of amino acid structure modifications in CPPs has been explored for
increased surface charge, cargo affinity, and biocompatibility to promote efficient and
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stable cellular uptake. 82,93 To avoid low synthesis yield, low solubility, aggregation, and
toxicity, modifications to the side chain of CPP transportan 10 (TP10), including
stearylation, addition of novel amino acids, and site-specific hydrophilic inclusions, were
implemented. 94–96 These design variants were complexed with oligonucleotide cargo and
delivered in HeLa cells, each showing higher levels of transfection and increased splicecorrection in comparison to unmodified peptides and Lipofectamine controls.

94–96

Additional modifications, including amidation and inclusion of pyroglutamic acid residues
at the N-terminus of CPP sequences, encourage increased peptide half-lives and higher
levels of cellular uptake. 97
In addition to promoting cellular internalization, CPPs can also enable release of
cargo from the endosome. Because CPPs are primarily cationic, their main route of
endosomal escape is through the proton-sponge effect. 98,99 The cationic charges associated
with CPPs and additional pH-responsive residue modifications become reactive to the
acidic environment within the endosome and can absorb free protons, increasing the
peptide charge. 98 This significant proton concentration causes an influx of extravesicular
water and chloride ions, giving rise to a dramatic increase in osmotic pressure, resulting in
destabilization of the endosomal membrane and eventual endosomal lysing. 100 Rupture of
the endosome releases the internal components, including therapeutic cargo, into the
cytosol. However, a drawback of CPPs is that they have been known to increase
nonspecific delivery, resulting in off-target effects, and increase cytotoxicity compared to
other delivery systems due to highly acidic conditions created by a large number of
positively charged residues. 14,80,101–103
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1.3.2 Therapeutic Applications
Incorporating conjugate CPPs to a nanoparticle, or using CPPs alone, to deliver
therapeutics has been extensively studied since 1988.

104

Delivering various cargoes

including nucleic acids, polymeric nanoparticles, lipid nanoparticles, and other
pharmacologic agents with high levels of cellular uptake, with several uses listed in table
2, CPPs are rapidly conjugated via electrostatic interactions or short-sequences of peptide
linkers. 82,105 Nucleic acids, specifically, have been used extensively through CPP delivery
through the ease of electrostatic complexation, but conjugation with other nanoparticle
systems does allow for CPP-enhanced chemotherapeutic delivery.
TAT has been used extensively in drug delivery systems as a conjugated moiety to
NPs including lipid, metallic, and microbubble-based therapeutic carriers. 13,82,84–88 TAT,
conjugated to lipid-based nanobubbles, was delivered to triple negative breast cancer cells,
MDA-MB-231, in vitro and in vivo. 87 Significant internal cell fluorescent siRNA signal
was observed in the CPP-complexed nanobubble. 87 In comparison, delivery with siRNA
alone and nanobubbles without the CPP demonstrated much lower internalized fluorescent
signal. 87 Another instance of CPP conjugation to a particle system highlights the selective
cell penetrating peptide (SCPP) addition to a polymersome (PS) nanoparticle encapsulating
methotrexate disodium (MTX).

106

The SCPP-PS-MTX nanoparticle was delivered to

human lung cancer cells, A549, in vivo and exhibited rapid penetration into cells and
efficient cargo release in comparison to PS-MTX and free MTX. 106 Additionally, Gao et
al demonstrated the RLW CPP conjugated to poly(ethyleneglycol)-poly(ε-caprolactone)
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nanoparticles increased A549 lung cancer tumor spheroid penetration and delivery of
docetaxel compared to octo-arginine conjugated NPs and docetaxel alone.

107

Complexation of CPPs to other nanoparticle formulations significantly improves delivery
of therapeutics, but CPPs can also be used as stand-alone delivery systems for enhanced
nucleic acid delivery.
Poly-arginine (pR) CPP sequences are extensively used in peptide delivery systems
as complementary sequences for efficient cargo delivery and complexation with negatively
charged nucleic acids.

101,108,109

NP1, a stearylated modification of a pR CPP, was

developed to improve delivery of bioactive siRNAs and increase levels of gene silencing.
86

NP1 complexed with fluorescently labeled GAPDH specific siRNA, siGAPDH-Cy3,

exhibited significantly higher levels of uptake in 2 and 3-dimensional models of HCT 116
human colon cancer cells in comparison to Lipofectamine-2000.

86

Furthermore, NP1

complexed with Bcl2-siRNA (siBcl2) enhanced knockdown of Bcl-2 protein and compared
to delivery of siBcl2 alone and siBcl2 delivered via Lipofectamine 2000. 86 Modifications
to pR, similar to NP1, in addition to the formulation of multi-peptide and CPP-complexed
nanoparticles, have exhibited increased levels of cellular internalization and subsequent
gene knockdown when delivering siRNA.

64,110

Lyp-1, a tumor-penetrating peptide

sequence, complexed in tandem with numerous CPPs, including pR formulations,
significantly increased cellular uptake of the delivery system and level of GFP silencing in
HeLa cells compared to a lipofectamine control. 109 This study also demonstrated that pR
CPP-mediated delivery was more effective in silencing GFP than both TAT and penetratincomplexed tandem systems.
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Although CPPs can enhance cellular uptake and therapeutic activity, their
cytotoxicity has caused significant limitations in the clinical translatability of CPP systems
both alone and when complexed to other NPs.111 Thus, it is important to evaluate and
minimize cytotoxicity of CPPs to avoid viability loss in off-target and healthy cells.
Cationic CPPs have been shown to elicit significantly less cytotoxicity in vitro in
comparison to amphipathic CPPs. 112–114 Transportan, an amphiphilic CPP, was shown to
induce oxidative stress through a metabolic panel analysis in comparison to cationic CPPs
R9, MAP, and pTAT. 115 Additionally, the cargo attachment site has been shown to affect
the toxicity profile. TP10 exhibited significant proliferation reduction in HeLa and CHO
cells compared to penetratin and TAT; however, with orthogonal cargo complexation, a
significant reduction in long-term toxicity was observed compared to N-terminal loading.
116

Selection and design of future CPPs should include these considerations to yield low

toxicity both in vitro and in vivo and thus improve the clinical translatability of these
systems.

Table 1.2 Cell-penetrating peptides conjugated to other nanoparticles or
used alone for delivery of chemo and gene therapeutics.
Peptide

Sequence

Application

TAT

GRKKRRQRRRPQ

599

GLFEAIEGFIENGWEGMIDGWYGGGGRRRRRRRRRK
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TAT complexed to paclitaxel-loaded
poly(DL-lactide-co-clycolide),
PLGA NPs was delivered to
mesenchymal stem cells in vivo117
Chimeric peptide delivering siCIP2A
to oral squamous cell carcinomas in
vitro and in vivo64,65

R9

(d)R9

Penetratin

RQIKIWFQNRRMKWKK

M918

MVTVLFRRLRIRRACGPPR
VRV

ARF

MVRRFLVTLRIRRACGPPR
VRV

N/A

NRPDSAQFWLHH

NP1

STR-H16R8

Azurin-p28

LSTAADMQGVVTDG
MASGLDKDYLKPDD

PepFect-1

KETWWETWWTEWSQPKK
KRKV
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caPeptide containing R9-conjugation
as the CPP and cytotoxic component
was delivered to triple-negative
breast cancer cells MDA-MB-436 in
vitro and in vivo 108
FITC-labeled penetratin complexed
with Grb7 targeting peptide
displayed high levels of
internalization in MDA-MB-231
breast cancer cells 118
M918-mediated delivery of peptide
nucleases targeting luciferase premRNA displayed 119
ARF(1-22) delivered to breast cancer
MDA-MB-231 cells displayed a
dose-dependent decrease in cell
viability 120
The CPP significantly enhanced
levels of A431 squamous cell
carcinoma uptake and delivery of
virus-like nanoparticles observed
with NRPDSAQFWLHH
complexation 121
When complexed with siRNA, NP1
displayed significant cellular uptake
in a tumor spheroid model as well as
Bcl2 gene knock down in human
colon cancer cells HCT 116 86
P28 exhibited preferential and
temperature dependent entry into
A549 lung cancer, DU145 prostate
cancer, MCF-7 breast cancer,
HCT116 colon cancer, HT1080
fibrosarcoma, and SKOV3 ovarian
cancer compared to corresponding
CCD-13Lu healthy lung, CRL11611
healthy prostate, MCF-10A healthy
breast, CCD33Co healthy colon, and
HOSE6-3 healthy ovarian cells122
PepFect-1 enhanced intracellular
delivery of FITC-labelled proteins in
human fibroblasts 123–125

PepFect-2

KETWFETWFTEWSQPKKK
RKV

PepFect-3

KETWFETWFTEWSQPKKK
RKV

PepFect-14

AGYLLGKLLOOLAAAALO
OLL

Transportan
10

AGYLLGKINLKALAALAK
KIL

PepFect-2, and its derivatives
PepFect-20 through PepFect-47,
exhibited high levels of fluorescently
labeled HypNA-pPNA in HeLa
cervical cells 123,126
PEGylated PepFect-3 effectively
delivered DNA mimics to PC3
prostate adenocarcinoma cells in
vivo 123,126
PepFect-14 complexed to splicecorrecting oligonucleotides and
ciproxifan modulated cell signaling
pathways in HeLa cells 127
Transportan 10 improved the
delivery and anticancer effects of
cisplatin in HeLa cervical cancer and
OS143B osteosarcoma cells 128

1.4 Targeting Peptides and Cancer Specificity
Although the toxicity profiles of CPPs can be reduced through amino acid sequence
and biochemical modifications, integrating advanced targeted delivery systems can provide
significant improvement of uptake, and reduce off-target adverse effects, improving
clinical translatability compared to non-targeted delivery systems.

129

Used as

complementary moieties to NP systems, targeting peptides have shown high cell specificity
and affinity for cancer cells with unique, overexpressed cell receptors, depicted in figure
4. 130 Conjugation of a targeting peptide to a nanocarrier or drug increases precision for
targeting cancerous cells and decreases off-target effects, diminishing the quantity of drug
that must be administered and enhancing drug concentration at target sites. 131 Targeting
peptides are largely used in cancer therapeutics to target various receptors present on cancer
cells or tumors with little to no expression on healthy tissues, but can also be implemented
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for specific delivery of therapeutics to endothelial, cardiac, and even chondrocytes to elicit
cell differentiation and recovery after injury or due to degenerative disease. 132–135

Figure 1.4 Targeting peptides bind to overexpressed cell receptors commonly seen
in cancer cells.
Specific receptor binding can induce receptor-mediated endocytosis, enhancing peptidecargo cell uptake. Created with Biorender.com.
Before targeting peptides became more prevalent as active targeting moieties,
monoclonal antibodies (mAb) were explored as targeting moieties, but many drawbacks
were reported 132,136. mAbs are large (molecular weight around 150 kDa), which can hinder
infiltration of mAb-conjugated nanoparticles into tumors.136,137 Another complication is
the uptake of mAbs by the spleen, liver, and other organs of the reticuloendothelial system
(RES) due to the presence of phagocytic cells that bind to these circulating antibody
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complexes. 138 Use of peptides as targeting entities can overcome these barriers because of
their significantly lower molecular weight and decreased immunogenicity. 138 Additional
advantages of using peptides as targeting agents include lower manufacturing costs,
increased efficiency for infiltrating tumor masses, high stability, and high tunability. 139,140
Targeting peptides increase the specificity of drug delivery systems for targeting tumors
and cancer cells, enhancing uptake of therapeutics in cancer cells and minimizing off
target-effects. However, a disadvantage of targeting peptides is that nonspecific uptake is
still possible, especially if the target is expressed in healthy cells.

1.4.1 Identification and Synthesis of targeting peptides
Various techniques have been developed to identify and synthesize targeting
peptides. One common technique is phage display, which utilizes bacteriophage libraries
to screen for a peptide sequence that has the highest affinity for a given target. 140 Among
bacteriophage libraries are Ph.D.™-7 and Ph.D.™-12 phage display peptide libraries.
These libraries use M13 bacteriophages that express multiple copies of a randomized 7- or
12-amino acid peptide sequence on their surfaces. 141,142 Peptide phenotypes are altered by
fusing genes that encode for peptides to genes that encode for phage surface expression. 143
These phages can be introduced in vivo; however in vitro panning has been proven to be
more effective for identifying targeting peptides more quickly. 144 For in vitro panning,
phages are incubated with target cells or target receptors; phages that do not bind to the
target are washed away, while the bound phages are amplified using bacteria, completing
one round of biopanning. 145 This procedure is repeated up to 3-5 times, narrowing the
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library to sequences with the highest affinity for the chosen cell receptor. 145 The peptides
present on these phages, commonly 10-20 amino acids in length, can then be identified
through DNA sequencing and enzyme-linked immunosorbent assays. 145
An alternative method of identifying targeting peptides is the one-bead onecompound (OBOC) combinational library. 146 This method utilizes resin beads that each
display one peptide sequence. 147 The OBOC library is synthesized by adding peptide
sequences to the bead through PEG linkers, then incubated with the target of interest. 148–
150

Usually, this method is performed in vitro by incubating the beads with target cell

receptors or cell lines. 150 The beads that bind to the target of interest are separated from
the nonbinding beads and can be characterized through microsequencing.

148,149

An

advantage of the OBOC method over phage display is that an OBOC library can consist of
peptides that have not only L-amino acids, but also unnatural amino acids and D-amino
acids. 146

1.4.2 Targeting Receptors
Table 1.3 Targeting peptides conjugated to other nanoparticles or used
alone to deliver chemo and gene therapeutics.
Peptide
LuteinizingHormone-Releasing
Hormone (LHRH)
MQLPLAT
T7

Target

Delivery System

Cell Type

LHRH Receptor

Complexed with PEG
and campothecin 151

ovarian, breast,
and prostate
cancer cells

M13 phage displaying
MQLPLAT in vivo152

gastric cancer
cells

Lipid nanoparticles
conjugated with T7

lung cancer cells

Fibroblast
Growth Factor
Receptor
Transferrin
Receptor
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MC11
GE11

KCCYSL
RDG peptide
Derivative

Fibroblast
Growth Factor
Receptor
Epidermal
Growth Factor
Receptor
Human
Epidermal
Growth Factor
Receptor 2
αvβ3 integrin

AP Peptide

Interleukin-4
receptor

P1c

αvβ3 integrin

loaded with antisense
nucleotides in vitro153
MC11 was conjugated
to branched PEI and
PEG 25
Doxorubicin (DOX)
loaded liposomes
conjugated to GE11 154

HepG2
lung cancer cells

KCCYSL-TGX-D1
conjugate 155

prostate cancer
cells

Paclitaxel conjugated to
RDG peptide156
Polymeric micelles
loaded with doxorubicin
conjugated to AP
peptide 157
Liposomes loaded with
doxorubicin conjugated
to P1c 158

breast cancer
cells
breast cancer
cells
glioblastoma
cells

Targeting peptides can bind to a variety of cell receptors that are either
overexpressed by or unique to cancer cells. Targeting receptors can be sorted into three
main groups: integrins, G-protein coupled receptors, and growth factor receptors. Integrins
are transmembrane cell receptors that bind to proteins in the extracellular matrix.

159

Integrin αvβ3, which is often overexpressed in ovarian, prostate, and breast cancers, has
been a popular integrin for target studies. 160 G-protein coupled receptors (GPCRs) are
membrane receptors that transduce stimuli into various cellular activities by activating G
proteins when they bind to ligands. 161 Luteinizing hormone-releasing hormone receptor is
a GPCR which has been demonstrated to be overexpressed in a range of tumors including
prostate, breast, and ovarian tumors.

162

Growth factor receptors (GFRs) are surface
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receptors that are activated by binding to growth factors and can cause cell proliferation.
163

A common targeting receptor in this category is the epidermal growth factor receptor

(EGFR), which is found overexpressed on breast, lung, and colon cancer cells and tumors.
154,164

1.4.3 Targeting peptides conjugated to therapeutics
Once targeting peptides are developed, they can be conjugated to nanoparticles that
carry therapeutics or even to the therapeutic itself.

132,136

conjugated to cancer therapeutics with the help of linkers.

Targeting peptides can be
132

For example, cleavable

linkers are commonly used because of their ability to release a drug once it has reached its
target site.

132

Cleavable linkers can be separated into two main groups: chemically-

cleavable or enzyme-cleavable. 165 Chemically-cleavable linkers can be cleaved in acidic
environments such as the lysosome or endosome since they are designed to be stable only
in a pH of 7. 165 Enzyme-cleavable linkers can be cleaved by proteases or other enzymes
relevant to the tumor microenvironment. 132,136 Peptide hydrolysis, acid-base catalysis, or
covalent restructuring of amide bonds are methods by which enzymatically-cleaved linkers
are broken after peptide-mediated arrival of nanocomplexes to the TME and cancer cells
is achieved. 166 These sites can act as activators of prodrug conjugates, causing release of
activated

chemotherapeutics.

A

leucine-linked

daunorubicin,

dissociated

via

aminopeptidase cleavage, delivered to L1210 leukemia cells exhibited significantly higher
anticancer effects and TME homing capabilities compared to free daunorubicin when
delivered intravenously to subcutaneous tumor-bearing mice. 167
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In another application of TME-targeted cleavable linkers, the previously described
CPPs can be conjugated to, and deliver chemotherapeutics. The doxorubicin prodrug,
R8DB, comprised of an octa-arginine peptide complexed to doxorubicin via a glycinephenylalanine-leucine-glycine linker enabled high levels of free doxorubicin delivery upon
cleavage via cathepsin-B, a lysosomal protease, in drug-resistant ovarian cancer, ADRRes.

168

Most notable, was the ability to include a DOX quencher, allowing for drug

tracking prior to release via cathepsin-B cleavage, a phenomenon not seen with free DOX.
166,168

DOX is a popular drug conjugate to evaluate linker efficacy, as chemically cleavable

linkers have also been shown to enhance internalization and release of DOX in cancer.
Modified human α-fetoprotein receptor binding peptide, containing a conjugate polyglutamic acid linker, bound to DOX increased solubility, tumor selectivity, and pHdependent disulfide bond degradation between the peptide sequence and DOX conjugate
within the lysosome in SKOV3 ovarian cancer and MCF7 breast cancer cells. 169
Many successful studies have included targeted peptide-drug systems conjugated
via enzymatically or chemically cleavable linkers. An RGD peptide derivative conjugated
to paclitaxel (PTX) via ester bond coupling has proven effective in targeting breast cancer
cells with overexpression of αvβ3 integrin and delivering PTX following esterase cleavage
in an acidic environment. 156 An in vivo study showed that the tumor uptake of tritiumlabeled (3H) particles, 3H-RGD-PTX, in MDA-MB-435 tumors via αvβ3 integrin binding
was higher at all time points in comparison to nontargeted 3H-PTX and 3H-PTX + RGD.
156

Tumor to muscle ratio was also higher for 3H-RGD-PTX at each recorded time point,

indicating selective tumor targeting over muscle cells, and 3H-RGD-PTX treatment also
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exhibited greater tumor growth inhibition in comparison to the free PTX controls.

156

Human epidermal growth factor receptor 2 (HER2) targeting peptide, KCCYSL,
conjugated to TGX-D1 , a chemotherapeutic, enhanced cell-specific binding and uptake
into LNCaP prostate cancer cells. 155 The targeting peptide-drug conjugate, KCC-TGX,
was compared to a cleavable linker-drug conjugate, containing the SSKYQ prostate
specific antigen-cleavable peptide (Ac-SSKyQSL-TGX), the TGX-D1 intermediate (NH2SL-TGX), and free TGX-D1. 155 LNCaP prostate cancer cellular uptake studies showed
that KCC-TGX had the highest cellular uptake. 155 Furthermore, a competitive binding
assay with preincubation of anti-HER2 ligand followed by delivery of KCC-TGX resulted
in significantly lower cellular uptake, demonstrating that internalization of the drug was
largely due to the HER2 targeting peptide. 155 These overexpressed cell receptors provide
an area of attack for peptide-based delivery systems and exhibit greatly improved targeting
abilities. With these attributes, drug payloads can be reduced, as off-target uptake becomes
less of a barrier, lending to reduced gene and chemotherapeutic dosages resulting in
possible systemic side effects.

1.4.4 Targeting peptides conjugated to nanocarriers
Although research on targeting peptides initially focused on direct conjugation of
the peptide to a drug, most recent work focuses on conjugating peptides to nanocarriers
such as micelles, polymers, or liposomes with proven abilities to effectively deliver not
just monotherapies, but also types of combination therapy to cancer cells. 132 AP peptide
(CRKRLDRN) is a targeting peptide that binds to interleukin-4 receptor and has been
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conjugated to pH-responsive polymeric micelles carrying doxorubicin. 157 DOX-loaded
micelle uptake in MDA-MB-231 breast cancer tissue was enhanced at each time point for
the micelles conjugated to the targeting peptide when compared to micelles alone when
delivered intravenously. 157 As a result, 15 days after micelle-DOX injection, breast cancer
tumors in mice injected with DOX-loaded targeting micelles were 18.6% the weight of the
tumors in mice injected with saline and 57% the weight of tumors treated with non-targeted
micelles.

157

In another study, P1c peptide (CIRTPKISKPIKFELSG) targeting αvβ3

integrin was conjugated to doxorubicin-loaded liposomes. 158 P1c-conjugated liposomes
had a significantly higher mean fluorescence intensity following incubation with αvβ3
positive U87MG glioblastoma cells compared to non-targeted liposomes. 158 A CCK-8
assay in vivo confirmed that P1c conjugated liposomes loaded with DOX mediated
significantly higher cytotoxicity in U87MG cells compared to nontargeted DOX-loaded
liposomes, while the MCF-7 cell line, an integrin αvβ3 negative cell line, did not exhibit a
significant difference in cytotoxicity between the targeted and nontargeted liposomes. 158
U87MG tumors were significantly smaller for mice that were treated with P1c-conjugated
liposomes loaded with DOX compared to free DOX, nontargeting DOX-loaded liposomes,
or saline. 158
Fibroblast growth factor receptor (FGFRs) has been shown to be overexpressed on
cancer cells, and a targeting peptide, MC11, has been identified for receptor-specific
binding with fibroblast growth factor. 25,152 A polyplex consisting of eight-armed PEG
(EAP), PEG600, and MC11 was constructed and delivered to HepG2 hepatocellular
carcinoma cells in vitro and displayed significantly higher luciferase gene transfection

51

compared to the nontargeted polyplex.

25

Similarly, the T7 peptide was developed to

specifically target transferrin receptor (TfR) in breast cancer cells, MCF-7, and was
complexed with core-shell nanoparticles to form DSPE-PEG2000-T7 nanocomplexes. 21
DSPE-PEG2000-T7 nanoparticles displayed increased fluorescence in the cytoplasm of
MCF-7 cells compared to nontargeted nanoparticles and also showed significantly reduced
epithelial growth factor receptor (EGFR) protein expression when delivering siEGFR
intravenously into mice bearing MCF-7 mammary tumors compared to nontargeted
complex formulations. 21
The development of targeting regions on cancer therapeutics has been advantageous
in delivering therapeutics to targeted sites on cancer cells. Targeting peptides are efficient
for this goal due to their low molecular weight and abundant versatility, especially when
compared to monoclonal antibodies. Use of targeting peptides to enhance current
nanoparticle delivery systems or as additional moieties with fusogenic or cell penetrating
peptide systems to deliver cell-specific therapeutics may help to establish peptides as
promising candidates for clinical translation.

1.5 Clinical Implications and Uses
While many preclinical studies have demonstrated the utility of peptides as a
component of nanoparticle delivery systems, in most clinical applications, peptides are
used as the therapeutic modality alone, as epitopes in vaccines, or as nanoparticletherapeutic conjugates. The initial forms of therapeutics to involve peptides, with insulin
being the most notable, were introduced in the 1920s. 170 Insulin was then followed by other
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common drugs, such as oxytocin, vasopressin, and calcitonin throughout the mid to late
20th century. As the genomic era emerged, more drug targets surfaced because of
strategized therapeutic targeting. These strategies have led to recent developments in
peptide therapeutics and can be applied to the peptide-conjugated nanoparticle strategies.
More recently, a glutathione S-transferase recombinant peptide, P28GST, has been shown
to reduce immune responses. 171 As a result, it was hypothesized that P28GST would reduce
severity of intestinal inflammation in irritable bowel disease (IBD) patients. A phase 2a
clinical study was completed in 2018 and showed promise after displaying decreased
Crohn’s disease activity index scores and blood calprotectin.

172

Ultimately, P28GST

proved to be a safe therapeutic option in a phase II clinical safety study. Other peptide
therapeutics have also shown promise in recent developments. 173 While these therapies
have highlighted the capabilities of peptides as therapies, they do not highlight the ability
for peptides to serve as delivery systems or provide nearly the amount of support that
polymeric and lipid-based systems have had in clinical applications.
The most commonly used drug delivery systems in clinical applications include
polymers and liposomes. 174,175 Comparing the use of these systems to peptide applications,
a significant gap exists in preclinical and clinical uses. Potential causes for the lack of
clinical use may include the high cost of peptide research endeavors compared to other
small molecules and suffering a long-time gap between research studies to mass
production/commercialization.176 The latter can be mostly attributed to difficulty in the
upscaling of peptides due to rigor in the production process, such as peptides folding upon
themselves during solid phase peptide synthesis. 177,178 When using peptides as or a part of
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a therapeutic, the likelihood of approval is 8%. 179 For peptide therapeutics approved from
2010 to 2017, the median development time was 9.4 years

180

, contrasting with other

molecule types that had a median of 8.1 years. 180 Increased development time may deter
research in not only peptide therapeutics but also peptide nanocarriers. However, with a
compound annual growth rate of 7.9% in global peptide therapeutics by 2027, there is
promise for upcoming peptide-based research. 181 In addition, the proportion of conjugated
peptides entering clinical development has increased over time, consisting of 30% of all
peptides entering clinical trials since 2010. 182 To continue the improvements of peptide
inclusion in clinical work, extensive funding and research is necessary to translate peptide
delivery systems from the bench to the bedside.

1.5.1 Peptide-Prodrug Conjugate
Pro-drugs using a peptide delivery system have been developed to circumvent the
limitations in drug metabolism, such as activation and elimination. 183 Irinotecan is a prodrug chemotherapeutic effective against colorectal cancer used in combination with 5fluorouracil (5-FU) as of early last decade. 183,184 It is limited by hepatic activation, resulting
in variable effects from patient-to-patient. 183,185 To overcome this limitation, peptide-drug
conjugate DTS-108 was developed, consisting of a chemotherapy drug, SN38, and an
oligopeptide, DPV1047. 185 SN38 (7-ethyl-10-hydroxycamptothecin), a topoisomerase I
inhibitor, is an active metabolite of the anticancer drug irinotecan formed by
carboxylesterases in the liver through hydrolysis. 185 DPV1047 is a part of a family of cellpenetrating peptides named Vectocell® peptides (also referred to as Diatos peptide vectors,
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DPVs) and is derived from anti-DNA antibodies. 186 This cell penetrating peptide consists
of 19 amino acids, with 35% representing basic amino acids, and is internalized
independent of caveolar pathways.

186

Due to its insolubility, SN38 was linked to an

oligopeptide, DPV1047, to form a water-soluble conjugate peptide: DTS-108. 183,184,187
DTS-108 is cleaved by esterases in the blood via esterase-cleavable linkers on the peptide,
resulting in non-hepatic release of SN38. 188 This mechanism proves to be an advantage of
peptides conjugates, given the efficacy of irinotecan is limited by hepatic activation.
Preclinical studies showed that the release of SN38, antitumoral efficacy, and cytotoxicity
of DTS-108 outperformed irinotecan. 183 Notably, systemic exposure of SN38 in the gut
was decreased using the DPV1047 peptide, which could significantly decrease adverse side
effects, as life threatening diarrhea is observed in some irinotecan-treated patients as a
result of accumulation of SN38 from the pro-drug via bile excretion. 183,189 Ultimately,
DTS-108 allowed for delivery of higher doses of SN38 without increased gastrointestinal
toxicity. These characteristics were attributed to the SN38 oligopeptide, which served as
the vector in efficient SN38 delivery in this model.
Higher levels of blood circulating SN38 observed with the use of the DTS-108 in
comparison to irinotecan led to the first in-human clinical trial completed in 2016. 183,188
This study revealed SN38 drug concentration levels in DTS-108 four times higher than
irinotecan at similar dosage amounts. 188 While diarrhea and other gastrointestinal problems
were observed in patients, they were less problematic and manageable with patients
subjected to DTS-108 treatment in comparison to those historically treated with irinotecan.
188

The clinical trial investigators attributed this to the location of cleavage within the body

55

(blood for DTS-108 and liver for irinotecan). Although tumor responses were not observed,
disease stability was sustained for six or more cycles in several patients. 188 As a whole, the
clinical study reinforced the observations seen in the preclinical models including reduced
toxic side-effects and overcoming pharmacokinetic barriers.

183,188

Moreover, this trial

highlights the possibilities of peptides in increasing therapeutic effectiveness by
circumventing the barriers imposed by natural human mechanisms.

1.5.2 Peptide Epitopes
Peptides are most commonly used clinically as epitopes in subunit vaccines. 190
Subunit vaccines present antigens to the immune system using any molecule associated
with the pathogen; in this case – peptides. Peptide vaccines are usually synthetic and serve
as antigenic epitopes that will induce lymphocytic responses. These qualities allow
peptide-vaccines to be highly versatile. However, they must be engineered with close
attention to epitope structure and immunodominance to render an effective immune
response. Successful peptide vaccines mimic the structures of naturally occurring antigens
such as pathogens, which tend to cross-link B-cell receptors to promote antibody affinity
maturation for increased immunogenicity.190 Others may yield a T-cell by binding to Tcell receptors of class I or II major histocompatibility complexes of antigen presenting
cells. 190 However, these require a free N-terminal amine group and an epitope peptide
backbone that conforms to the class I or II major histocompatibility complex for successful
recognition.

190

This alludes to the versatility in peptide-epitope structure engineering,

which must be within fine detail to yield an effective immune response.
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UV1 is a vaccine peptide designed based on epitope spreading, the formation of an
immune response to epitopes that are distinct from those that cause disease, to target
telomerase upregulated tumors. 191 Epitope spreading is common in vaccine development,
leading to the diversification of the immune system to recognize multiple targets on a
pathogen.

191,192

With the ability to modify peptides for targeting of certain antigens,

epitope spreading can be used as an advantage in vaccine development. UV1 is composed
of three telomerase reverse transcriptase (hTERT) peptides, known as GV1001. Previous
work established that hTERT peptides elicit CD4+ T-cell reactivity.192 hTERT, the
catalytic subunit of telomerase, is an attractive antigen target since telomerase is often
upregulated and contributes to proliferation of human tumors and cancer progression. 193–
195

Upon vaccination with a peptide corresponding to hTERT, an immune response would

be generated to eradicate tumors with upregulated telomerase activity. A phase I clinical
trial using UV1 and granulocyte macrophage colony stimulating factor (GM-CSF) in
metastatic hormone-naïve prostate cancer (mPC) demonstrated that 18 of 21 patients
exhibited an immune response to the peptide.

196

When used as androgen deprivation

therapy, 13 of 21 patients who received >10 UV1 vaccinations had decreased prostatespecific antigen (PSA) levels and 10 patients no longer had persisting tumors in the prostate
gland. 196 However, the efficacy of the vaccine must be studied further, given moderate
adverse side effects were observed in patients that could not be attributed specifically to
UV1 or GM-CSF. Several other clinical trials have been conducted using an hTERT
peptide and other adjuvants. 197–200 More recently, the GV1001 peptide has been explored
as a heat shock protein-mediated cell penetrating peptide.
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201

These clinical studies

highlight the versatility of peptides in bridging the gap between research and human
application.
Table 1.4 Peptides in clinical trials and their therapeutic mechanisms.
Peptide

Therapeutic System

Disease Treated

DPV1047

SN38 conjugated to
positively charged CPP
to form DTS-108

Colorectal Cancer

XG-102

TAT (CPP) conjugated
to dextrogyre peptide

Uveitis/ocular
inflammation

KAI-1678

Synthetic CPP
composed an inhibitor
of epsilon PKC and
carrier moiety

Postherpetic
neuralgia

P28GST

Sole protein derived
from schistosome
helminth

Crohn’s disease

p28

CPP fragment of
cupreodexin azurin

Solid tumors

UV1

Three epitope peptides
corresponding to
reverse transcriptase
subunit of telomerase

Metastatic hormonenaïve prostate cancer

KIF20A-66

HLA-A24-restricted
epitope peptide

Pancreatic cancer

NA-1 (TatNR2B9c)

CPP

Ischemic infarction
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Mechanism of
Action
SN38 released upon
cleavage of ester
bond within blood
via plasma
esterases183
Inhibition of the JNK
pathway202–204
Inhibition of epsilon
protein kinase C
(εPKC) and isozymespecific receptor for
active C kinase
(RACK)205
Downregulating
Th1/Th17 immune
response to reduce
intestinal
inflammation172
Inhibits proteasomal
degradation via
HDM2-independent
pathway206
Vaccine to induce
immune response
towards achieving
tumor eradication via
targeting of
hTERT192,196
Vaccine targeting
tumor-associated
antigen kinesin
family member 20A
(KIF20A)207
Disrupts protein–
protein interactions

of PSD-95, a
postsynaptic
scaffolding protein208
Peptide-based delivery systems have performed successfully in in vitro and in vivo
studies, but few are translated to clinical studies, a gap that must be addressed further. In
the vast majority of peptide-based therapies, peptides are used as the therapeutic system
rather than as the delivery system. The success of peptide therapeutics in early clinical
trials only helps to support the ongoing studies of peptide biocompatibility and efficacy
when used as drug delivery methods. Nevertheless, peptide systems are largely
investigatory and come with advantages and disadvantages that should always be
considered in weighing the applicability of their use.
Though numerous advantages to using peptides as a delivery system have been
discussed, there are disadvantages that must be addressed. Without the following
considerations, utilization of some peptide complexes can hinder the capabilities of
delivery systems and cause negative effects including peptidase degradation and local and
systemic toxicity. Peptides with strong net charges can be targeted for rapid degradation
via peptidase activity or succumb to phagocytosis after opsonization. 209 While a large
degree of peptide destruction can occur prior to arrival at a target cell, peptide systems can
also be subject to degradation intracellularly. That degradation kinetics of peptides can
depend on many factors, including cell type, cell density, and peptide biochemical
attributes, emphasizes the importance of delivery system design and understanding of the
cancer model in use in development of the delivery system. 210 Still, the use of fusogenic,
cell-penetrating, and targeting peptide systems in cancer drug delivery has shown great
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success in academic and preclinical studies, and the continued understanding of cancer
biology, tumorigenesis, and the tumor microenvironment will continue to improve these
methods of delivery.
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CHAPTER 2 – SIGNIFICANCE, INNOVATION, AND SPECIFIC AIMS

2.1 Research Significance
The complexity and severity with which ovarian cancer grows and metastasizes
overshadows the current treatment advantages and rate of therapeutic success. New
methods of treatment, focusing on targeted medicine, are necessary to improve patient
quality of life, life expectancy after diagnosis, and the significant costs and resources
associated with treating ovarian cancer. Although it is the 7th most commonly diagnosed
cancer and the 8th leading cause of cancer-related death among women, diagnosis does not
occur until the cancer has reached stage III or stage IV classification due to a broad
spectrum of symptoms that present with common peritoneal issues.1,2 In conjunction with
being the most lethal of gynecological cancers, late diagnosis results in low five-year
survival rates.1 The majority of ovarian tumors are located in the epithelial cell layer and
quickly differentiate and migrate to the peritoneal cavity within ascites fluid, causing
symptoms that may be mistaken for general stomach discomfort, leading to misdiagnosis
until the disease has progressed to late stages.3 At advanced stages of disease, over 70% of
patients require aggressive debulking surgery and an intense regimen of non-cell specific
chemotherapeutics that can cause several adverse systemic effects.4 Moreover, at least 80%
of patients who undergo treatment for advanced-stage cancer experience recurrence,
development of drug resistance, or distant metastasis, further reducing the efficacies of
currently available treatment methods.4
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There is a need for more personalized, targeted, and robust treatment strategies to
begin to see improvements in the survival and recurrence rates for ovarian cancer patients.
However, there are many barriers to developing new, targeted treatment methods, none
more daunting than that of an efficient delivery mechanism.
Several studies have examined both natural and synthetic peptides as possible
therapeutic delivery methods and have shown that each of the shortcomings mentioned can
be addressed with varying designs and peptide properties.5–8 Peptide designs include
biochemical properties that create three major classifications of peptides: cell penetrating,
fusogenic, and targeting.6 Cell penetrating peptides consist of primarily cationic residues
that, when complexed with siRNAs, increase cellular translocation through electrostatic
interactions and cause endosomal escape through the proton-sponge effect.9,10 Fusogenic
peptides can be characterized by their amphipathic nature, consisting of both hydrophobic
and hydrophilic residues, that act independently to complex RNAi therapeutics and also
cause endosomal membrane destabilization through pH-responsive protonation, causing a
conformational change and membrane insertion.7 Fusogenic peptides are also designed
with many similarities to viral-fusion proteins and can exploit this basis to prevent
degradation through native biochemical similarities by macrophage activity.7 Targeting
peptides possess specific affinity to disease-associated biomolecules and peripheral cell
receptors.6 Fusogenic and targeting peptides will be utilized for this work and can also be
modified to include linkers that will prevent steric hindrance from altering functionality.
Additionally, they will contain C-terminal cationic residue chains to achieve sufficient
siRNA complexation through electrostatic interactions and improved cell translocation.
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RNAi, a naturally occurring process, can be exploited as a therapeutic modality by
delivering bioactive siRNAs to cause cleavage of specifically targeted messenger RNAs,
mRNAs, responsible for protein production via translation that may aid in cancer cell
survival and proliferation.11–16 Activation of RNAi is achieved by delivery of siRNAs into
the cell cytoplasm, causing mRNA cleavage by the RNA-induced silencing complex
(RISC) through endonuclease argonaute 2 enzyme binding activity and the sequencespecific binding of antisense siRNA strand to target mRNA.12 Recent studies have shown
a reduction in ovarian cancer oncogene expression and the reduction in tumor weight and
volume in vivo when treated with siRNAs for the knockdown of genes responsible for
cancer cell survival and growth.11,17 The use of RNAi is advantageous in several difficultto-treat cancers as this therapeutic has the ability to silence targets not easily affected by
traditional chemotherapeutic treatments and has also shown clinical relevance with a 2010
study reporting systemic siRNA delivery in humans.11 This work introduces a novel,
modular tandem peptide system that takes advantage of targeting and fusogenic peptide
properties for efficacious delivery of bioactive siRNAs. This system will exploit cancer
cell-specific receptor overexpression as well as natural endocytotic mechanisms for
targeted delivery and uptake as well as using the endosomal pH-environment as an escape
mechanism via membrane destabilization. Delivery of bioactive siRNAs, selected
specifically for overexpressed, cancer-type specific oncogenes, will be achieved and gene
knockdown is expected. The various roles of this system will efficiently overcome
significant barriers to delivery, namely, ovarian cancer cell-specific targeting and
inefficient endosomal escape, establishing a new genre of peptide systems that can be
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tailor-made for patient and cancer type-specific targeting and gene knockdown using an
ovarian cancer model as a proof-of-concept.

2.2 Innovation
With the discovery of RNAi applications in specific gene silencing in 1998 and
implementation of peptide-based delivery methodologies of gene therapeutics, several
major advances have been made, but not without several drawbacks.11,12,18 Development
of novel synthetic peptide designs, avoiding rapid degradation of therapeutic cargo, and
reducing off-target effects are three areas that require improvement for peptide-based
delivery strategies of gene therapies. The overarching goal of this research is to establish a
novel peptide delivery system that will act in tandem to deliver bioactive siRNAs. This will
be accomplished by developing a novel series of fusogenic peptides that will efficiently
bind and protect siRNAs from degradation through delivery and endosomal escape.
Although studies have reported some positive results from using fusogenic peptides alone,
the majority of these studies have utilized viral-derived sequences, entire peptide-sequence
Table 2.1 – Fusogenic peptides widely used as delivery systems
Peptide

Mechanism

Sequence

HA2

pH Conformation Change

GLFGAIAGFIENGWEGMIDGWYG

INF7

pH Conformation Change

GLFEAIEGFIENGWEGMIWDYG

E5

pH Conformation Change

GLFEAIAAEFIEGGWEGLIEG

GALA
Tat

pH Conformation Change WEAALAEALAEALAEHLAEALAEALEALAA
Photo Induced

RKKRRQRRR
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copies with minimal edits, or slight variants of known synthetic designs.6,19 Table 1
highlights several of the most widely used fusogenic designs in drug and siRNA
delivery.20–26 This work will expand on previous research by incorporating a complete
fusogenic redesign based on biochemical properties rather than sequence alone. This design
will be complexed with a targeting component, to be sequenced and developed as a novel
peptide as well, forming a complete tandem peptide system. The targeting region will
selectively bind with the luteinizing hormone releasing hormone receptor, LHRH.27 LHRH
has been shown to be successfully targeted using NP delivery systems and to be
overexpressed in a set of cancerous ovarian tissue when compared to non-cancerous
ovarian tissue.27,28 Most relevant to hormone regulation and gonadal development, LHRH
plays an important role in the pituitary system, but shows implications in the development
of ovarian cancer through autocrine stimulation.29 Together, these peptides will make up a
tandem-peptide delivery system capable of cell-specific uptake and protection from
degradation through endosomal escape. Furthermore, the target gene of interest,
CSNK2A1, is an emerging target oncogene for new therapeutic applications. Several
prognostic, genomic, and proteomic studies have confirmed the presence and role of the
CK2α subunit protein product of the CK2 gene family, dubbed CSNK2A1.30–34 The role of
CSNK2A1 has been determined to be multifaceted. Several cellular processes, including
DNA damage response, apoptosis, cell cycle regulation, transcription, and translation,
include some form of CSNK2A1 activation for completion.31 However, overexpression of
this gene can cause severe effects as they pertain to cancer progression including lack of
apoptotic activity and increased DNA repair for progressive cancer survival, which may
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also lead to drug resistance.31,32 The knockdown of CSNK2A1 is hypothesized to create a
recovery of apoptotic activity, resulting in a loss of cancer cell viability and inability to
migrate and invade into nearby areas both in vitro and in vivo.
Additionally, the modularity of our treatment strategy, depicted in figure 1, can be
exploited for further applications in other disease models. The proposed design exploits
the overexpression of a receptor found on ovarian epithelial cancer cells as well as the
role played by the CSNK2A1 gene in cancer development. These two facets of the delivery
system can be interchanged for a different disease model depending on that model’s
upregulated receptors and genes. This allows for rapid design, development, and testing
of a disease-type specific approach that may foster a more streamlined effort to achieve
patient-specific medicine.

Figure 2.1 Schematic of tandem peptide-siRNA complex for treatment of ovarian cancer.

2.3 Specific Aims
The goal of this research is to develop a novel tandem peptide delivery system,
featuring complimentary targeting and fusogenic regions, for siRNA delivery that can
provide cell-specific uptake into ovarian cancer epithelial cells, OVCAR3 and CAOV3,
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efficient endosomal escape, and gene silencing. This delivery approach will address current
significant delivery barriers including cell specificity and endosomal escape. Delivered as
a tandem peptide, each facet will retain its respective properties through extracellular linker
cleavage, enabling localized endocytosis caused by cell-specific receptor targeting and
resulting escape due to the fusogenic properties, releasing bioactive siRNAs. These
expectations of the design and implementation of the delivery system will be attainable due
to the numerous studies available that highlight peptide based delivery systems that carry
siRNA efficiently to achieve gene knockdown.6,8,19,35,36 The siRNAs that will be used in
this study target the alpha subunit of protein kinase CK2, CSNK2A1. CSNK2A1 is a
catalytic subunit of a multifaceted gene responsible for various cellular processes including
DNA damage response, apoptosis, cell cycle regulation, and cell growth and
proliferation.31,32,33 We hypothesize that use of a tandem peptide for self-assembly with
siRNAs, consisting of fusogenic and targeting peptide regions, will enhance cell specific
uptake of CSNK2A1 siRNAs into ovarian cancer and mediate endosomal escape, resulting
in gene silencing, and a marked decrease in cell proliferation. The hypothesis will be tested
using the following specific aims, addressing each experimental objective through this
work:

Aim 1: Develop a novel fusogenic peptide and analyze its ability to deliver bioactive
siRNAs into ovarian cancer cells in vitro.
Several fusogenic peptide variants will be designed based on current fusogenic
peptides derived from viral models that have been shown to enhance cellular uptake and
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endosomal escape.8,36,37 Each variant will be tested for siRNA complexation and
protection, cellular uptake and endosomal escape levels, and gene silencing efficacy. The
peptide variant displaying the most positive results will be selected for further study and
complexation with the targeting peptide region.

Aim 2: Examine the in vivo biodistribution and oncogene silencing effects of the
fusogenic peptide complexed with siRNAs targeting CSNK2A1 using a xenograft
mouse model of ovarian cancer.
Intraperitoneal or flank tumors will be grown in mice using tumorigenic ovarian
cancer cell line OVCAR3/OVCAR3-Luc. Intraperitoneal or subcutaneous flank delivery
of the fusogenic peptide/siRNA complex will be performed to determine the tumoral and
systemic biodistribution of siRNAs in addition to tumor excision and tissue
homogenization to examine gene and protein expression of CSNK2A1.

Aim 3: Form a tandem peptide with a targeting peptide specific for luteinizinghormone-releasing-hormone (LHRH) and examine the specificity in targeting
delivery of bioactive siRNAs into ovarian cancer cells in vitro.
Improvements in targeted cancer therapy can help minimize cytotoxicity in healthy
tissues and translate to lower adverse systemic effects in the clinic. A peptide targeting the
luteinizing-hormone-releasing-hormone will be delivered in vitro in tandem with the
fusogenic sequence to determine improvements in cell uptake and gene silencing efficacy.
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The tandem peptide complexed with siRNAs will be compared against the targeting and
fusogenic-siRNA complexes.
Completion of this work will establish a novel delivery system that optimizes two
separate peptide delivery systems into one singular, modular design for siRNA delivery in
clinically relevant ovarian cancer cell lines that will cause a loss of cancer cell viability
and proliferative activity.38,39 This work will also establish a basis for future developments
in personalized cancer therapy by providing a modular design in which the targeting
peptide region and siRNA therapeutic can be exchanged based on other upregulated
receptors and genes of various cancer types.
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Abstract
One of the most lethal gynecological cancers, epithelial ovarian cancer, has shown
little improvement in patient survival in advanced stage patients over the past decade.
Current treatment strategies, including surgical debulking and administration of platinumbased therapeutics, have been largely unsuccessful in treating advanced disease, with many
patients experiencing significant systemic toxicity and drug-resistant metastatic cancer.
This study explores novel fusogenic peptide carriers for delivery of short-interfering RNA
targeting casein kinase II, CSNK2A1, as a gene target for reducing the aggressiveness of
ovarian cancer in vitro. Failure to encourage high rates of cellular uptake and lack of
therapeutic escape from endosomal entrapment, two significant barriers to siRNA delivery,
are the primary design functions of fusogenic peptides. The three peptide variants
developed, DIVA3, DIV3H, and DIV3W, contain a novel fusogenic sequence with
amphipathic attributes and a nona-arginine tail capable of rapid electrostatic complexation
with siRNA cargo. Results show that DIV3W is able to rapidly complex siRNA cargo,
protect siRNAs from serum and RNase degradation, optimally deliver bioactive siRNAs
into ovarian cancer cells with high cellular uptake efficiency and targeted knockdown of
CSNK2A1 mRNA and CK2α protein in comparison to non-targeting siRNAs, up to 94%
gene knockdown, and cause decreased cell migration and recolonization in vitro. These
results demonstrate the capabilities of this peptide delivery system to efficiently and
effectively deliver bioactive siRNAs and the role of CSNK2A1 in cell-cell communication
and proliferation, specifically in ovarian cancer.
Keywords – peptide delivery, fusogenic, RNAi, ovarian cancer, siRNA, CSNK2A1
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3.1 Introduction
Epithelial ovarian cancer is the 7th most commonly diagnosed cancer among
women in the United States and has the highest mortality among all gynecological cancers.
Ovarian cancer is commonly diagnosed in late stages with low response to therapeutic
interventions and in the past 10 years, advanced-stage patients have only had an increase
in survival rates by 1%.1,2 Because over 90% of ovarian cancer are derived from epithelial
cells, tumors are prone to rapid proliferation and spreading, causing both local and distant
metastases within ascites fluid.3 Approximately 80% of patients will experience
recurrence, multidrug resistance, or distant metastasis when treated for advanced-stage
disease.4 To improve patient outcomes, there is a need for more effective ovarian cancer
treatment strategies delivered via robust, biocompatible, and reliable mechanisms.
Gene therapy through RNA interference (RNAi) has been extensively studied as a
potential therapeutic intervention in many cancer types since its discovery in 1998.5–8
RNAi enables gene silencing through sequence-specific inhibition of messenger RNA
(mRNA) translation using short hairpin RNA (shRNA) or short interfering RNA (siRNA).9
RNAi technology has significant implications in cancer treatment through the silencing of
proteins responsible for cancer cell survival, migration, invasion, regrowth, and
development of multidrug resistance.10 Although this mechanism is highly specific and has
been shown to be advantageous in drug resistant cancers, siRNA delivery can be difficult
to achieve without a nanocarrier due to its size, negative charge, and rapid degradation
within the endosome.11–16
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Peptide-based systems have shown great ability to complex with and efficiently
deliver siRNA for sequence-specific mRNA degradation in cancer, providing a method of
eluding barriers to siRNA delivery including rapid RNase-induced degradation inefficient
cell uptake, and lack of endosomal escape..5,17,18 More specifically, fusogenic peptide
sequences efficiently complex siRNA through electrostatic interactions, are taken up via
endocytosis, and can cause endosomal escape via membrane disruption.19–22 Due to their
amphipathic nature, fusogenic peptides interact with the cell membrane via hydrophobic
amino acid residue affinity for the lipid bilayer membrane, inducing endocytosis. When
encapsulated in the endosome, fusogenic peptides undergo a pH-dependent conformational
change, primarily forming an α-helical structure, though some β-sheet formation has been
recorded and reported to have similar fusion with the endosomal membrane.16,23 This newly
conformed peptide structure can then insert itself into the endosomal membrane via the
projection of hydrophobic amino acid residues, resulting in membrane structure
destabilization and breakdown, allowing for the internalized cargo to dissociate from the
fusogenic peptide delivery system and escape into the cytosol (Fig. 3.1).16
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Figure 3.1 Fusogenic nanoparticle delivery and endosomal membrane fusion
Fusogenic peptides may address two primary barriers to siRNA therapeutic delivery in
cancer through encouraging endocytosis and facilitating endosomal escape via pHdependent protonation, conformational shift of the peptide, and insertion into the
endosomal membrane. Upon membrane puncture, therapeutic cargo can dissociate
from the peptide and escape into the cytosol for RNA-induced silencing complex
formation and mRNA degradation.

We have developed a set of rationally designed fusogenic peptides for
complexation with siRNAs to be delivered into epithelial ovarian cancer cell lines,
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OVCAR3 and CAOV3. Each peptide was design to maintain amphipathic properties and
include a sequence of d-Arginine residues responsible for siRNA complexation. In this
study, we have demonstrated the ability of three fusogenic peptides to electrostatically bind
with siRNAs, protect siRNA cargo from serum degradation, and encourage endosomal
escape and delivery of bioactive siRNAs. Specifically, we examined the potential of
CSNK2A1 as a gene target in ovarian cancer via delivery of novel fusogenic peptides
complexed with siRNAs targeting the gene. into genetically relevant ovarian cancer cells,
for reducing cell aggressiveness using CSNK2A1 targeted siRNA.24 CSNK2A1 is an
oncogene found overexpressed is several cancer types, including ovarian cancer and is
responsible for increased growth and cell survivability in the presence of chemotherapeutic
agents.25,26 The protein encoded by CSNK2A1, CK2α, plays a major role in cell cycle
regulation, DNA repair activation, and apoptosis in response to external stimuli in lung
adenocarcinoma, urothelial carcinoma, and pancreatic adenocarcinoma.27,28 Roles in
ovarian cancer, however, have only been suggested through observation of upregulation of
CK2α and combination treatment with chemotherapeutics including dasatinib, cisplatin,
and gemcitabine.29,30 RNA-based therapies alone, targeting CSNK2A1, have not been
comprehensively studied and this work illustrates the therapeutic efficacy of siRNA
monotherapy in ovarian cancer.
Consistent with other cancer-knockout models, knockdown of CK2α protein using
siRNA targeting CSNK2A1 delivered with the DIV3W peptide primarily results in
decreased cell migration and invasion in ovarian cancer . The DIV3W peptide encouraged
high cellular uptake efficiency and significant gene and protein silencing, but cytotoxic
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effects were not observed. Despite this, the reduction in cell migration and colonization
does show promise for CSNK2A1 as a gene target to reduce ovarian cancer aggressiveness
in early to mid-stage patients, possibly alleviating the major issue of recurrence and distant
metastatic spread.

3.2 Results
3.2.1 Characterization of DIVA3, DIV3H, and DIV3W peptides
Peptides were systematically designed based on the prominent fusogenic peptide,
GALA, a synthetic peptide derived from the viral fusion sequence of the HA2 protein found
in the influenza virus.31,32 Each amino acid was selected to formulate an amphipathic
sequence repeat, consisting of hydrophilic and hydrophobic residues. The N-terminus
includes a nona-d-arginine sequence to enable electrostatic complexion with siRNAs,
which is separated from the amphipathic, fusogenic sequence at the C-terminus by a
glycine linker. The three peptides, DIVA3, DIV3H, and DIV3W, were designed to follow
these formulations, with an additional histidine residue and tryptophan residue present in
DIV3H and DIV3W respectively.
Agarose gel electrophoresis was used to determine the ability of DIVA3, DIV3H,
and DIV3W (all three denoted as DIV3(X)) peptides to completely complex free siRNAs
and protect siRNAs from degradation. The DIVA3 peptide was able to completely complex
free siRNAs at the lowest peptide (positively charged amine content):siRNA (negatively
charged phosphate content) (N:P) molar ratio, at 20:1. In contrast, a molar ratio of 40:1

112

was the minimum required for complete complexation of DIV3H and DIV3W with siRNAs
(Fig. 3.2A).

Figure 3.2 Fusogenic peptide characterization.
Peptides were electrostatically complexed with siRNAs at increasing N:P ratios and
immediately subjected to agarose gel electrophoresis (A) or following incubation in
50% fetal bovine serum (FBS) (B) or RNase A (C) for 1 hour. Size distribution (D),
polydispersity index (PDI), and surface ζ-potential (E) were determined by dynamic
light scattering and Doppler voltage velocities for each DIV3(X) peptide/siRNA
complex at a 60:1 ratio. Data are mean ± SD performed in triplicate. Transmission
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electron microscopy confirmed the size and morphology of DIV3W-siRNA complexes
at a 60:1 ratio (F). Scale bar: 200 nm.
To mimic physiological conditions, DIV3(X) peptides were complexed with nontargeting siRNA (siNT) at several N:P ratios and exposed to 50% serum (Fig. 3.2B) or
RNase A (Fig. 3.2C) for 1 hour. White bands indicate intact siRNA and can be observed
for DIV3(X)-siRNA complexes subjected to 50% serum conditions at all N:P ratios.
Reduction of intact siRNA signal was only detected for DIVA3 complexes at a 20:1 and
80:1 molar ratio when incubated with RNase A (Fig. 3.2C). Minimal degradation,
specifically in DIV3H and DIV3W formulations after incubation in RNase A, indicates that
the peptides protected siRNA from degradation (Fig. 3.2C).
Peptide ratios 40:1, 60:1, and 80:1 were selected for subsequent experiments
following confirmation of full siRNA complexation at each of these ratios for all three
peptide formulations. Each peptide/siRNA complex was characterized by dynamic light
scattering to determine the nanoparticle size distribution and surface charge to ensure
stability (Fig. 3.2D, E). All DIV3(X)-siRNA complexes exhibited monodisperse
nanoparticle formation and were within the bounds of sizes that are advantageous for
passive targeting through the enhanced permeability and retention effect.33 DIV3W-siRNA
and DIV3H-siRNA complexes were the largest, with a hydrodynamic diameter of 100.38
+ 3.59 nm and 98.66 + 3.62 nm respectively, while DIVA3 formed complexes sized 85.07
+ 3.15 nm.(Fig. 3.2D, E). Transmission electron microscopy (TEM) of DIV3W-siRNA
complexes (Fig. 3.2F) confirmed the results of particle sizing and spherical nanoparticle
formation.
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3.2.1 DIV3(X) peptides exhibit biocompatibility with ovarian cancer cells
To evaluate the effect of the peptides on cell viability, OVCAR3 and CAOV3 cells
were treated with DIV3(X) peptides alone at concentrations equivalent to 40:1, 60:1, and
80:1 molar ratios for each formulation. After a 48-hour treatment, none of the peptide
formulations demonstrated any significant cytotoxicity compared to untreated cells (Fig.
3.3). These results confirm the biocompatibility of the DIV3(X) peptides and their potential
for in vivo evaluation.

Figure 3.3 Fusogenic peptide biocompatibility via MTS assay.
MTS analysis of cell viability 48-hour after treatment with each peptide formulation
using OVCAR3 (A) and CAOV3 (B) cells. Data are mean ± SEM of three independent
experiments performed in triplicate.
3.2.2 DIV3(X) peptides enable siRNA uptake into ovarian cancer cells via endocytosis
A major barrier to siRNA delivery is inefficient cellular uptake. Through
fluorescence microscopy and flow cytometry, we examined the ability of the DIV3(X)
peptides to deliver fluorescently labeled siRNAs into ovarian cancer cells. Fluorescence
microscopy revealed that uptake of DY547 fluorescently labeled non-targeting siRNA,
siNT-DY547, into OVCAR3 and CAOV3 cells increased with increasing N:P ratios across

115

each peptide variant. Furthermore, siNT-DY547 uptake into ovarian cancer cells also
increased with use of DIV3W compared to DIVA3 and DIV3H (Fig. 3.4A, 3.S1A).
Qualitative observations of siRNA uptake were confirmed with flow cytometry, which also
demonstrated increasing uptake efficiency with increasing N:P ratios (Fig. 3.4B, 3.S1B).
Molar ratio-dependent increases in siRNA uptake were apparent for all formulations,
except DIV3W, which displayed high levels of uptake across all molar ratios in OVCAR3
cells (Fig. 3.4C). DIV3W uptake efficiency was 70.0%, 69.7%, and 66.6% for 40:1, 60:1,
and 80:1 molar ratios, respectively. DIV3H and DIVA3 peptides exhibited optimum cell
uptake at an 80:1 ratio at 52.1% and 63.6% efficiency, respectively (Fig. 3.4C). In CAOV3
cells, no statistically significant results were present between peptide variants, but uptake
did increase with higher N:P ratios (Fig. 3.S1C).
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Figure 3.4 Fusogenic peptide uptake efficiency in vitro in OVCAR3 cells.
(A) Fluorescence microscopy of siRNA uptake in OVCAR3 cells left untreated
(UNTD), treated with siNT alone, or DIV3(X) peptide-siNT-DY547 (red) complexes
for 4 hours. Cells are counterstained with Hoechst (blue). Scale bar: 100 µm. (B, C)
Flow cytometric analysis of DIV3(X)-siNT-DY547 uptake into OVCAR3 cells after 4
hours. Data are mean ± SEM of three independent experiments analyzed with one-way
ANOVA and posthoc Tukey multiple comparisons testing, where * p < 0.05, ** p <
0.01, *** p < 0.001, **** p < 0.0001.
Another significant barrier to delivery of endocytosed nanocarriers is endosomal
entrapment, resulting in lysosomal trafficking and degradation, inhibiting the bioactivity
of the delivered cargo. The primary functional characteristic of the DIV3(X) fusogenic
peptides is their ability to overcome this barrier my mediating endosomal escape through
fusion of exposed hydrophobic amino acids with the endosomal membrane following
protonation of anionic residues. Each DIV3(X) peptide was complexed with siNT-DY547
at a 60:1 molar ratio and incubated with OVCAR3 cells (Fig. 3.5) and CAOV3 cells (Fig.
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3.S2) for 4 and 8 hours prior to staining for early endosome antigen-1 (EEA1). Endosomal
accumulation of siRNA indicates intracellular locations of the delivered complexes and
was observed for all peptide complexes after 4 hours. However, colocalized signal of siNTDY547 and EEA1 stain decreased after allowing the complexes to incubate for 8 hours
prior to imaging, suggesting successful release of siRNA cargo from the endosome and
into the cytosol.

Figure 3.5 Endosomal escape ability of DIV3W in OVCAR3 cells.
Immunofluorescence microscopy of early endosome antigen-1 (green) after incubation
of OVCAR3 cells with siNT-DY547 (red) complexed with DIV3(X) peptides at a 60:1
N:P ratio for 4 and 8 hours. Colocalized green and red fluorescence (yellow) indicates
endosomal entrapment of the peptide/siRNA complexes, identified with white arrows,
while siRNA that has escaped can be seen in red in the overlay image. Cell nuclei are
counterstained with Hoechst 33342 (blue). Scale: 20 µm.
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3.3.3 DIV3W-siCSNK2A1 complexes silence CSNK2A1 mRNA and CK2α protein
expression in ovarian cancer cells

Figure 3.6 Fusogenic-mediated bioactivity of siRNAs in OVCAR3 cells.
qPCR analysis of CSNK2A1 mRNA after treatment of OVCAR3 cells with DIVA3
(A), DIV3H (B), and DIV3W (C) peptides complexed with siNT or siCSNK2A1 for 48
hours. Data are mean + SEM of three independent experiments analyzed with
Student’s t-test within each N:P ratio, where * p < 0.05 and ** p < 0.01. (D) Western
blot analysis of CSNK2A1 protein product, CK2α, after treatment of OVCAR3 cells
with DIV3W-siCSNK2A1 for 48 hours. β-Actin expression was monitored to ensure
equal protein loading.
Confirmation of endosomal escape of siRNAs mediated by the DIV3(X) peptides
was further confirmed through evaluation of siRNA bioactivity via gene silencing. Higher
levels of gene silencing are associated with higher levels of cellular uptake, endosomal
escape, and release of bioactive siRNAs. Gene silencing efficiency was determined by
analyzing CSNK2A1 mRNA and CK2α protein levels in ovarian cancer cells treated with
DIV3(X) peptides complexed with siNT or siCSNK2A1 for 48 hours. DIVA3 (Fig. 3.6A)
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and DIV3H (Fig. 3.6B) complexes mediated significant reduction of CSNK2A1 mRNA
expression in OVCAR3 cells, but only at a 60:1 ratio in DIVA3 complexes and an 80:1
ratio in DIV3H complexes, at 47%% and 72% silencing efficacy (Fig. 3.6E, F) . DIV3WsiCSNK2A1 complexes significantly reduced CSNK2A1 mRNA expression in OVCAR3
cells compared to DIV3W-siNT

by 95% and 65% at 60:1 and 80:1 molar ratios

respectively (Fig. 3.6C). Significant reduction of CSNK2A1 mRNA expression was also
observed in CAOV3 cells when trated with DIV3W complexes, with a maximum of 80%
knockdown using an 80:1 complex ratio (Fig. 3.S3A). Due to their reduced silencing
efficiency compared to DIV3W, DIVA3 and DIV3H and were not included for protein
analysis or CAOV3 qPCR studies. Western blot analysis revealed that expression of CK2α
protein was silenced in OVCAR3 (Fig. 3.6D) and CAOV3 (Fig. 3.S3B) cells after
treatment with DIV3W-siCSNK2A1 complexes across all N:P ratios. The significant
CSNK2A1 mRNA and CK2α protein knockdown mediated by DIV3W warrants the
selection of this peptide for subsequent anticancer studies.

3.3.4 DIV3W peptide-mediated silencing of CSNK2A1 inhibits ovarian cancer cell
migration and colonization
Consequences of silencing CSNK2A1 mRNA and CK2α protein can provide
support for utilizing CSNK2A1 as a prospective therapeutic gene target for treatment of
ovarian cancer. Initial evaluation of the effect of CSNK2A1 knockdown on ovarian cancer
cell viability using an MTS assay did not produce statistically significant results (Fig.
3.S4A). To evaluate the effect of silencing CSNK2A1 on cell migration, a scratch wound
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assay was conducted by first treating OVCAR3 cells with DIV3W-siNT or DIV3WsiCSNK2A1 complexes for 48 hours. Following treatment, a vertical and horizontal scratch
wound was introduced on the cell monolayer in each treatment group. Consistent with our
uptake and knockdown studies, delivery of DIV3W-siCSNK2A1 complexes at the 40:1
N:P ratio did not exhibit significant inhibition of cell migration compared to treatment with
siNT, with cell migration across the scratch area covering 88.8 + 1.2% of the width in the
siNT group and 63.7 + 15.6% in the siCSNK2A1 group (Fig. 3.7A, B). Although 60:1 did
demonstrate some inhibited wound recovery, with 24.7 + 13.7% of the wound area being
repopulated with cells in the siCSNK2A1 group, only the 80:1 ratio demonstrated
statistically significant reduction of migration, with only 9.9 + 7.2% wound closure in
siCSNK2A1 treated cells compared to 82.2 + 14.7% closure in cells treated with siNT (Fig.
3.7A, B). CAOV3 cells, treated with 80:1 DIV3W-siNT and siCSNK2A1, did not
exemplify statistically significant migration reduction after 72 hours, but siCSNKA1 did
impede recovery by 15.7% at 24 hours compared to siNT (Fig. 3.S4B, 3.S4C, D) .
To determine the effect of CSNK2A1 gene silencing on the long-term proliferative
potential of ovarian cancer cells, a clonogenic assay was performed. Treatment of ovarian
cancer cells with DIV3W-siNT complexes was compared with DIV3W-siCSNK2A1
complexes at an 80:1 N:P ratio (Fig. 3.7C, D). OVCAR3 and CAOV3 cells both exhibited
a statistically significant decrease in their ability to recolonize, with 78.5 + 2.5% and 76.4
+ 4.3% relative colonization, respectively, when treated with siCSNK2A1 in comparison
to siNT (Fig. 3.7E). This reduction in the ability of both cell lines to produce clones
confirms the prospect of CSNK2A1 as a gene target for ovarian cancer.
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Figure 3.7 Downstream cellular effects of CSNK2A1 knockdown.
DIV3W complexed with (A) siNT or siCSNK2A1 at an 80:1 N:P ratio was delivered to
OVCAR3 cells for 24 hours and the ability of the cells to migrate across a scratch
wound was observed using phase microscopy imaging over 72 hours. Scale bar:
1000µm. (B) Cell regrowth over the course of 72 hours was quantified with ImageJ
and represented as percent wound heal relative to the initial scratch distance. (D) White
light imaging of clonogenic colony-forming assay of OVCAR3 (C) and CAOV3 (D)
cells 14 days after treatment with DIV3W-siCSNK2A1 at 80:1 N:P ratio. (E)
Colonization was quantified via plate absorbance at 490 nm and normalized to siNT
negative control groups. Data are mean ± SEM of three independent experiments and
were analyzed using a two-way ANOVA with Tukey’s multiple comparisons posthoc
test and one-tailed T-test for scratch and clonogenic results, respectively, where * p <
0.05, ** p < 0.01, and **** p < 0.0001.
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3.4 Discussion
Endosomal entrapment of nanocarriers encapsulating siRNA and activation of the
lysosomal degradation pathway significantly hinders the translatability of siRNA therapies
through acidic degradation.34 Several nanoparticle systems are able to encapsulate and
deliver siRNA to cancer cells, but may have reduced biocompatibility and allow
insufficient endosomal escape.35–37 Cell penetrating peptides cause endosomal escape via
the proton sponge effect, but have been shown to induce cytotoxic effects on cells because
of their strong positive charge.38 Conversely, lipid and polymer nanoparticles have high
biocompatibility, but require the addition of cationic peptides or lipid/polymer formulation
changes to increase charge necessary for endosomal escape capabilities, but these
modifications can hinder uptake and increase cytotoxicity.39–42 This work explores novel
fusogenic peptides as a viable carrier for RNAi therapeutics by overcoming barriers of
cellular uptake, biocompatibility, and endosomal entrapment.
We have designed three fusogenic peptide sequences with a core amphiphilic
sequence repeat to enable endosomal membrane fusion in response to the acidic endosomal
environment, which are each attached to a poly-D-arginine tail to allow efficient
complexing of peptides with siRNA cargo through electrostatic interactions.22,43 We have
shown that each DIV3(X) peptide variants can efficiently complex with siRNAs, form
monodisperse nanoparticles, and protect siRNAs from serum and RNase degradation.
DIVA3 exhibited siRNA complexation at the lowest N:P molar ratio of 20:1, while DIV3H
and DIV3W completely complexed siRNAs at a 40:1 molar ratio. Lower peptide molar
ratios necessary for formation of DIVA3/siRNA complexes may contribute to the smaller
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hydrodynamic diameter of approximately 85 nm and lower zeta potential, near 20 mV,
whereas DIV3H and DIV3W require more peptide to complex siRNAs, contributing to
slightly higher diameters around 100 nm and zeta potentials near 30 mV. All DIV3(X)
peptide complexes formed monodisperse nanoparticles with sizes appropriate for
intravenous delivery. Analysis of the stability of the DIV3(X) complexes revealed that each
variant was able to protect siRNAs from degradation in the presence of serum and RNase
A. Protection from degradation in serum and RNase A provides support for the use of this
system in future work to include systemic administration and increased circulation time to
allow for complex accrual in the tumor microenvironment.
After characterizing the peptide/siRNA complexes, we examined the ability of the
fusogenic peptides to mediate efficient delivery of siRNAs into ovarian cancer cells in
vitro. DIV3W significantly outperformed DIVA3 and DIV3H in enhancing internalization
of siRNAs into OVCAR3 cells. We also observed that cellular internalization of siRNAs
into ovarian cancer cells increased with increasing N:P ratio for each peptide due to greater
hydrophobicity and positive charge. Increases in primary sequence hydrophobicity, and
therefore, hydrophobicity of the supramolecular assembled complex, conferred by the
tryptophan residue in DIV3W, may attribute to the increased internalization of siRNA by
DIV3W compared to the DIVA3 and DIV3H peptides. Peptide sequences including
tryptophan have previously been shown to increase cellular membrane affinity and
endocytotic activity,22,31,44 which was further validated in our studies with increased siRNA
internalization mediated by DIV3W. The DIV3W peptide demonstrated siRNA
internalization efficiencies of approximately 65% in OVCAR3 cells at each N:P ratio. The
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differences in endosomal entrapment and later escape, determined by levels of gene
knockdown, may be attributed to the increased affinity for pH-dependent conformation
change and increased hydrophobicity with the addition of histidine and tryptophan amino
acid residues, respectively.15,34,44,45 Though peptide conformational change to helical
secondary structure is required for α-helix formation,34 inclusion of the tryptophan residue
in DIV3W inherently enables higher membrane affinity with increased hydrophobicity
before pH changes occur, through the insertion of the hydrophobic R groups into the
endosomal membrane.44,45 Because of this, we suspect that DIV3W enhances endosomal
escape and release of bioactive siRNA into the cytosol. Furthermore, viability studies
demonstrated that DIV3(X) peptides did not cause cytotoxicity alone without siRNA cargo.
Selection of the optimal DIV3(X) peptide variant was confirmed through qPCR and
western blot analysis of siRNA bioactivity. DIV3W proved to significantly enhance
bioactivity of siRNAs, as evidenced by increased knockdown of CSNK2A1 mRNA in
ovarian cancer cells in comparison to the other peptide variants. At 60:1 and 80:1 molar
ratios, DIV3W-siCSNK2A1 complexes reduced the relative expression of CSNK2A1
mRNA in OVCAR3 cells by approximately 90% and 60%, respectively, compared to
treatment with DIV3W complexed with siNT. Although DIVA3 and DIV3H enabled
significant knockdown of the target gene at one of three N:P ratios, they did not cause
comparable knockdown to DIV3W-mediated delivery. We also confirmed significant
protein knockdown downstream of mRNA degradation following DIV3W-siCSNK2A1
delivery in ovarian cancer cells. DIV3W-siCSNK2A1 complexes exhibited significant
knockdown of CK2α protein expression at all N:P ratios. The bioactivity mediated by the
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DIV3(X) peptides also reflects the stability of the complexes in serum, since all gene
silencing experiments were conducted in the presence of serum to replicate physiologically
relevant conditions. The superior siRNA bioactivity achieved with DIV3W compared to
the other peptide variants aligns with previous assays, as DIV3W also demonstrated the
highest siRNA protection and endosomal escape. These results demonstrate the potential
of DIV3W as a delivery system for RNAi-based therapies and justify the selection of
DIV3W as the fusogenic peptide for analysis of ovarian cancer cellular response to
silencing the target gene.
CSNK2A1 has a vast array of roles in activation of cellular pathways and processes.
Many of these responses may be cancer type-dependent; studies have shown that CSNK2A1
activates phosphorylation of SIRT6 in breast cancer, the PI3K-Akt-mTOR pathway in
gastric cancer, and NF-κB in glioblastoma, all contributing to poor patient prognosis.46–48
In order to examine the effect of silencing CSNK2A1 expression on oncogenic activity in
ovarian cancer cells, viability, scratch migration, and colonization assays were completed
after treatment with DIV3W-siCSNK2A1 complexes. MTS viability experiments did not
show any significant loss of cell viability after a 48-hour treatment with DIV3WsiCSNK2A1 complexes compared to cells treated with DIV3W-siNT. Studies also show
that knocking down CSNK2A1 does not result in a loss in cell viability without additional
cell growth inhibition, due to CSNK2A1’s role in

cell processes and activation of

proliferative cell pathways in different cell types.25,28,49,50 Though silencing CSNK2A1 did
not affect cell viability, our results did demonstrate that silencing CSNK2A1 significantly
inhibited migration of ovarian cancer cells. Reduction in cell migration due to silencing
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CSNK2A1 is consistent with previous reports that show upregulated CSNK2A1 expression
contributes to increased cancer aggressiveness and decreased survivability rates in several
cancer types.46,49,51 Specifically, it has been demonstrated that CSNK2A1 expression
mediates the PI3K-Akt-mTOR pathway, attributing to increased oncogenesis, migration,
and invasion.47 Knockdown of CSNK2A1 via lentiviral transfection in gastric cancer cells
inhibited migration across a scratch wound in comparison to cells with high CSNK2A1
expression.47 It was also observed that CSNK2A1 knockdown in gastric cancer cells
reduced their invasion,47 which combined may correlate to decreased cancer cell regrowth
after treatment, reducing distant metastatic spread. Addionally, studies have shown that
overexpression of CSNK2A1 and its protein product, CK2α, enhance the clonogenic
survivability of melanoma cells.52 Our results are consistent with this observation;
silencing of CSNK2A1 mediated by the DIV3W peptide significantly reduced the
clonogenicity of OVCAR3 and CAOV3 ovarian cancer cells. This consistency between
cancer models also suggests that CSNK2A1’s roles in tumorigenesis can possibly be
narrowed to cell communication, enhancing migration and regrowth.
This study demonstrates the ability of a series of fusogenic peptides, comprised of
amphiphilic core repeats and a cationic poly-(D)-arginine tail, to efficiently complex with
and deliver siRNA into ovarian cancer cells. The fusogenic peptides are able to selfassemble with siRNAs to form monodisperse nanoparticles and protect siRNAs from
serum and RNase-mediated degradation. The DIV3W peptide proved optimal for
enhancing intracellular delivery, endosomal escape, and silencing of CSNK2A1 mRNA and
CK2α protein expression. Consequently, delivery of bioactive siCSNK2A1 resulted in
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significant inhibition of cancer cell migration and clonogenicity. These results demonstrate
the potential of the DIV3W peptide for delivery of RNAi therapeutics and the potential of
CSNK2A1 as a therapeutic gene target to reduce ovarian cancer invasiveness. Future studies
examining the efficiency or DIV3W-mediated siRNA delivery and efficacy of CSNK2A1
silencing in vivo are needed to further evaluate clinical translatability.

3.5 Materials and Methods
Cell Culture
Ovarian epithelial cancer cell lines, OVCAR3, obtained from the American Type
Culture Collection (ATCC, Manassas, VA), and CAOV3 (donated from Hollings Cancer
Center, Charleston, SC) were cultured in McCoy’s 5A culture medium and Dulbecco’s
Modified Eagles Medium (DMEM, ATCC) respectively, supplemented with 10% fetal
bovine serum (FBS, Corning, Corning, NY) and 1% penicillin/streptomycin (P/S)
antibiotic solution (Corning). All cultures were incubated at 37°C in 5% CO2.

Peptide Synthesis
Peptides

DIVA3

(WEADIVADIVADIVAGGG-(d)RRRRRRRRR),

(WEADIVADIVHDIVADIVAGGG-(d)RRRRRRRRR),

and

DIV3H
DIV3W

(WEADIVADIVWDIVADIVAGGG-(d)RRRRRRRRR) were synthesized, purified (>
95% purity), and analyzed via high performance liquid chromatography (HPLC) by
Genscript (Genscript USA Inc., Piscataway, NJ). All formulations contained an end
sequence of nine D-arginine residues with no terminal modifications. Lyophilized peptide
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formulations were resuspended in analytical grade dimethyl sulfoxide (DMSO) to create
stock peptide solutions of 100 µM (10 mg/mL). Working solutions of 10 µM (1 mg/mL)
were created using a 1:10 dilution of stock peptide in RNase-free water and all solutions
were stored at -80°C.

Gel Shift Assays
DIVA3, DIV3H, and DIV3W (all three denoted as DIV3(X)) peptides resuspended
in RNase-free water (10 µM) were thawed and kept on ice prior to complexation with 10
µM of negative control siGENOME non-targeting siRNA #5 (siNT, GE Healthcare
Dharmacon, Lafayette, CO) in RNase-free water and incubated for 20 minutes at room
temperature to allow formation of DIV3(X)-siNT complexes. Various molar ratios of
peptides were complexed with siNT at increasing N:P molar ratios to determine the
minimum molar ratio necessary to completely complex free siRNAs using an
electrophoretic mobility shift assay. To determine the ability of each peptide variant to
protect siRNAs from degradation, DIV3(X)-siNT complexes or siNT alone was left
untreated or incubated with either 50% v/v FBS or 5 µg/mL RNase A at 37°C for one hour.
After which, complexes were dissociated using 6% SDS. Samples were added to a 2%
agarose gel and run at 100 V. Gels were stained with ethidium bromide, subsequently
destained with Milli-Q water, and the gel was imaged using a ChemiDoc XRS imager (BioRad, Hercules, CA).

Dynamic Light Scattering and Transmission Electron Microscopy
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DIV3(X)-siNT complexes were prepared at 2 mg/mL in RNase-free water as
previously described. Hydrodynamic size and surface charge of the peptide/siRNA
complexes was determined using a Nano ZS Zetasizer (Malvern Panalytical, Malvern,
UK). All data was recorded using Malvern’s Zetasizer software.
In order to obtain transmission electron microscopy (TEM) images of the peptidesiRNA complexes, DIV3W-siNT complexes were prepared as previously described to a
concentration of 1 mg/mL in RNase-free water. After a 20-minute incubation, TEM
samples were prepared via drop casting onto a copper mesh grid. Following a 5-minute
drying period, remaining water was wicked away and the sample was background stained
with 1% uranyl acetate solution (Electron Microscopy Sciences, Hatfield, PA). Samples
were stored for 48 hours to allow for complete solution evaporation and sample
crystallization. TEM was completed using a Hitachi HT7800 microscope (Hitachi, White
Plains, NY and imaged at 80,000x magnification.

Cytotoxicity
Cells were seeded at 10,000 cells/well with complete culture media in a 96-well
plate and incubated overnight to allow the cells to attach. DIV3(X) peptides were
complexed with siNT at 40:1-80:1 N:P molar ratios. DIV3(X)-siNT complexes were
incubated with OVCAR3 or CAOV3 cells at a final concentration of 100 nM siRNA and
10% FBS for 24 hours, after which, media was aspirated, and cells were washed with 1x
phosphate buffered saline (PBS) and fresh media with 10% FBS was added to each well
and incubated another 24 hours.
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Viability was measured using an MTS Assay performed with CellTiter 96 AQueous
One Solution Cell Proliferation Assay (Promega, Madison, WI). Assay reagent was added
according to the manufacturer’s protocol and cells were incubated for 4 hours. Absorbance
was read using a BioTek Synergy LX (BioTek, Winooksi, VT) plate reader at 490 nm. An
MTS cell viability assay was also conducted as described for OVCAR3 and CAOV3 cells
treated with DIV3W-siRNA complexes.

Cellular Uptake
OVCAR3 and CAOV3 cells were prepared as previously described at 50,000
cells/well in a 24-well plate. DY547 fluorescently labeled siNT (siNT-DY547, GE
Healthcare Dharmacon). was complexed with the DIV3(X) peptides in RNase free water
at 40:1-80:1 N:P molar ratios and incubated with OVCAR3 or CAOV3 cells for 4 hours.
Post-incubation, media was aspirated, and cells were washed with 1x PBS. To counterstain
the nuclei, SuperSignal NucBlue Hoechst stain (Thermo Fisher, Waltham, MA) was added
to the cells for 30 minutes, followed by an additional 1x PBS wash. Subsequent imaging
was performed using an EVOS FL Microscope (Thermo Fisher) at 10x magnification. For
flow cytometric analysis, cells were detached, resuspended in 1x PBS, and analyzed using
an Attune NXT Acoustic flow cytometer (Invitrogen, Carlsbad, CA) with the blue laser line
and BL2 (574/26 nm) channel.
For analysis of endosomal escape, following the 4 and 8hour treatments, OVCAR3
and CAOV3 cells were fixed with 4% paraformaldehyde in 1x PBS and permeated with
0.5% Triton X-100 in 1x PBS for 15 minutes at room temperature Blocking was completed
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after washing three times with 1x PBS by incubating with 1% bovine serum albumin in 1x
PBS for 30 minutes at room temperature . Primary antibodies for early endosome antigen1 (rabbit anti-EEA1, Thermo Fisher) were diluted in 1x PBS (1:100) and incubated with
cells for 1 hour at 4°C in the dark. Following washing three times using 1x PBS, cells were
incubated with Alexa Fluor 488 goat anti-rabbit secondary antibodies (Invitrogen) in a
1:100 dilution at room temperature for 1 hour. Cells were washed three more times with
1x PBS, stained with SuperSignal NucBlue Hoechst 33342, and imaged using an EVOS
FL microscope at 10x magnification.

qRT-PCR
Cells were seeded at 50,000 cells/well as previously described and treated with
siRNA targeting CSNK2A1 (siCSNK2A1 #s3638, Thermo Fisher Scientific) at increasing
N:P ratios as described previously and incubated for a total of 48 hours in McCoys
5A/DMEM-10% FBS. Treated cells were washed with 1X PBS at 24 hours and fresh media
was added. RNA isolation was completed using a Qiagen Mini-RNeasy Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s protocol. RNA isolation quality and
quantity was measured through the Gen5 protocol using a Take3 plate (BioTek). RNA was
reverse-transcribed using the QuantiTect Reverse Transcription kit (Qiagen). Quantitative
real-time PCR was completed with a QuantStudio 3 qPCR system (Applied Biosystems)
using Applied Biosystems TaqMan FAST Master Mix (Thermo Fisher) and CSNK2A1 (ID#
Hs00751002_s1) and 18S (ID# Hs99999901_s1) predesigned TaqMan probes according
the manufacturer’s protocol.
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Western Blot
Cells were seeded at 100,000 cells/well with complete culture media in a 6-well
plate and left to incubate overnight. Cells were washed and treated with DIV3(X)-siRNA
complexes as previously described. Following the 48-hour treatment, cells were washed
with 1x PBS and lysed with cold radioimmunoprecipitation assay (RIPA) buffer
supplemented with protease inhibitor cocktail (Thermo Fisher). Protein concentrations
were determined via bicinchoninic assay according to the manufacturer’s protocol and
absorbance was read at 562 nm. Equivalent protein concentrations for each treatment
condition were separated by SDS-PAGE on a BioRad Stain-Free 10% gel according to
BioRad protocols and transferred to a Stain-Free PVDF membrane using a wet transfer
system. PVDF was cut at appropriate molecular weight intervals consistent with protein
weights analyzed and blocked for 1 hour with 5% non-fat dried milk solution in 1x TrisHCl-buffered-saline-0.1% Tween 20 (TBST) at room temperature. Blots were probed at
4°C overnight with rabbit monoclonal anti-CK2α antibody (1:1000, Invitrogen) or mouse
monoclonal anti-β-actin (1:10,000, Sigma-Aldrich, St. Louis, MO). Membranes were
washed five times with 1x TBST and incubated with goat anti-rabbit (1:1000, Thermo
Fisher) or goat anti-mouse (1:10,000, Thermo Fisher) secondary antibodies for 1 hour at
room temperature. Five additional washes with 1x TBST were performed and protein bands
were detected with SuperSignal West Pico Plus Chemiluminescent Substrate (Thermo
Fisher) and imaged using a BioRad ChemiDoc Imaging System.
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Cell Migration and Colonization Analysis
Scratch migration was completed by seeding OVCAR3 cells at 100,000 cells/well
in a 12-well plate to achieve near 100% confluency. Following a 48-hour treatment with
DIV3W-siCSNK2A1 or DIV3W-siNT complexes, a vertical and horizontal scratch was
made in the cell monolayer using a 200 µL micropipette tip and edges were smoothed using
a gentle wash with 1x PBS. Cells were imaged with an EVOS FL microscope at 4x
magnification at 24-hour intervals at the cross intersections to ensure consistent imaging
areas. Using image analysis software, measurements across the horizontal axis were taken
for each image with wound closure percentages calculated at each time point using the
equation below (Eq. 1) where ‘ti’ is the distance at any time point ‘i’ and ‘t0’ is distance at
time 0.
(𝑡𝑖 − 𝑡0 )
× 100] %
𝑡0
Equation 1. Formula for calulating percent wound heal in the scratch wound assay.
The distance at t = 0, t0, was deducted from each subsequent distance measurement, ti,
at t = i. Distance difference was normalized to t0 and subtracted from 100 to represent
the percent distance closed from t0 .
𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝑊𝑜𝑢𝑛𝑑 𝐻𝑒𝑎𝑙 (𝑡𝑖 ) = 100 − [

Colonization of treated cells was determined using a clonogenic assay and
quantified via absorbance at 490 nm. Cells were seeded at 50,000 cells/well in a 24-well
plate and treated with DIV3W- siCSNK2A1 or DIV3W-siNT complexes as previously
described. Cells were harvested, counted, and reseeded in a 6-well plate at a concentration
of 2,500 cells/well. Cell growth was monitored for a 14-day period with media changes
every 2 days. After the growth period, cells were washed with 1x PBS and stained with a
0.1% crystal violet solution for 30 minutes. Unbound crystal violet was washed with
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ddH2O and plates were air dried for 15 minutes and imaged with the ChemiDoc Imaging
System. Recolonization was quantified by dissolving bound crystal violet in a 33% acetic
acid solution and transferring 100 µL of each treatment group to a 96-well plate in
triplicate. Absorbance was measured at 490 nm using a BioTek Synergy LX plate reader.

Statistical Analysis
All data are mean + SEM of three independent experiments. Statistical comparisons
were carried out using GraphPad Prism 8.4.3. Comparisons between two independent
groups were conducted using a Student’s t-test. Three or more independent groups with
one factor was analyzed using ANOVA and post-hoc Tukey comparisons and three or more
independent groups with two factors was analyzed using two-way ANOVA, also with posthoc Tukey comparisons. Results are considered statistically significant where p < 0.05.
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3.6 Supplemental Data

Figure 3.S1 Fusogenic peptide uptake efficiency in vitro in CAOV3 cells.
(A) Fluorescence microscopy of siRNA uptake in CAOV3 cells untreated (UNTD),
treated with siNT alone, or treated with DIV3(X) peptide-siNT-DY547 (red)
complexes for 4 hours. Cells are counterstained with Hoechst (blue). Scale bar: 100
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µm. (B, C) Flow cytometric analysis of DIV3(X)-siNT-DY547 uptake into CAOV3
cells after 4 hours. Data are mean ± SEM of three independent experiments analyzed
with one-way ANOVA and posthoc Tukey multiple comparisons testing, where * p <
0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Figure 3.S2 Endosomal escape ability of DIV3W in CAOV3 cells.
Immunofluorescence microscopy of early endosome antigen-1 (green) after incubation
of CAOV3 cells with siNT-DY547 (red) complexed with DIV3(X) peptides at a 60:1
N:P ratio for 4 and 8 hours. Colocalized green and red fluorescence (yellow) indicates
endosomal entrapment of the peptide/siRNA complexes, identified with white arrows,
while siRNA that has escaped can be seen in red in the overlay image. Cell nuclei are
counterstained with Hoechst 33342 (blue). Scale: 20 µm.

Figure 3.S3 Fusogenic-mediated bioactivity of siRNAs in CAOV3 cells.

145

qPCR analysis of CSNK2A1 mRNA after treatment of CAOV3 cells with DIV3W (A)
peptide complexed with siNT or siCSNK2A1 for 48 hours. Data are mean + SEM of
three independent experiments analyzed with Student’s t-test within each N:P ratio,
where * p < 0.05 and *** p < 0.001. (B) Western blot analysis of CSNK2A1 protein
product, CK2α, after treatment of CAOV3 cells with DIV3W-siCSNK2A1 for 48
hours. β-Actin expression was monitored to ensure equal protein loading.

Figure 3.S4 Downstream cellular effects of CSNK2A1 knockdown con’t.
(A) DIV3W complexed with siNT or siCSNK2A1 was delivered to OVCAR3 and
CAOV3 cells, and the viability of the cells was quantified after 48-hour complex
treatment. (B) CAOV3 cell percent wound heal over the treatment period of 72 hours.
(C) CAOV3 ability to close a wound after treatment with 80:1 DIV3W-siNT or
DIV3W-siCSNK2A1 complexes. Data are mean ± SEM of three independent
experiments and were analyzed using a two-way ANOVA with Tukey’s multiple
comparisons posthoc test.
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Abstract
Analyzing therapeutic delivery systems in vitro provides a basis for determining
therapeutic efficacy but can fall short in reproducing a clinically relevant tumor
microenvironment. By examining the performance of a nanoparticle delivery vehicle in
vivo, conclusions can be made on the stability and efficacy when faced with delivery
barriers such as serum degradation, rapid clearance, and tumor penetration. Xenograft
mouse models have been extensively used to create a clinically relevant tumor
microenvironment both subcutaneously and intraperitoneally. With this work, we have
established both a subcutaneous and intraperitoneal xenograft tumor model in nude mice
to evaluate the efficacy of the DIV3W fusogenic peptide to deliver bioactive siRNAs. By
establishing these models, we shown that the DIV3W peptide is able to complex with and
deliver siRNAs to both subcutaneous and intraperitoneal tumors visualized with IVIS
fluorescent imaging. Subcutaneous tumors specifically showed significant siRNA
fluorescence and were selected for bioactivity and anticancer studies due to
intraperitoneal tumor metastasis and rapid abdominal fluid accumulation. When delivered
intratumorally to subcutaneous tumors, DIV3W-mediates tumor penetration and uptake,
and release of bioactive siRNAs to reduce expression of the CSNK2A1 gene in a single
dose and in multidose treatment regimens. The multidose study gives support to the
DIV3W peptide as a viable delivery vehicle and CSNK2A1 and a relevant gene target by
showed significantly reduced tumor growth rates compared to saline and siNT controls.
Keywords – fusogenic peptide, RNAi, gene therapy, ovarian cancer, in vivo, mouse
model
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4.1 Introduction
With nearly 21,000 deaths due to ovarian cancer expected in the U.S. in 2021 and
a 5-year survival rate of 27% in stage III and 16% in stage IV diagnoses, there is a
significant need for improved treatment strategies and options.1 The growth and migration
rate of epithelial ovarian cancer is the largest contributor to disease severity and late-stage
diagnoses, as most patients are not diagnosed until distant metastases are observed, leading
to the low survival rates mentioned.2,3 Upon diagnosis, aggressive therapeutic approaches
are implemented through surgical mass removal and systemic administration of platinumbased chemotherapeutics; however, a vast majority of patients experience relapse and
progression of disease.4–7
Gene therapy through RNA interference (RNAi) has garnered much attention in
recent years and has had several successful applications both in vivo and in clinical
models.8–11 While this mechanism of cancer therapy is attractive, there are several barriers
that complicate efficient delivery of bioactive siRNA: degradation by serum endonucleases
and RNases, poor interaction with the cell membrane restricting cellular uptake, and
entrapment in the endosomal compartment resulting in lysosomal trafficking and
degradation.12,13 These issues necessitate a robust nanocarrier that can fully complex and
protect siRNAs as well as deliver the siRNA cargo into target cells and facilitate endosomal
escape. Peptide-based nanocarriers have shown great ability to deliver RNAi therapeutics
to cancer cells in vitro and in vivo.14–17 Specifically, fusogenic peptides have been used to
encourage rapid endosomal membrane destabilization and release of siRNA cargo into the
cytosol, allowing for recruitment of RNAi machinery and mRNA destruction.18–21 We have
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previously demonstrated the efficacy of a novel fusogenic peptide, termed DIV3W, to
deliver siRNAs to ovarian cancer cells in vitro, causing significant knockdown in target
gene mRNA and protein expression (See chapter 3).
Our previous results demonstrated that silencing of CSNK2A1 inhibited migration
of ovarian cancer cells across a scratch wound and recolonization in comparison to nontargeting siRNA (siNT). Though CSNK2A1 and its protein product, CK2α, is not entirely
well understood in ovarian cancer, our in vitro results suggest a significant role in cell-cell
communication and increased cell migration, possibly causing high rates of metastasis,
recurrence, and aggressiveness in clinical models.22–25 Thus, our current work evaluates
the ability of the DIV3W peptide to efficiently deliver siRNAs in vivo and mediate
knockdown of CSNK2A1 gene expression in a well-characterized xenograft mouse model
of ovarian. Two tumor models, intraperitoneal (IP) and subcutaneous (SQ), were
established for examination of DIV3W-mediated siRNA biodistribution and bioactivity to
ensure consistent tumor formation using OVCAR3 cells in at least one model. SQ tumors
were treated via intratumoral (IT) injection and IP tumors were treated via IP
administration of peptide-siRNA complexes. Our results showed that DIV3W effectively
enhanced siRNA localization in ovarian tumor tissue in both models via IP or SQ
administration. siRNA uptake was most enhanced via IT administration in SQ tumors,
causing significant knockdown of CSNK2A1 mRNA after 48 hours. Further, a multidosing
study of DIV3W-siCSNK2A1 in SQ ovarian tumors resulted in 42.6% reduction in tumor
volume, further supporting the role of CSNK2A1 in oncogenesis.
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Figure 4.1. Graphical abstract of in vivo experimental procedures using DIV3W
peptide to deliver siRNAs in a xenograft tumor model of ovarian cancer.

4.2 Materials and Methods
Peptide Synthesis and siRNA Complexation
DIV3W peptide (WEADIVADIVWDIVADIVAGGGGG-dR9) was synthesized to
> 95% purity at GenScript Inc. (Piscataway, NJ). Complexation of the DIV3W peptide
with Cy5.5-labeled siGENOME non-targeting #5 siRNA (siNT-Cy5.5, Dharmacon,
Lafayette, CO), non-targeting siRNA, (siNT, Dharmacon), and CSNK2A1-targeted
siRNA, (siCSNK2A1, #s3638, ThermoFisher, Waltham, MA) was previously described
(See chapter 3). Briefly, DIV3W peptides (10 µM) were incubated for 20 minutes with 100
µM siNT, siNT-Cy5.5, or siCSNK2A1 to a final siRNA dosage of 0.5 mg/kg.

Cell Culture
The epithelial ovarian cancer cell line OVCAR3 was purchased from the American
Type Culture Collection (ATCC, Manassas, VA). OVCAR3 cells were cultured in RPMI
1640 media supplemented with 20% fetal bovine serum (FBS), 1% penicillin/streptomycin,
and 0.1% bovine insulin. Cells were maintained at 37°C, 5% CO2. RPMI 1640 media was
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replaced with phenol-red free RPMI 1640 prepared with the same supplements two days
prior to harvesting and preparation of cells for animal injections.

Generation of Tumor Xenografts
All mouse procedures and experiments were approved by the Clemson University
Institutional Animal Care and Use Committee (IACUC) and completed in accordance with
the Guide for the Care and Use of Laboratory Animals (NIH) and Godley-Snell Animal
Research Facility (GSRC) Animal Use policies. Procedures for the generation of xenograft
subcutaneous and intraperitoneal ovarian cancer tumors were derived and modified from
previous works.9,26,27 Athymic nude-FoxN1nu mice were obtained at 6-7 weeks of age
(Envigo, Indianapolis, IN). OVCAR3 cells were cultured and grown to 70-75% confluence
as described previously, harvested, and 10 x 106 cells were suspended in 100 µL of 10%
Matrigel matrix suspension (Corning, Corning, NY) in 1:1 ratio (v/v) of media/Matrigel.
Cell suspensions were injected into mice either SQ on the right flank or IP into the lower
right quandrant from animal perspective. Tumors were allowed to grow for 14 days before
administration of treatment.

In Vivo and Ex Vivo Imaging
After tumor growth was established and tumors measured at least 50 mm3, siNTCy5.5 alone or DIV3W-siNT-Cy5.5 complexes at an siRNA dosage of 0.5 mg/kg were
delivered intratumorally to SQ tumors or intraperitoneally to IP tumors. Animals were
imaged at 3, 6, 12, and 24 hours post-treatment using the PerkinElmer IVIS Spectrum In
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Vivo Imaging System (PerkinElmer, Waltham, MA). Gray scale images were obtained
using 2x2 binning and fluorescent images were captured using the Cy5 optical filter also
using 2x2 binning. Images were acquired and formatted to inverted rainbow spectrum using
LivingImage software (PerkinElmer) and exported for fluorescence intensity quantification
using Aura software (Spectral Instruments, Tucson, AZ).Following the final 24-hour
imaging, animals were euthanized according to IACUC and GSRC protocols, and tumor,
heart, lungs, liver, kidneys, and spleen were explanted for ex vivo imaging with
quantification as described.

qPCR Analysis
SQ and IP tumors were treated with saline, DIV3W-siNT, or DIV3W-siCSNK2A1
for either 48 hours or in a multidose schedule over a 2-week period. Mice were injected
with 0.5 mg/kg of siRNA at each treatment, and multidosing occurred every 3 days for 4
doses. Tumors were measured in two dimensions using digital calipers and tumor volumes
calculated using the formula: d2 x D/2, where d is the smaller dimension.18 Mice were
euthanized 48 hours post-injection of the final dose. Tumors were resected after euthanasia
and stored in RNAlater (Thermo Fisher). Tumors were measured for volume using the
equation described and weighed. Tumor tissue was then homogenized, and lysate was
processed using a Qiagen AllPrep RNA/Protein kit (Qiagen, Hilden, Germany). RNA
isolation was performed according to Qiagen protocols and was quantified using a Take3
plate (BioTek, Winooksi, VT) and the Gen5 analysis software. RNA was reversetranscribed using the QuantiTect Reverse Transcription kit (Qiagen). Quantitative real-time
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PCR was completed with a QuantStudio 3 qPCR system (Applied Biosystems) using
Applied Biosystems TaqMan FAST Master Mix (Thermo Fisher) and CSNK2A1 (ID#
Hs00751002_s1), AKT1 (ID#Hs00178298_m1), VMAC (ID#Hs00418522_m1), CD274
(ID#Hs00204257_m1), and 18S (ID# Hs99999901_s1) predesigned TaqMan probes
according the manufacturer’s protocol.

Western Blot Analysis
Tumors were homogenized as previously described. Lysates was processed using
the Qiagen AllPrep RNA/Protein kit (Qiagen) and total protein was quantified via
bicinchoninic assay according to the manufacturer’s protocol. Equivalent protein
concentrations for each treatment condition were separated by SDS-PAGE on a BioRad
Stain-Free 10% gel according to BioRad protocols and transferred to a Stain-Free PVDF
membrane using a wet transfer system. PVDF was cut at appropriate molecular weight
intervals consistent with protein weights and blocked for one hour with 5% non-fat dried
milk solution in 1x Tris-HCl-buffered-saline-0.1% Tween 20 (TBST) at room temperature.
Blots were probed at 4°C overnight with rabbit monoclonal anti-CK2α antibody (1:1000,
Invitrogen) or mouse monoclonal anti-β-actin (1:10,000, Sigma-Aldrich, St. Louis, MO).
Membranes were washed five times with 1x TBST and incubated with goat anti-rabbit
(1:1000, Thermo Fisher) or goat anti-mouse (1:10,000, Thermo Fisher) secondary
antibodies for one hour at room temperature. Five additional washes with 1x TBST were
performed and protein bands were detected with SuperSignal West Pico Plus
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Chemiluminescent Substrate (Thermo Fisher) and imaged using a BioRad ChemiDoc
Imaging System (BioRad, Hercules, CA).

Immunocytochemistry
Tumor tissue was snap frozen in OCT compound and sectioned to 5 µm using a
Microm HM550 Cryostat (Thermo Fisher). Sections were placed on slides and allowed to
thaw for 10 min at room temperature before being fixed and permeated with ice cold
acetone for another 10 min. Tissues were blocked using 10% BSA in 1x PBS solution for
20 min and incubated with anti-CSNK2A1 mouse monoclonal anitbodies (1:100, SigmaAldrich) diluted in 1% BSA containing 1x PBS for 1 hour at room temperature. Tissues
were washed twice with 1x PBS and incubated for 1 hour with Alexa Fluor 488-conjugated
donkey anti-mouse secondary antibodies also in 1% BSA 1x PBS solution. Slides were
mounted with a glass coverslip using VECTASHIELD HardSet Mounting Medium with
4′,6-diamidino-2-phenylindole (DAPI, VECTOR Laboratories, Burlingame, CA) and
imaged using an EVOS FL Microscope at 20x magnification. Fluorescence area data were
calculated using Fiji ImageJ Color Threshold and Analyze Particles tools.

Statistical Analysis
Data were acquired to N = 3 in biodistribution studies, N = 4 in bioactivity analysis,
and N = 5 in anticancer effects for all experimental groups. Saline controls were complete
to N = 2 in bioactivity experiments. All data are reported as mean + SEM and comparisons
between groups of three or more with one independent variable being analyzed by one-
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way ANOVA and groups of three or more with more than one independent variable
analyzed by two-way ANOVA, all with multiple comparisons between groups using
GraphPad Prism 8.4.3.

4.3 Results
4.3.1 DIV3W-siCy5.5 Distribution via Intratumoral and Intraperitoneal Route of
Administration
Mice with subcutaneous and intraperitoneal tumors were treated with either
DIV3W-siNT-Cy5.5 or siNT-Cy5.5 alone. SQ tumors were directly injected intratumorally
and IP tumors were treated via intraperitoneal injections. Over the course of 24 hours,
DIV3W-mediated delivery of siNT-Cy5.5 exhibited significant tumor localization of
fluorescent siNT signal, specifically at 3, 6, and 12-hour post-injection in comparison to
siNT-Cy5.5 for all IP treatments (Fig. 4.2A, B, E). Intratumorally delivered DIV3W-siNTCy5.5 complexes exhibited a significantly higher fluorescence intensity over the course of
24 hours, at nearly all time points, in comparison to siNT-Cy5.5 alone. Additionally, these
intratumoral injections of DIV3W-siNT-Cy5.5 remained localized to the tumor when
compared to the intraperitoneal diffusion in the IP tumor model.
Regarding intraperitoneal delivery, DIV3W-siNT-Cy5.5 also showed higher
fluorescence intensity in comparison to siNT-Cy5.5 alone (Fig. 4.2E). Further, IVIS
imaging revealed differences in the localization of flurescent signal; focal distribution of
siRNA over the SQ tumor was observed in intratumoral treatments (Fig. 4.2A) while
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regional fluorescence within the entire IP cavity was observed for IP tumors with
intraperitoneal treatment (Fig. 4.2B). Both SQ and IP injection of DIV3W-siNT-Cy5.5
complexes exhibited higher fluorescence across the entire 24-hour period in comparison to
siNT-Cy5.5 alone, suggesting increased peptide protection of siRNA cargo. Ex vivo
imaging of harvested organs and tumors from the SQ group (Fig. 4.2C) and IP group (Fig.
4.2D) revealed higher fluorescence intensity of siNT-Cy5.5 in the SQ tumor tissue in
comparison to other tissues. Both SQ and IP tumors exhibited some distribution of siRNA
fluorescence in the liver, Low siRNA fluorescence was also being observed in the kidneys
of mice with SQ tumors and spleen of mice with IP tumors.
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Figure 4.2 Intratumoral and intraperitoneal biodistribution of siNT-Cy5.5 cargo.
Mice with SQ tumors (A) and IP tumors (B) were treated with either siNT-Cy5.5 or
DIV3W-siNT-Cy5.5. SQ tumors and IP tumors received intratumoral and
intraperitoneal injection of siRNA, respectively. Images were acquired at 3, 6, 12, and
24 hours prior to ex vivo imaging of SQ (C) and IP (D) tumors and organs, with image
normalization to siNT-Cy5.5 mice using Aura software for quantitative analysis (E).
siNT-Cy5.5 fluorescence intensity is indicated through redshift using an inverted
rainbow heatmap. Quantification of siRNA biodistribution is reported as total photon
emission in the tumor area (photons/s) + SEM of three independent samples, where
**** p < 0.0001, * p < 0.05 as determined by two-way ANOVA with multiple
comparisons.
4.3.2 DIV3W-Mediated Delivery of siCSNK2A1 Causes Gene Silencing in SQ Tumors
After a Single-Dose Treatment
Bioactivity of siRNAs delivered via DIV3W was evaluated in both SQ and IP
tumor models (Fig. 4.3A) 48 hours post-treatment. In a single dose of 0.5 mg/kg siRNA,
DIV3W-siCSNK2A1 efficiently silenced expression of CSNK2A1 mRNA to 22.53% +
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8.24% when delivered intratumorally to SQ tumors in comparison to saline and DIV3WsiNT controls (Fig. 4.3B). Thus, subsequent multidosing treatments were conducted using
SQ tumors which successfully demonstrated efficient siRNA delivery and gene
knockdown. Also noted were multiple IP metastatic events prior to DIV3W-siRNA
treatments (Fig. 4.4). Delivery of OVCAR3 cells to the IP cavity, even with 50% v/v
matrigel substrate, were not able to be confined to one location, resulting in spreading
throughout the abdomen. Several mice with intraperitoneal metastasis were identified in
the DIV3W-siCSNK2A1 group, which may have contributed to the increased CSNK2A1
expression within the IP harvested tumors.

Figure 4.3 DIV3W-siCSNK2A1 delivery causes knockdown of CSNK2A1 when
delivered intratumorally to SQ tumors.
Subcutaneous (A) treated with DIV3W-siCSNK2A1 have significantly reduced
CSNK2A1 mRNA expression in comparison to DIV3W-siNT and saline control
treatments (B). Data are reported as mean + SEM of relative CSNK2A1 expression
normalized to siNT for four independent experiments for siNT and siCSNK2A1, and
two experiments for saline-treated groups, where * p < 0.05 and ** p < 0.01 compared
to saline and DIV3W-siNT determined by one-way ANOVA.
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Figure 4.4 OVCAR3 cells cause metastasis in DIV3W-siNT treated animals in the
IP cavity.
Internal metastasis of OVCAR3 cells in IP-developing mice indicated with red circles.

4.3.3 DIV3W-siCSNK2A1-mediated Knockdown of CSNK2A1 Reduces Tumor Burden
in SQ Tumors Following a Multidosing Schedule
A multidosing study was completed to evaluate the clinical efficacy of the
DIV3W peptide delivery system and CSNK2A1 as a gene target with therapeutic
relevance. 5 animals in each treatment group, saline, DIV3W-siNT, and DIV3WsiCSNK2A1 received 4 therapeutic doses over a 2-week period and were evaluated for
CSNK2A1 gene silencing (Fig. 4.5A), CK2α protein silencing (Fig. 4.5B, C) and,
changing tumor volume over time (Fig. 4.6A).
Through qPCR analysis, mice treated with DIV3W-siCSNK2A1 yielded only
37.7 + 11.2% CSNK2A1 gene expression when compared to saline controls and to 16.4%
+ 11.2% compared to DIV3W-siNT treated animals (Fig. 4.5A). Downstream from
mRNA knockdown, a reduction in CK2α protein production was also noted through
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western blotting (Fig. 4.5B) and immunocytochemistry (Fig. 4.5C). In response to this
significant knockdown of CSNK2A1, DIV3W-siCSNK2A1 treatments reduced the tumor
growth rate such that the final measurement was just 33.37 + 26.68 mm3 larger than the
tumor volume at the time of the first injection in the multidose schedule (Fig. 4.6B).
DIV3W-siNT treated animals resulted in 205.25 + 25.77 mm3 total tumor volume
increase and saline treated animal tumors grew 224.22 + 78.51 mm3 over the course of
the study (Fig. 4.6B). Final tumor masses and volumes were also recorded following
tumor retrieval (Fig. 4.6C, D). Tumor volume was most affected by the DIV3WsiCSNK2A1 treatment, as this treatment group yielded a total mean final volume of 78.29
+ 18.07 mm3, significantly smaller than the saline growth to a final volume of 270.67 +
80.21 mm3 and DIV3W-siNT volume of 266.74 + 27.37 mm3.
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Figure 4.5 DIV3W-siCSNK2A1 mediates CSNK2A1 and CK2α silencing delivered
in a multidose regimen.
CSNK2A1 gene expression was quantified via qPCR relative to DIV3W-siNT treated
controls and analyzed via one-way ANOVA where N = 5 and ** p < 0.01 (A). Western
blot analysis of CK2α knockdown caused by CSNK2A1 gene silencing (B).
Immunocytochemistry of CK2α protein expression (green) in 0.5 µm tumor tissue
sections with nuclei stained DAPI (blue) (C). Scale = 50 µm.
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Figure 4.6 DIV3W-siCSNK2A1 mediates tumor growth reduction.
Tumor growth over time (A) for saline, DIV3W-siNT, and DIV3W-siCSNK2A1
treated animals of the multidose schedule. (B) Tumor volume change from treatment
injection 1 through final excised volume measurement. Tumor mass (C) and tumor
volumes (D) recorded after euthanasia and tumor harvesting. Data were acquired to N
= 5 and analyzed via one-way ANOVA where * p < 0.05.
4.4 Discussion and Conclusions
RNAi is an promising option as an alternative or supplementary treatment to
chemotherapy in the oncologic clinical space.28 Several studies have shown the potency of
gene knockdown by delivering siRNAs either locally or systemically to tumor tissue,
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yielding anticancer effects and reduction of tumor growth when compared against saline
or non-targeting controls.9,29,30 However, barriers to clinical translation are still prevalent,
with many delivery systems via serum degradation and rapid clearance through the
reticuloendothelial system.13,31 Peptide systems, particularly fusogenic peptides, have
exhibited the ability to complex and protect siRNAs to overcome hallmark barriers to
translation of drug and gene delivery systems.32–34 We have shown in previous work that
the fusogenic DIV3W peptide can mediate delivery of bioactive siRNAs in vitro, causing
a significant reduction in targeted mRNA and protein expression. Further, silencing of the
target oncogene, CSNK2A1, reduced the ability of ovarian cancer cells to migrate and
recolonize after treatment (See chapter 3). To further evaluate the clinical translatability of
this peptide system as a gene delivery tool, we examined the DIV3W peptide’s ability to
delivery bioactive siRNAs into ovarian tumor tissue using a xenograft murine model.
The cell line used in this study, OVCAR3, was selected because of its clinical
relevance to high-grade serous ovarian adenocarcinoma in addition to its use in our
previous in vitro work.35,36 However, this cell line has had some difficulty in developing
xenograft tumor models without the use of a supplementary basement matrix or delivering
high quantities of cells.26,36–39 To address this issue, we delivered 10x106 cells OVCAR3
cells in a 50% v/v solution containing 10% Matrigel. Using this cell dosage, tumors were
formed subcutaneously and were easily observed, but IP injected cells exhibited sporadic
development of palpable tumors. Additionally, IP delivery of cell/Matrigel suspensions
were easily disseminated throughout the IP cavity, and resulted in the growth of multiple
tumors with higher likelihood of significant tumor burden.
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After establishing the tumor model both through SQ and IP growth, we examined
the ability of the DIV3W peptide to deliver fluorescent siRNAs to the tumor environment
and remain local to the TME for 24 hours. Following the in vitro results discussed in
chapter 3, DIV3W-mediated delivery of siNT-Cy5.5 resulted in increased fluorescence in
the tumor for both the SQ and IP groupings in comparison to siNT-Cy5.5 alone.
Additionally, intratumoral injected SQ tumors exhibited high fluorescence intensity in a
focal area, suggesting DIV3W’s ability to remain in the TME and protect these siRNAs in
a physiological environment over time. This protection was also observed in the
intraperitoneal delivery route, though fluorescence was not as locally observed in the tumor
area. It is important to consider though that the DIV3W peptide is not functionalized with
an active targeting system, so distribution across the abdominal area is not a surprising
result.
Significant fluorescence intensity and localization to the tumor through
intratumoral delivery in SQ models caused the selection of this model for bioactivity and
anticancer studies, in addition to the metastatic events observed in animals with IPdeveloped tumors. When treated with DIV3W-siCSNK2A1, SQ tumor homogenate
yielded significantly less CSNK2A1 mRNA expression. Compared to saline and DIV3WsiNT controls, DIV3W-siCSNK2A1 groups only showed 22.53% + 8.24% gene
expression. In addition to tumor retention, the DIV3W peptide is causing cellular uptake
and endosomal membrane fusion, releasing bioactive siRNAs for activation of the RNAi
pathway. These results are in alignment with our previous work and suggest a therapeutic
potential for our delivery system and for CSNK2A1 as a target (see chapter 3). However,
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in order to further support this claim, a multidose schedule of saline, DIV3W-siNT, and
DIV3W-siCSNK2A1 was completed to evaluate the downstream effects of tumor growth
after gene knockdown.
Anticancer studies were completed through a two-week multidose schedule of
saline, DIV3W-siNT, or DIV3W-siCSNK2A1 treatment every 3 days for a total of 4
doses. Significant knockdown of the CSNK2A1 gene and its protein product CK2α were
observed for animals treated with DIV3W-siCSNK2A1. Tumor volume and mouse mass
changes were recorded over the total treatment period and DIV3W-siCSNK2A1 caused a
repressed rate of tumor growth compared to saline and DIV3W-siNT controls. Saline and
DIV3W-siNT treated animals were reported to grow tumors to 208.7 + 40.7 mm3 and
189.76 + 15.36 mm3 respectively, with DIV3W-siCSNK2A1 treated SQ tumors only
grew to an average volume of 119.82 + 29.7 mm3. Translating these measurements to
relative total growth, DIV3W-siCSNK2A1 treated tumors only grew to 57.41% +
14.23% of saline treated tumors. The significance of tumor growth suppression speaks to
the ability of siCSNK2A1 to reduce cell migration as reported in our previous work (see
chapter 3). This migration reduction possibly plays a role in expansion of the tumor
volume and reduced growth rates observed using DIV3W-siCSNK2A1 in SQ tumors.
The work highlighting the ability of the DIV3W fusogenic peptide to deliver
bioactive siRNAs in vivo and suppressing tumor growth provides support to the clinical
applicability of the peptide system and gene target CSNK2A1. We have shown the
increased tumor retention and fluorescence of siRNA when delivered via DIV3W in
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comparison to siRNA delivered alone, highlighting the complexation and protection of
therapeutic cargo in a physiological environment. Additionally, the significant
knockdown of CSNK2A1 in a SQ tumor showing efficient endosomal escape and release
of bioactive siRNAs, lends to the fusogenic capabilities of the DIV3W peptide and role
fusogenic peptides play in therapeutic delivery. This gene knockdown caused reduction
in tumor growth and reinforces the clinical relevance of CSNK2A1 in ovarian cancer
growth. DIV3W has the ability to be a robust delivery vehicle for nucleic acid therapies
and future works will evaluate further enhancements of the peptide system as well as
whether this peptide system has the ability to complex and deliver other gene therapies.

167

References
1.

Siegel RL, Miller KD. Cancer Statistics , 2021. CA: A Cancer Journal for Clinicians.
2021;71(1):7-33. doi:10.3322/caac.21654

2.

Doubeni C, Doubeni A, Myers A. Diagnosis and management of ovarian disorders.
American Family Physician. 2016;93(11):937-944. doi:10.1016/s0301-2115(96)02679-6

3.

Grunewald T, Ledermann JA. Targeted Therapies for Ovarian Cancer. Best Practice &
Research Clinical Obstetrics & Gynaecology. 2017;41:139-152.
doi:10.1016/j.bpobgyn.2016.12.001

4.

Pepa C Della, Tonini G, Pisano C, et al. Ovarian cancer standard of care: Are there real
alternatives? Chinese Journal of Cancer. 2015;34(1):17-27. doi:10.5732/cjc.014.10274

5.

Marth C, Reimer D, Zeimet AG. Front-line therapy of advanced epithelial ovarian
cancer: standard treatment. Annals of Oncology. 2017;28(suppl_8):viii36-viii39.
doi:10.1093/annonc/mdx450

6.

Penet MF, Krishnamachary B, Wildes FB, et al. Ascites volumes and the ovarian cancer
microenvironment. Frontiers in Oncology. 2018;8(DEC):1-8.
doi:10.3389/fonc.2018.00595

7.

Luvero D, Milani A, Ledermann JA. Treatment options in recurrent ovarian cancer:
Latest evidence and clinical potential. Therapeutic Advances in Medical Oncology.
2014;6(5):229-239. doi:10.1177/1758834014544121

8.

Alexander-Bryant AA, Zhang H, Attaway CC, et al. Dual peptide-mediated targeted
delivery of bioactive siRNAs to oral cancer cells in vivo. Oral Oncology.
2017;72(9):123-131. doi:10.1016/j.oraloncology.2017.07.004

168

9.

Hatakeyama H, Wu SY, Mangala LS, Lopez-berestein G, Sood AK, Medicine R.
Assessment of in vivo siRNA delivery in cancer mouse models. 2016;(3):189-197.
doi:10.1007/978-1-4939-3378-5

10.

Zhang MM, Bahal R, Rasmussen TP, Manautou JE, Zhong X bo. The growth of siRNAbased therapeutics: Updated clinical studies. Biochemical Pharmacology. 2021;189.
doi:10.1016/j.bcp.2021.114432

11.

Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A. RNAi-mediated genetargeting through systemic application of polyethylenimine complexed siRNA in vivo.
Gene Therapy. 2005;12:461-466.

12.

Cummings JC, Zhang H, Jakymiw A. Peptide carriers to the rescue: overcoming the
barriers to siRNA delivery for cancer treatment. Published online 2019:92-104.
doi:https://doi.org/10.1016/j.trsl.2019.07.010

13.

Sajid MI, Moazzam M, Tiwari RK, Kato S, Cho KY. Overcoming barriers for siRNA
therapeutics: From bench to bedside. Pharmaceuticals. 2020;13(10):1-25.
doi:10.3390/ph13100294

14.

Hou K, Pan H, Schlesinger P, Wickline S. A Role for Peptides in Overcoming
Endosomal Entrapment in siRNA Delivery – A Focus on Melittin. Biotechnoogy Ad.
2015;33:931-940. doi:10.1016/j.biotechadv.2015.05.005.A

15.

Egorova A, Shubina A, Sokolov D, Selkov S, Baranov V, Kiselev A. CXCR4-targeted
modular peptide carriers for efficient anti-VEGF siRNA delivery. International Journal
of Pharmaceutics. 2016;515(1-2):431-440. doi:10.1016/j.ijpharm.2016.10.049

169

16.

Sakurai Y, Hatakeyama H, Sato Y, et al. Endosomal escape and the knockdown
efficiency of liposomal-siRNA by the fusogenic peptide shGALA. Biomaterials.
2011;32(24):5733-5742. doi:10.1016/j.biomaterials.2011.04.047

17.

Al-Husaini K, Elkamel E, Han X, Chen P. Therapeutic potential of a cell penetrating
peptide (CPP, NP1) mediated siRNA delivery: Evidence in 3D spheroids of colon cancer
cells. Canadian Journal of Chemical Engineering. 2020;98(6):1240-1254.
doi:10.1002/cjce.23743

18.

Cantini L, Attaway CC, Butler B, Andino LM, Sokolosky ML, Jakymiw A. FusogenicOligoarginine Peptide-Mediated Delivery of siRNAs Targeting the CIP2A Oncogene into
Oral Cancer Cells. PLoS ONE. 2013;8(9). doi:10.1371/journal.pone.0073348

19.

Charloteaux B, Lorin A, Brasseur R, Lins L. The “Tilted Peptide Theory” Links
Membrane Insertion Properties and Fusogenicity of Viral Fusion Peptides. Protein &
Peptide Letters. 2010;16(7):718-725. doi:10.2174/092986609788681724

20.

Lau WL, Ege DS, Lear JD, Hammer DA, DeGrado WF. Oligomerization of Fusogenic
Peptides Promotes Membrane Fusion by Enhancing Membrane Destabilization.
Biophysical Journal. 2004;86(1 I):272-284. doi:10.1016/S0006-3495(04)74103-X

21.

Oliveira S, van Rooy I, Kranenburg O, Storm G, Schiffelers RM. Fusogenic peptides
enhance endosomal escape improving siRNA-induced silencing of oncogenes.
International Journal of Pharmaceutics. 2007;331(2):211-214.
doi:10.1016/j.ijpharm.2006.11.050

170

22.

Jiang C, Ma Z, Zhang G, Yang X, Du Q, Wang W. Csnk2a1 promotes gastric cancer
invasion through the pi3k-akt-mtor signaling pathway. Cancer Management and
Research. 2019;11:10135-10143. doi:10.2147/CMAR.S222620

23.

Ortega CE, Seidner Y, Dominguez I. Mining CK2 in cancer. PLoS ONE. 2014;9(12):125. doi:10.1371/journal.pone.0115609

24.

Litchfield DW. Protein kinase CK2: Structure, regulation and role in cellular decisions of
life and death. Biochemical Journal. 2003;369(1):1-15. doi:10.1042/BJ20021469

25.

Bae JS, Park SH, Jamiyandorj U, et al. CK2α/CSNK2A1 Phosphorylates SIRT6 and Is
Involved in the Progression of Breast Carcinoma and Predicts Shorter Survival of
Diagnosed Patients. American Journal of Pathology. 2016;186(12):3297-3315.
doi:10.1016/j.ajpath.2016.08.007

26.

Tudrej P, Kujawa KA, Cortez AJ, Lisowska KM. Characteristics of in Vivo Model
Systems for Ovarian Cancer Studies. Published online 2019.

27.

Huang Y hung, Bao Y, Peng W, et al. Claudin-3 gene silencing with siRNA suppresses
ovarian tumor growth and metastasis. Published online 2009.

28.

Tian Z, Liang G, Cui K, Liang Y, Wang Q, Lv S. Insight Into the Prospects for RNAi
Therapy of Cancer. Frontiers in Pharmacology. 2021;12(March):1-15.
doi:10.3389/fphar.2021.644718

29.

Roberts CM, Shahin SA, Wen W, et al. Nanoparticle delivery of siRNA against TWIST
to reduce drug resistance and tumor growth in ovarian cancer models. Nanomedicine:
Nanotechnology, Biology, and Medicine. 2017;13(3):965-976.
doi:10.1016/j.nano.2016.11.010

171

30.

Alexander-Bryant AA, Dumitriu A, Attaway CC, Yu H, Jakymiw A. Fusogenicoligoarginine peptide-mediated silencing of the CIP2A oncogene suppresses oral cancer
tumor growth in vivo. Journal of Controlled Release. 2015;218:72-81.
doi:10.1016/j.jconrel.2015.09.026

31.

Thomas OS, Weber W. Overcoming Physiological Barriers to Nanoparticle Delivery—
Are We There Yet? Frontiers in Bioengineering and Biotechnology. 2019;7(December).
doi:10.3389/fbioe.2019.00415

32.

Lehto T, Ezzat K, Wood MJA, Andaloussi SEL. Peptides for nucleic acid delivery.
Advanced Drug Delivery Reviews. 2016;106(2016):172-182.
doi:10.1016/j.addr.2016.06.008

33.

Tai W, Gao X. Functional peptides for siRNA delivery. Advanced Drug Delivery
Reviews. 2017;110-111:157-168. doi:10.1016/j.addr.2016.08.004

34.

Miller EM, Samec TM, Alexander-Bryant AA. Nanoparticle delivery systems to combat
drug resistance in ovarian cancer. Nanomedicine: Nanotechnology, Biology, and
Medicine. 2021;31. doi:10.1016/j.nano.2020.102309

35.

Marcotte R, Brown KR, Suarez F, et al. Essential gene profiles in breast, pancreatic, and
ovarian cancer cells. Cancer Discovery. 2012;2(2):172-189. doi:10.1158/2159-8290.CD11-0224

36.

Beaufort CM, Helmijr JCA, Piskorz AM, et al. Ovarian cancer cell line panel (OCCP):
Clinical importance of in vitro morphological subtypes. PLoS ONE. 2014;9(9).
doi:10.1371/journal.pone.0103988

172

37.

Hernandez L, Kim MK, Lyle LT, et al. Gynecologic Oncology Characterization of
ovarian cancer cell lines as in vivo models for preclinical studies. Gynecologic Oncology.
2016;142(2):332-340. doi:10.1016/j.ygyno.2016.05.028

38.

Mitra AK, Davis DA, Tomar S, et al. In vivo tumor growth of high-grade serous ovarian
cancer cell lines. Gynecologic Oncology. 2015;138(2):372-377.
doi:10.1016/j.ygyno.2015.05.040

39.

Hernandez L, Kim MK, Lyle LT, et al. Characterization of ovarian cancer cell lines as in
vivo models for preclinical studies. 2017;142(2):332-340.
doi:10.1016/j.ygyno.2016.05.028.Characterization

Acknowledgements
We would like to thank the entire staff at GSRC, specifically, Tina Parker, Cindy
Smoak, Travis Pruitt, and Dr. John Parrish, DVM. Thank you to Chad MacMahan for his
assistance in OCT embedding and tissue sectioning. Also thanks to the team of students
in the Nanobiotechnology lab for their support and assistance in cell preparation and
animal measurements.

Author Contributions
TS and AAB designed experiments, constructed the original manuscript, and
performed revisions. TS, CC, and SG prepared cell suspensions and peptide nanoparticles
as well as ex vivo experiments. TS, JB, and KLA performed animal experiments.

173

Funding
This work was supported by the National Science Foundation EPSCoR program
under NSF Award #OIA-1655740, the National Science Foundation Faculty Early Career
Development Program under NSF Award #204669, a Clemson University R-Initiatives
Core Incentivized Access (CU-CIA) Award, and the South Carolina Bioengineering
Center for Regeneration and Formation of Tissues (SC BioCRAFT) at Clemson
University. This work is also supported in-part by the Hollings Cancer Center Lowvelo
Doctoral Fellowship Program (T.S.). Any Opinions, findings and conclusions or
recommendations expressed in this material are those of the author(s) and do not
necessarily reflect those of the National Science Foundation, the Hollings Cancer Center,
or Clemson University.

Ethical Approval
All animal experiments were performed in accordance with relevant guidelines
according to the Guide for the Care and Use of Laboratory Animals (NIH) and GodleySnell Animal Research Facility (GSRC) Animal Use policies. Procedures were approved
for use by the Clemson University Institutional Animal Care and Use Committee
(IACUC).

Competing Interests
The authors declare no competing interests regarding this work.

174

Correspondence
Email correspondence and requests for materials should be addressed to Dr.
Angela Alexander-Bryant.

175
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Abstract
Active targeting of overexpressed cell receptors can be a method of increasing
therapeutic delivery and efficacy using nanoparticle systems. Through advantageous
utilization of overexpressed cell receptors present on cancer cells, active targeting can
provide opportunities to enhance therapeutic effects while reducing off-target and
systemic side effects. The luteinizing hormone releasing hormone receptor (LHRH) is a
target site that is significantly over expressed in ovarian cancer and also causes receptor
mediated endocytosis. By including a peptide targeting the LHRH receptor in sequence
with the fusogenic DIV3W peptide, it is hypothesized that cellular uptake of complexed
siRNAs will drastically increase and cause a significant reduction in target gene
expression. This study establishes a tandem peptide, consisting of both an LHRH
targeting and DIV3W fusogenic peptide, to efficiently bind, protect, and deliver bioactive
siRNAs in vitro. Using siRNAs specific for the CSNK2A1 gene, this work seeks to
improve on current delivery efficacy seen using the DIV3W peptide alone. Results show
that the LHRH-DIV3W tandem peptide can complex with and protect siRNAs from
degradation. Additionally, this peptide is able to selectively target the LHRH receptor and
cause receptor-mediated endocytosis, significantly increasing internalized siRNAs.
Further, there is release of bioactive siRNAs and significant reduction in CSNK2A1
mRNA expression as well as reduction in OVCAR3 cells to recolonize over a wide area.
These results highlight the ability of a tandem system to selectively target an
overexpressed ovarian cancer cell receptor and utilize this method of delivery to enhance
siRNA uptake.
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5.1 Introduction
Ovarian cancer is the 5th leading cause of cancer-related death among women with
over 60% of diagnoses in stage III or stage IV.1,2 In 2021, it is predicted that nearly 21,000
women will be diagnosed with ovarian cancer and over 13,000 will succumb to metastatic
disease and its complications.2 As a result, aggressive strategies are implemented via
debulking surgery and a regimen of platinum-based chemotherapeutics.3,4 These measures
are taken to effectively eliminate local masses and to treat or prevent the formation of
distant metastasis.4 However, nearly 60% of late-stage patients still experience relapse and
the development of chemoresistant tumors, reducing therapeutic efficacy and limiting
further treatment options.4 As such, there is a significant need for advances in ovarian
cancer therapy to reduce disease severity, risk of metastasis, and development of drugresistant tumors.
Gene therapies, specifically RNA-based therapies, have gained attention in recent
history with the discovery of RNA interference (RNAi). RNAi was first observed in 1990
but was not fully described as a silencing mechanism for endogenous genes until 1998.5,6
Activation of RNAi and specific mRNA degradation can be achieved through delivery of
microRNA, short hairpin RNA, or short interfering RNA (siRNA). Successfully achieved
in 2001, the intracellular delivery of siRNA has been a large area of focus for improvement
of cancer therapeutic efficacy.7–9 Briefly, siRNA is a double-stranded, 21 base pair
sequence of RNA that, upon delivery into the cell, is enzymatically cleaved by Dicer-2,
bound to the RNA induced silencing complex, and trafficked by the antisense siRNA strand
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to the target mRNA, which is degraded via Argonaut 2 nuclease activity.10 RNAi-based
therapies face significant barriers to clinical translation, including degradation via RNases
in serum, poor cellular uptake, and the inability to escape endosomal entrapment.11,12
Several studies have attempted to facilitate delivery of bioactive siRNAs via peptide-based
delivery systems through electrostatic complexation of siRNA with cell penetrating
peptides, fusogenic peptides,

targeting peptides, or a combination of these peptide

systems.13,14 Cell penetrating peptides offer the ability to efficiently complex nucleic acid
cargo via electrostatic interactions and cause endosomal escape, releasing bioactive cargo,
via the proton sponge effect. 15–19 Fusogenic peptides also encourage endosomal escape,
but through direct interaction with the endosomal membrane resulting from postprotonation conformational shifts.17,20,21 Targeting peptides allow for active targeting of
disease areas and can enhance the uptake efficiency of nanoparticle delivery vehicles.22,23
Not only can peptide systems efficiently protect siRNA cargo from degradation via
electrostatic complexation and internal packing, but they can also deliver bioactive siRNAs
through endosomal membrane disruption via membrane fusion and destabilization with
fusogenic peptides and causing the proton sponge effect due to high cationic charges in
cell penetrating peptides.13,14
Peptide-based delivery systems have been well-described as prospective nucleic
acid cargo carriers and can overcome the obstacles of degradation, cellular uptake, and
endosomal entrapment.24,25 We designed a novel fusogenic peptide, termed DIV3W,
specifically to enhance endosomal escape of nucleic acids and enhance bioactivity of
released cargo. We have previously demonstrated the ability DIV3W to form monodisperse
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nanoparticles with siRNA, protect siRNA from degradation, deliver bioactive siRNA
targeting the CSNK2A1 gene in ovarian cancer cells, and induce significant silencing of
gene and protein expression (see chapter 3). Reduction in CSNK2A1 mRNA and its protein
product, CK2α, resulted in a significant reduction in ovarian cancer cell migration and
recolonization. Though we have demonstrated the potential of DIV3W for enabling
endosomal escape of siRNA cargo and highly efficient knockdown of target genes, delivery
of cargo is nonspecific. Thus, to increase cell and tissue specificity, we have included a
targeting peptide within the fusogenic delivery system. tandem peptide, will not only
enhance cellular uptake, but will also implement the fusogenicity of the DIV3W peptide to
cause endosomal membrane destruction and release of bioactive siRNAs.
The current work highlights the propensity of a targeting peptide for the luteinizing
hormone releasing hormone receptor (LHRH), also known as gonadotropin releasing
hormone (GNRH), to enhance the ability of DIV3W to mediated targeted delivery of
bioactive siRNAs into ovarian cancer cells. LHRH is a commonly overexpressed cell
receptor in several cancers, including epithelial ovarian cancer.26–29 By introducing the
LHRH peptide sequence to create a tandem peptide with DIV3W, it is hypothesized that
uptake will be enhanced in cells overexpressing LHRH, while also enabling endosomal
escape of bioactive siRNA. We demonstrated that the LHRH peptide, complexed to
DIV3W via a glycine-linker, enabled targeted delivery of siRNAs into ovarian cancer cells
through active targeting, enhancing uptake of siRNAs via receptor-mediated endocytosis
after specific binding interactions with the LHRH receptor. We also demonstrated that the
tandem LHRH-DIV3W peptide delivered bioactive siRNAs, causing significant
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CSNK2A1 gene knockdown and resulting in downstream reduction of ovarian cancer cell
migration and recolonization. The ability of the tandem peptide to cause receptor-specific
binding and endocytosis of siRNA cargo, in addition to resultant gene knockdown and
reduction in cell recolonization, shows potential for this system to be a potent delivery
vehicle in in vivo or clinical applications.

5.2 Materials and Methods
Cell Culture
Ovarian epithelial cancer cell lines, OVCAR3, obtained through the American Type
Culture Collection (ATCC, Manassas, VA) and CAOV3 (Hollings Cancer Center,
Charleston, SC) were cultured in McCoy’s 5A culture medium and Dulbecco’s Modified
Eagles Medium (DMEM) (ATCC) respectively, supplemented with 10% fetal bovine
serum (FBS) (Corning, Corning, NY) and 1% penicillin/streptomycin (P/S) antibiotic
solution (Corning). All cultures were incubated at 37°C in 5% CO2. Cell lysate of the
healthy ovarian surface epithelial cell line (HOSEpiC, ScienCell, Carlsbad, CA) was stored
at -80°C.

Peptide Synthesis
Peptides DIV3W (WEADIVADIVWDIVADIVAGGG-(d)RRRRRRRRR), LHRH
(pGHWSY-(d)L-LRP),

and

LHRH-DIV3W

(d)LLRPGGGGGWEADIVADIVWDIVADIVAGGG-(d)RRRRRRRRR)

(pGHWSYwere

synthesized, purified (> 95% purity), and analyzed via high performance liquid
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chromatography (HPLC) at Genscript USA Inc. (Genscript, Piscataway, NJ). All
formulations contained C-terminal sequence of nine D-arginine (dR) residues with no
terminal modifications. Peptide formulations were dissolved, diluted, and stored as
previously described (chapter 3.5).

siRNAs
The siRNA targeting CSNK2A1 (siCSNK2A1) was synthesized by Thermo Fisher
Scientific (#s3638, Thermo Fisher Scientific, Waltham, MA). Negative control
siGENOME non-targeting siRNA #5 (siNT) and Cy5.5 fluorescently labeled siNT (siNTCy5.5.5) were purchased from GE Healthcare-Horizon Discovery, Dharmacon (GE
Healthcare Dharmacon, Lafayette, CO).

Characterization of Nanoparticle Size and Stability
To determine the minimum molar ratio necessary to completely complex free
siRNAs, increasing N:P molar ratios of LHRH, DIV3W, and LHRH-DIV3W peptide were
complexed with siRNAs and electrophoresed using a electrophoretic mobility shift assay.
Molar ratios, shown as N:P, are representations of the molar amine peptide content in
relation to 1 mole of phosphate group siRNA content. To determine the ability of the
peptides to protect siRNAs from serum- or RNase-mediated degradation, LHRH and
LHRH-DIV3W complexes were formed in RNase-free water with siNT at increasing N:P
molar ratios and incubated at 37°C, 5% CO2 50% v/v FBS, 5 µg/mL RNase A, or 50% v/v
RNase free water for 1 hour. Peptide/siRNA complexes were dissociated using 6% sodium
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dodecyl sulfate (SDS) prior to electrophoresis in a 2% agarose gel run at 100 V. Gels were
stained with ethidium bromide, subsequently washed with Milli-Q water, and imaged with
a BioRad ChemiDoc XRS imager (BioRad, Hercules, CA).
To determine nanoparticle size and zeta potential, peptides resuspended in RNasefree water (10 µM) were thawed and kept on ice prior to complexation with 10 µM of siNT
in RNase-free water and incubated for 20 minutes at room temperature to form DIV3WsiNT and LHRH-DIV3W-siNT complexes. Peptide complexes were prepared at 2 mg/mL
in RNase-free water. Hydrodynamic size and surface charge analysis was conducted using
a Malvern Nano ZS Zetasizer (Malvern Panalytical, Malvern, UK). All data was analyzed
using Malvern’s Zetasizer software.

Peptide Biocompatibility
OVCAR3 or CAOV3 cells were seeded at 10,000 cells/well with complete culture
media in a transparent 96-well plate and incubated overnight to allow the cells to attach.
LHRH and LHRH-DIV3W peptides were delivered to cells without siRNA cargo. After 24
hours of incubation the media was exchanged and after another 24-hour incubation at 37°C
in 5% CO2, viability was measured using an MTS Assay performed with the CellTiter 96
AQueous One Solution Assay (Promega, Madison, WI). Assay reagent was added
according to the manufacturer’s protocol and cells were incubated for 4 hours. Absorbance
was read using a BioTek Synergy LX (BioTek, Winooksi, VT) plate reader at 490 nm.

Immunofluorescence of LHRH Expression
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Visualization of LHRH expression in OVCAR3 and CAOV3 cells was completed
by seeding cells at 50,000 cells/well in a 24-well plate. Cells were fixed with 4%
paraformaldehyde for 15 minutes at room temperature and washed three times with 1x
PBS. After washing, cells were blocked with 1% bovine serum albumin (BSA) solution for
30 minutes at 4ºC. Three additional 1x PBS washes were completed and cells were then
incubated with GnRHR primary antibody at 1:100 dilution (Invitrogen, Carlsbad, CA)
overnight at 4 ºC in the dark. After primary antibody incubation, cells were once again
washed with 1x PBS and subsequently incubated with Secondary SuperSignal Alexa Fluor
488 antibodies (Invitrogen) according to the manufacturer’s protocol. Nuclear stain was
also performed with SuperSignal NucBlue according to Invitrogen protocol and cells were
imaged at 20x using an Evos FL microscope (Thermo Fisher).
Western blotting of LHRH expression in OVCAR3 and CAOV3 cells was
completed by seeding cells at 100,000 cells/well in a 6-well plate. Cells were washed and
lysed with cold radioimmunoprecipitation assay (RIPA) buffer supplemented with protease
inhibitor cocktail (Thermo Fisher). Protein concentrations were determined via
bicinchoninic assay according to the manufacturer’s protocol and absorbance was read at
562 nm. OVCAR3, CAOV3, and HOSEpiC (ScienCell) protein isolate at equivalent
amounts was separated by SDS_PAGE on a BioRad Stain-Free 10% gel according to
BioRad protocols then transferred to a Stain-Free PVDF membrane. PVDF was cut at
appropriate molecular weight intervals and blocked for 1 hour with 5% non-far dried milk
solution in 1x Tri-HCl-buffered-saline-0.1% Tween 20 (TBST) at room temperature.
Mouse anti-GnRHR antibody (1:1000, Invitrogen) and mouse anti- β-actin (1:10,000,
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Sigma-Aldrich, St. Louis, MO) was incubated with membranes at 4ºC overnight.
Membranes were washed three times with 1x TBST and incubated with goat anti-mouse
(1:1000 or 1:10,000, Thermo Fisher) secondary antibodies for 1 hour at room temperature.
Five additional washes with 1x TBST were performed, and protein bands were detected
with SuperSignal West Pico Plus Chemiluminescent Substrate (Thermo Fisher) and
imaged using a BioRad ChemiDoc Imaging System.

Cellular Uptake and Targeting Specificity
Observation of cell uptake was performed by seeding OVCAR3 and CAOV3 cells
at a density of 50,000 cells/well in a 24-well plate. LHRH and LHRH-DIV3W peptides
were complexed with siNT-Cy5.5.5 as previously described and delivered to cells at 20:180:1 N:P ratios. Each cell line was incubated with tandem peptide complexes for both 4and 24-hour treatment periods. Following incubation, cell media was removed, and cells
were washed with 1x PBS prior to the addition of 500 µL of 1x PBS and SuperSignal
NucBlue Hoescht 33342 nuclear stain (Thermo Fisher, Waltham, MA). Cellular imaging
was completed using an EVOS FL Microscope (Thermo Fisher) at 10x, 20x, and 40x
magnification. Flow cytometry was completed after cell imaging and cells were
trypsinized, resuspended in 1x PBS, and analyzed with an Attune NXT Acoustic Flow
Cytometer (Invitrogen) with the red laser line and RL2 (wavelength) channel.
To analyze the specificity of the LHRH-DIV3W tandem peptide targeting LHRH,
a competitive binding assay was performed by incubating OVCAR3 and CAOV3 cells with
GnRH primary antibody (1:100) in 1x PBS overnight at 4°C after being blocked with a 1%
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bovine serum albumin solution for 30 minutes at room temperature. LHRH-DIV3W-siNTCy5.5 complexes were delivered after the overnight primary antibody incubation and
incubated again for 4 hours. Secondary SuperSignal Alexa Fluor 488 antibodies were
delivered dropwise to cells following Invitrogen SuperSignal protocols and left to incubate
at room temperature for 30 minutes and subsequently stained with SuperSignal NucBlue
Hoescht 33342 for an additional 30 minutes at room temperature. Cells were imaged at 20x
and 40x using an Evos FL microscope (Thermo Fisher).

Gene and Protein Knockdown
Bioactivity of siRNAs was determined via qPCR and western blot analysis.
OVCAR3 or CAOV3 cells were seeded at 50,000 cells/well as previously described and
treated with siRNA targeting CSNK2A1 and siNT at N:P ratios 30:1, 40:1, 50:1, 60:1, and
70:1. LHRH-DIV3W peptide complexed with either siNT or siCSNK2A1 was incubated
for a total of 48 hours in RPMI 1640/DMEM-10% FBS, with one media exchange
occurring after the 24-hour timepoint. Treated cells were washed with 1x PBS at 24 hours
and fresh media was added. RNA isolation was completed using a Qiagen Mini-RNeasy
Kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. RNA isolation
quality and quantity was measured through the Gen5 protocol using a Take3 plate
(BioTek). RNA was reverse transcribed using the QuantiTect Reverse Transcription kit
(Qiagen) according to the manufacturer’s protocol. Quantitative real-time PCR was
completed with a QuantStudio 3 qPCR system (Applied Biosystems, Waltham, MA) using
Applied

Biosystems

TaqMan

FAST
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Master

Mix

(Thermo

Fisher)

and CSNK2A1 (ID# Hs00751002_s1)

and

18S

(ID# Hs99999901_s1)

predesigned

TaqMan probes according to the manufacturer’s protocol.

Clonogenic Recolonization
Clonogenicity, or the ability for cells to recolonize a large area, was analyzed to
determine the ability of cells to recover and regrow into viable colonies after treatment with
LHRH-DIV3W-siNT or siCSNK2A1. Recolonization of cells harvested after treatment
with LHRH-DIV3W-siNT or siCSNK2A1 was analyzed via a clonogenic assay and
quantified through absorbance spectroscopy using a BioTek Synergy LX plate reader
(BioTek) at 490 nm. OVCAR3 cells were seeded at 50,000 cells/well in a 24-well plate
and treated with N:P ratios 30:1, 40:1, 50:1, 60:1, and 70:1 of LHRHDWIV3W-siNT or
siCSNK2A1 complexes. After a 48-hour period, cells were harvested, centrifuged into a
pellet, and reseeded at 2,500 cells/well in a 6 well plate, yielding 1.25 cells/µL. All
treatment groups were allowed to colonize for a 14-day period with 1x PBS washes and
media changes at 2-day intervals. Following the growth period, cells were stained using a
0.1% crystal violet solution for 30 minutes, washed with ddH2O, and left to rest in ddH2O
overnight at 4ºC. The following morning, ddH2O was removed and cells were dried for 15
minutes before being UV imaged with a ChemiDoc Imaging System using the white light
filter. Quantification was completed by dissolving the stained cells in 33% acetic acid and
transferring 100 µL of each sample to a 96-well plate in triplicate. Well absorbance was
measured at 490 nm.
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5.3 Results
5.3.1 The Targeting and Tandem Peptides form Monodisperse Nanoparticles and are
Biocompatible
The LHRH targeting peptide, a known sequence implemented in several cancer
targeting research efforts,30–35 was conjugated to the DIV3W peptide via a flexible pentaglycine linker to form a tandem peptide as shown in Fig. 5.1A. Results of the gel shift
assay showed that the tandem LHRH-DIV3W peptide electrostatically bound with siRNAs
at a minimum molar ratio of 20:1 (Fig. 5.1B); thus, N:P ratios of 20:1 to 80:1 were used
for subsequent experiments. DLS results demonstrated that LHRH-DIV3W peptide
complexes formed the largest nanoparticles compared to DIV3W and LHRH peptide
complexes, at 154.2 + 15.9 nm, with a polydispersity index of 0.18 (Fig. 5.1E),
demonstrating formation of monodisperse nanoparticles. Additionally, the tandem peptide
complexes exhibited the highest positive charge when compared to LHRH and DIV3W
complexes, at 33.37 + 2.00 mV. After confirmation of nanoparticle formation, LHRHDIV3W was evaluated for its ability to protect siRNA in physiological conditions.
Simulation of physiological conditions was performed by incubating the LHRH-DIV3WsiNT complexes in 50% fetal bovine serum (FBS) or RNase A and detecting in-tact siRNAs
using electrophoretic gel shift (Fig. 5.1C). Each N:P ratio incubated with 50% FBS
displayed high protection of siRNAs evidenced by bright white banding. However, RNase
A degradation protections required increased N:P ratios, with degradation of siRNAs
appearing at 20:1 and 30:1 in comparison to higher 40:1 and 50:1 N:P ratios.
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Ensuring the biocompatibility of these nanoparticles was pivotal in understanding
that any anticancer effects observed downstream were resulting from RNAi mechanisms
and not peptide cytotoxicity. It was determined that LHRH-DIV3W did not cause cytotoxic
effects in OVCAR3 and CAOV3 cells when delivered without siRNA cargo but did cause
a slight statistically significant increase in viability in OVCAR3 cells at the 20:1 ratio, with
viability measured at 109.66% + 0.8%. N:P ratios greater than 20:1 though, caused viability
values to return to insignificant levels in comparison to untreated controls, suggesting
mitogenesis is rate limited by LHRH binding capacity.
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Figure 5.1 LHRH-DIV3W peptide forms monodisperse nanoparticles, protects
from cargo degradation, and is biocompatible.
LHRH-DIV3W peptide sequences and characteristics (A). Peptide/siRNA complexation
at increasing N:P ratios through electrophoretic shift assay with unbound siRNA shown
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as white banding (B). Gel shift assay of tandem peptide/siRNA complexes incubated
with (+) or without (-) 50% serum or RNase A (C). Intact siRNA shown with
white banding. Peptide diameter measured via DLS (D) and quantified (E) including zeta
potential and PDI. LHRH-DIV3W cytotoxicity analysis in OVCAR3 and CAOV3 cells
(F). Experiments were completed to N = 3 and data was analyzed using a two-way
ANOVA with multiple comparisons. * p < 0.05.
5.3.2 LHRH is Overexpressed in OVCAR3 and CAOV3 Cells
LHRH receptor expression in ovarian cancer confirmed that both OVCAR3 and
CAOV3 cells exhibited expression of LHRH when analyzed with immunofluorescent
microscopy (Fig. 5.2A). For comparison to a healthy epithelial cell line, HOSEpiC cell
lysate was blotted for LHRH, in addition to OVCAR3 and CAOV3 lysate. HOSEpiC cells
did not display a protein band for LHRH, while OVCAR3 and CAOV3 both expressed
LHRH (Fig. 5.2B) protein in direct correlation with the immunofluorescence imaging.
OVCAR3 had the highest LHRH expression between the three cell lines.
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Figure 5.2 LHRH is overexpressed in ovarian cancer cells OVCAR3 and CAOV3.
Immunofluorescence microscopy of LHRH receptor (green) in OVCAR3 and CAOV3
cells (A) with nuclei stained with Hoescht 33342. Supporting western blot analysis of
LHRH protein expression in HOSEpiC lysate, OVCAR3, and CAOV3 cells (B). Scale:
100 µm.
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5.3.3 The LHRH-DIV3W Tandem Peptide Specifically Targets the LHRH Receptor on
Ovarian Cancer Cells
Cellular uptake of siRNAs via active targeting mechanisms is the major goal of
including the LHRH peptide with the DIV3W fusogenic sequence, forming the LHRHDIV3W peptide. Active targeting and uptake were examined using immunofluorescent
imaging and flow cytometry. The LHRH-DIV3W peptide complexed with siNT-Cy5.5.5
was delivered to OVCAR3 and CAOV3 cells and exhibited increasing cell internalization
with increasing N:P ratios for all treatment groups except 50:1-80:1 in CAOV3 after 4
hours (Fig. 5.3A, B). Quantitation using flow cytometry showed OVCAR3 uptake
efficiencies reaching 79.58% + 0.61% at the 80:1 ratio, which was significantly greater
than CAOV3 cell uptake efficiency at the same ratio, reaching 36.19% + 9.67% (Fig. 5.3C).
However, after 24-hour incubation with tandem-siNT-Cy5.5 complexes, this discrepancy
was no longer observed and CAOV3 cells also had consistent uptake efficiency levels,
reaching 63.47% + 4.61% at the 80:1 ratio (Fig. 5.3D).

Compared against the LHRH

peptide alone, LHRH-DIV3W tandem significantly improved cell uptake at the ratios 40:1,
60:1, and 80:1 with uptake efficiencies of 66.81% + 4.3%, 72.59% + 6.87%, and 76.26%
+ 14.9% respectively (Fig. 5.3E). LHRH-mediated uptake efficiencies at these ratios were
34.3% + 0.56%, 34.83% + 2.75%, and 33.87% + 1.63%.
To confirm that the LHRH-DIV3W peptide binds specifically to the LHRHreceptor, comparative imaging was completed with OVCAR3 and CAOV3 cells first
incubated with LHRH antibody. Preincubation with LHRH antibody would ensure LHRHreceptor-antibody binding, blocking the binding of the LHRH-DIV3W peptide. Shown in
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Fig. 5.3F and Fig. 5.S2, when both cell lines were preincubated with LHRH antibody,
siRNA internalization was drastically decreased.

194

195

196

Figure 5.3 Tandem peptide uptake efficiency against LHRH alone and receptor
specificity.
4hr uptake imaging of OVCAR3 (A) and CAOV3 (B) cells incubated with LHRHDIV3W-siNT-Cy5.5 complexes at increasing N:P ratios. siNT-Cy5.5 is stained red and
nuclei are stained using Hoechst 33342 and appear blue. Uptake was quantified with
flow cytometry at 4 hr (C) and 24 hr (D). LHRH targeting peptide uptake efficiency
compared to LHRH-DIV3W tandem peptide uptake efficiency analyzed by flow
cytometry at 4 hr (E). OVCAR3 cell uptake imaging comparison between LHRH
receptor bound with antibody (green) prior to complex delivery, LHRH-siNT-Cy5.5, and
LHRH-DIV3W-siNT-Cy5.5 (F). All data are mean + SEM of three independent
experiments analyzed via two-way ANOVA (C, D) and multiple t-tests (E), where * p <
0.05 compared to CAOV3 80:1 at 4 hours (C) and * p < 0.05, ** p < 0.01 compared to
LHRH-mediated uptake. Scale (A, B): 200 µm, (F) 50 µm.
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5.3.4 LHRH-DIV3W Mediates Delivery of Bioactive siRNAs at Higher N:P Molar
Ratios
We have previously shown that the DIV3W fusogenic peptide can deliver
bioactive siRNAs and mediate silencing of CSNK2A1 in OVCAR3 and CAOV cells (See
chapter 3). Thus, we examined whether the tandem peptide, containing LHRH conjugated
via a penta-glycine linker to DIV3W, retained the ability to delivery bioactive siRNAs into
ovarian cancer cells. qPCR results revealed silencing of CSNK2A1 mRNA expression
mediated by LHRH-DIV3W-siCSNK2A1 at 50:1, 60:1, and 70:1 N:P ratios, with
statistically significant knockdown of 48.2% at a 70:1 ratio in OVCAR3 cells (Fig. 5.4A).
50:1 and 60:1 ratios of LHRH-DIV3W-siCSNK2A1 yielded a knockdown of 40.3% and
27.8%, respectively. Western blot analysis of CK2α protein also revealed decreased protein
expression in 50:1 N:P ratio (Fig. 5.4B).
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Figure 5.4 Tandem-mediated delivery of bioactive siRNAs.
Tandem-mediated bioactivity of siRNAs in OVCAR3 cells. qPCR analysis of CSNK2A1
mRNA after treatment of OVCAR3 cells with LHRH-DIV3W (A) peptide complexed
with siNT or siCSNK2A1 for 48 hours. Data are mean + SEM of three independent
experiments analyzed with Student’s t-test within each N:P ratio, where * p < 0.05. (B)
Western blot analysis of CSNK2A1 protein product, CK2α, after treatment of OVCAR3
cells with LHRH-DIV3W-siCSNK2A1 for 48 hours. β-Actin expression was also
examined to confirm equivalent protein loading.
5.3.5 Recolonization Responds to CSNK2A1 Gene Knockdown
Characterization of cell response to knocking down the CSNK2A1 gene is an
important aspect of determining the clinical applications for this gene target in ovarian
cancer. Silencing of CSNK2A1 results in reduction of cell migration and recolonization in
ovarian cancer cells, as shown in previous work (See chapter 3). Clonogenic recolonization
of OVCAR3 cells treated with LHRH-DIV3W-siSCNK2A1 displayed a significant
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reduction in colonization compared to treatment with LHRH-DIV3W-siNT at 50:1, 60:1,
and 70:1 ratios with only 41.9% + 7.8%, 56.8% + 15.3%, and 52.5% + 6.7% colonization
shown for each ratio, respectively (Fig. 5.5A, B).

Figure 5.5 Downstream clonogenicity of OVCAR3 cells treated with siCSNK2A1.
Downstream knockdown of CSNK2A1 colony reformation analysis at multiple N:P
ratios. LHRH-DIV3W-siNT and -siCSNK2A1 treated OVCAR3 cells (A) were
harvested after treatment, reseeded, and allowed to regrow over a 2-week period.
Relative colonization percent + SEM was quantified via absorbance spectroscopy at 490
nm (B). Experiments were completed to N = 3 and data analyzed with two-way ANOVA.
* p < 0.05, ** p < 0.01, *** p < 0.001 compared to LHRH-DIV3W-siNT treatment.
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5.4 Discussion and Conclusions
The design of the LHRH-DIV3W peptide was intended to take advantage of the
functional properties of the LHRH and DIV3W peptides to create a tandem peptide with
both targeting and fusogenic properties to enhance delivery of bioactive siRNAs. LHRH
has been successfully targeted in ovarian cancer drug delivery systems and enhances cell
internalization through its receptor-mediated endocytotic behavior.31–36 Many drug and
gene delivery systems have utilized targeting peptides as complementary systems to
enhance active targeting in the tumor microenvironment or to evaluate systemic routes of
therapeutic delivery.22,37–40 Identified and synthesized primarily via phage display
techniques, targeting peptides have the capacity to continue to expand in their uses as more
overexpressed cellular receptors are identified on cancer cells.38,41–43 Though targeting is
advantageous for increasing therapeutic delivery, another significant barrier to RNAi
therapeutic efficacy is endosomal escape after targeted uptake has taken place. Thus,
additional components must be added to create a robust delivery system capable of not
only targeted delivery, but delivery of bioactive therapeutics.
Our work introduces the use of an LHRH targeting peptide as a complement to the
DIV3W fusogenic peptide that has previously shown the ability to deliver bioactive
siRNAs in vitro and in vivo (Chapters 3 and 4). The LHRH and DIV3W peptides are joined
through the inclusion of a flexible penta-glycine linker at the junction between the
sequences, and another glycine liker is included at the junction between DIV3W and the
arginine tail, a cationic sequence necessary for electrostatic binding of anionic siRNAs.44
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Characterization of the tandem system revealed the ability of the LHRH-DIV3W peptide
to completely bind siRNAs starting at an N:P ratio of 20:1 and form monodisperse
nanoparticles sized 154.2 + 15.9 nm, allowing for passive targeting through the enhanced
permeability and retention effect in addition to active targeting via the LHRH receptor.
Compared to DIV3W and LHRH peptides alone, the tandem system formed the largest,
most monodisperse nanoparticles and contained the highest surface charge, which is
attributed to the longer amino acid sequence in the tandem system as well as the
combinatorial effect of cationic residues in both the LHRH and DIV3W regions. While
complexation efficiency is pivotal, it is also important to show that the tandem system can
effectively protect the siRNA cargo from degradation when exposed to RNases and/or
serum. The LHRH-DIV3W peptide was able to fully protect siRNA cargo from
degradation in a 50% serum environment, shown as white banding indicating intact siRNA.
Higher N:P ratios were required for full protection of siRNAs when exposed to RNase A.
Similar to results seen using the DIV3W fusogenic peptide, enhanced ability for the peptide
systems to protect siRNA cargo in these simulated physiological environments provides
support for their systemic use in vivo by increasing circulation time and allowing the
targeted delivery system to navigate to the target tissue site.45–48
Before using the tandem peptide to deliver therapeutics, it is important to ensure
that the delivery vehicle is not causing cytotoxic effects on its own. Our results
demonstrated that the tandem peptide can be delivered without causing reduction in cell
viability in OVCAR3 and CAOV3 cells. However, due to the binding of the LHRHreceptor, it was observed that an increase in cell viability occurs at a 20:1 N:P ratio. LHRH
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is known to be an activator of cell communication with possible enhanced cell
proliferation.49 However, it was observed that changes in viability were insignificant
compared to untreated cells at N:P ratios greater than 20:1.
The goal of incorporating a the LHRH peptide with the DIV3W fusogenic peptide
system was to enhance targeted delivery of siRNAs. We were able to visualize and quantify
the efficiency of siRNA delivery via the tandem complex through fluorescence microscopy
and flow cytometric analyses. The LHRH-DIV3W peptide enabled enhanced siRNA
uptake in both OVCAR3 and CAOV3 cells after 4 hours compared to the LHRH peptide
alone. Consistent with delivery by the DIV3W peptide, siRNA uptake increased linearly
with increasing N:P ratios for OVCAR3 cells and a statistically significant difference in
uptake efficiency between OVCAR3 and CAOV3 was observed at an 80:1 ratio. As
expected, the flow cytometry results and uptake imaging of the tandem peptide complexes
directly correlated with the level of LHRH expression between the two cell lines used.
CAOV3 cells exhibited a lower LHRH expression in comparison to OVCAR3 cells and is
reflected in the reduced ability of CAOV3 cells to bind with the tandem complex at higher
N:P ratios over a short time period of 4 hours. This can be explained by crowding of
nanoparticles at few LHRH-receptor sites, with each nanoparticle competing for lesser
available receptors in comparison to the availability of binding sights in OVCAR3 cells,
shown in our immunofluorescence and western blot characterization of LHRH expression
levels between OVCAR3 and CAOV3 cell lines. To confirm this effect, uptake of the
tandem peptide complexes was also analyzed after 24 hours. The increased time-period
allowed CAOV3 cells to recycle the LHRH receptor and caused increased levels of siRNA
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internalization, from 36.19% + 16.76% after 4 hours to 63.4% + 4.6% after 24 hours at an
80:1 N:P ratio. In contrast, OVCAR3 cells, which had higher LHRH expressed, exhibited
high uptake efficiencies at both time points, where 80:1 N:P ratio yielded 79.58% + 1.05%
uptake at 4 hours and 76.26% + 15.56% uptake at 24 hours. Compared to DIV3W uptake
highlighted in our previous work, LHRH-DIV3W complexes mediated uptake efficiencies
12% higher in OVCAR3 cells and 11% higher in CAOV3 cells.
Though high levels of siRNA uptake was evident through fluorescence imaging
and flow cytometry, it is also crucial to ensure that the LHRH-DIV3W peptide specifically
targets the LHRH receptor. Evaluation of the targeting specificity was performed through
inhibiting the LHRH receptor using an LHRH receptor antibody. LHRH-bound cells
exhibited minimal siRNA internalization in comparison to cells treated with LHRHDIV3W complexes without receptor inhibition in both OVCAR3 and CAOV3 cells.
Through these observations, we can confirm that the tandem peptide complex effectively
targeted the LHRH receptor, causing increased receptor-mediated endocytosis and
internalization of siRNAs.
After confirming active targeting of the LHRH receptor, we examined the ability
of the tandem peptide to mediate delivery of bioactive siRNAs through western blot and
qPCR analysis. When delivered at high N:P ratios, the LHRH-DIV3W peptide was able to
achieve statistically significant knockdown of the CSNK2A1 gene, with 70:1 reducing
mRNA expression to 51.88% + 9.87% of the negative control treated with LHRH-DIV3WsiNT. 60:1 and 50:1 also caused gene knockdown to 72.17% + 23.19% and 59.75% +
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12.61%, respectively. Additionally, western blot analysis displayed slight reduction in
protein band intensity at 50:1 ratio. Due to the reduction in protein with the negative control
at 60:1 and 70:1 ratios, conclusions could not be drawn on the protein silencing at each of
those ratios using siCSNK2A1. Compared to the fusogenic DIV3W peptide, the LHRHDIV3W tandem delivery did not cause an equivalent amount of CSNK2A1 mRNA
reduction. Shown previously, the DIV3W peptide is able to efficiently escape the
endosome and cause mRNA reduction of up to 94%. Because of the reduction in silencing
efficacy using the LHRH-DIV3W tandem peptide, it can be inferred that there is inefficient
fusogenicity with the endosomal membrane due to the penta-glycine flexible linker
between the LHRH and DIV3W regions. With his flexible linker, the LHRH region could
be causing difficulties in DIV3W protonation and failing to cause endosomal membrane
fusion.
A full understanding of CSNK2A1 pathways is yet to be determined, but it is known
that that gene plays a role in increasing cancer aggressiveness and oncogenesis through
PI3K-Akt-mTOR pathway activation.50–53 Our previous work demonstrates that silencing
CSNK2A1 reduces cell migration and recolonization in ovarian cancer cells. Though
knockdown of CSNK2A1 mediated by LHRH-DIV3W-siCSNK2A1 was not as efficient as
that observed with DIV3W-siCSNK2A1, the tandem peptide complexes did still cause
reduction in cell migration and recolonization ability. When seeded at very low densities,
the ability for cells to recolonize simulates tumor resection where clear margins may be
difficult to obtain. Residual cancerous cells may remain and, without effective treatment,
can recolonize and grow, resulting in disease recurrence, a common complication in late-
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stage ovarian cancer patients.54,55 Treatment of these cells with LHRH-DIV3WsiCSNK2A1 significantly reduced the ability of OVCAR3 cells to recolonize at low
densities in comparison to cells treated with LHRH-DIV3W-siNT. Additionally, silencing
of CSNK2A1 caused a significant reduction in ovarian cancer cells migration across a
scratch wound, lending support to the role of CSNK2A1 in cell-cell communication and has
implications for reduced risk of metastasis.50,56–59 These results are consistent with the
delivery of DIV3W-siCSNK2A1 and provide support into the clinical relevance of
CSNK2A1 as a therapeutic gene target.
Through this work we have sought to improve upon the delivery and bioactivity of
siRNA therapeutics for ovarian cancer by incorporating a peptide targeting the LHRH
receptor with the fusogenic DIV3W peptide. We have confirmed the ability of this tandem
peptide, LHRH-DIV3W, to efficiently complex with and protect siRNA cargo in
physiological conditions as well as form monodisperse nanoparticles. Incorporation of the
LHRH targeting peptide increases siRNA uptake efficiency through specific binding of the
LHRH-receptor but exhibited decreased endosomal escape compared to the previously
examined DIV3W peptide, also resulting in reduced mRNA and protein knockdown when
compared to DIV3W-mediated delivery of siCSNK2A1. However the knockdown
achieved was still sufficient in causing reduction in cell migration and recolonization and
continue to support the potential of CSNK2A1 as a therapeutic target for ovarian cancer
treatment. Additionally, the achievement of active targeting using the LHRH peptide
sequence to form a tandem peptide can assist in increasing endocytotic uptake of siRNA
cargo. With enhanced targeting and manipulation of the linker sequence to allow for high
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fusogenicity via the DIV3W region, there is potential for great therapeutic potency using
RNAi as an interventional modality.
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Supplemental Information

Figure 5.S1. LHRH peptide efficiently binds and protects siRNAs at specific N:P
ratios.
Gel shift analysis of LHRH complexation with siRNAs (A) and protection from RNase
A and 50% serum degradation (B). White bands indicate in-tact, unbound siRNAs (A)
and siRNAs released from complexes protected from degradation (B). Viability of
OVCAR3 and CAOV3 cells treated with LHRH peptide alone exhibiting
biocompatibility (C).
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Figure 5.S2. Competitive inhibition of LHRH binding in CAOV3 cells.
CAOV3 cells incubated with LHRH antibody prior to treatment with LHRH-DIV3WsiNT-Cy5.5. LHRH competitively bound by antibody and Alexa Fluor 488 (green) in
each cell line was also incubated with LHRH-DIV3W-siNT-Cy5.5 (red) fluorescence.
Cells were also incubated with LHRH-DIV3W-siNT-Cy5.5 without the presence of
LHRH antibody.

217

CHAPTER 6 - CONCLUSIONS AND FUTURE WORK RECOMMENDATIONS

6.1 Conclusions
This work was tailored around developing a novel peptide delivery system to
efficiently complex and protect siRNA cargo, encourage high rates of cell specific
uptake, and disrupt the endosomal membrane integrity causing release of bioactive
siRNAs into the cytosol in ovarian cancer. Ovarian cancer does not have an effective
treatment regimen for late-stage diagnoses and RNAi-based gene therapy via siRNA
delivery is an attractive alternative to current standards of care. We have shown that the
DIV3W fusogenic peptide successfully forms monodisperse nanoparticles capable of
protecting siRNA cargo from serum and RNase degradation. In addition, this fusogenic
peptide efficiently delivers fluorescent, non-targeting, and targeted CSNK2A1 siRNAs
into ovarian cancer cells, reduces endosomal entrapment, and causes significant
knockdown of the target CSNK2A1 gene. Downstream of gene knockdown in vitro, we
showed a significant decrease in ovarian cancer cell migration and recolonization,
lending to the in vivo and clinical applications of CSNK2A1 as a therapeutic target.
Moving to an in vivo system, the DIV3W peptide mimicked in vitro results by
delivering fluorescent siRNAs to both SQ and IP tumors at levels higher than siNT-Cy5.5
delivered alone. In SQ tumors, DIV3W-siNT-Cy5.5 exhibited significant fluorescence
and was found to be localized to the tumor area, where complexes delivered
intraperitoneally were distributed throughout the abdominal cavity. When delivering
siCSNK2A1 to SQ tumors, DIV3W caused a significant decrease in CSNK2A1
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expression, suggesting efficient endosomal escape and activation of the RNAi pathway in
a single dose and in a multidose treatment regimen. Downstream from gene knockdown
in a multidose schedule, DIV3W-siCSNK2A1 was able to significantly repress tumor
growth compared to saline and DIV3W-siNT negative controls. With positive results
using the DIV3W fusogenic peptide in vitro and in vivo, we sought to further enhance the
delivery system through the inclusion of a targeting peptide.
Inclusion of a targeting moiety to the fusogenic peptide, specific for the LHRH
receptor, which is overexpressed in ovarian cancer, was thought to increase cellular
uptake of siRNAs and cause increased efficacy of therapeutic siRNAs. The LHRHDIV3W complex was able to specifically target the LHRH receptor, resulting in receptormediated endocytosis, and significantly increase siRNA internalization in comparison to
LHRH and DIV3W peptides alone. Delivery of targeted siRNAs for CSNK2A1 resulted
in significant gene knockdown, but only at one ratio and was not as effective as the
DIV3W peptide alone. The flexible glycine linkage between the LHRH and DIV3W
peptide regions retains the complex as a tandem system throughout delivery and, without
dissociation between the regions, is believed to be hindering the fusogenicity of DIV3W.
To improve upon these results, continue improvements of the DIV3W and LHRHDIV3W delivery system, and enhance clinical translatability, several future studies are
proposed below.
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6.2 Cathepsin-B Cleavable Linkage
Although there is a significant increase in complex-siRNA uptake via delivery
with the tandem LHRHDIV3W peptide, bioactivity of siCSNK2A1 seems to falter.
Inclusion of a cleavable linker in place of the flexible glycine bridge between LHRH and
DIV3W could encourage higher levels of dissociation between the targeting and
fusogenic peptide sequences, encouraging higher levels of endosomal escape of siRNAs.
Cleavable linkers, including valine-alanine (VA) and glycine-phenylalanine-leucine glycine (GFLG), are enzyme-responsive in the presence of cathepsin-B.1–3 Cathepsins,
specifically cathepsin-B, are common proteolytic enzymes that have higher prevalence in
the TME and within cancer cells.4,5
To improve the tandem peptide efficacy, inclusion of a cathepsin-B sensitive
linker is hypothesized to cause dissociation between the targeting LHRH peptide and the
fusogenic DIV3W peptide within the endosomal environment. Cathepsin-B is primarily
present within endosomal and lysosomal compartments but also is found within caveolaeformed vesicles.4–6 Cathepsin-B cleavage of VA or GFLG will allow for the targeting
peptide to completely detach from the DIV3W region, resulting in the desired fusogenic
effect of DIV3W, endosomal destruction, and release of bioactive siRNAs. Because of
the increased levels of cell uptake observed with tandem peptide delivery, it is expected
that siRNA bioactivity levels will also be greater than DIV3W delivery alone.
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6.3 3D-Spheroid Penetration and Delivery of RNAi Therapeutics
In vitro development of a cancer model does not capture the complexity and
heterogeneity of clinically relevant systems when created in 2-dimensions. 3D-spheroids,
however, have shown to develop similar TME characteristics seen in vivo such as cell
proliferation, density, and metabolism.7 Ovarian cancer 3D models have been well
studied and show that they can establish clinically relevant TME and ECM both with and
without supplemental matrix substrates.8,9 Specifically, ES2 and OVCAR3 cells were
observed to have higher expression of proteins responsible for cancer dissemination when
cultured in 3D spheroids, consistent with expression levels seen in clinical tumor
samples.8 Additionally, 3D models of epithelial ovarian cancer have supplied information
on chemoresistance.10
Constructing the complex environment could help in the development of our
delivery system prior to beginning more animal studies. These investigations may lend
insight into the ability of the DIV3W or LHRHDIV3W system to penetrate and deliver
siRNA within a tumor. Complimenting the previous in vivo work reported, 3D-spheroid
models will provide support for these peptide systems to be clinically applicable and
examine the possibilities of delivering various therapeutic cargo. These 3D in vitro
models could also be a strong source of support for combination therapy delivery of
RNAi via peptide systems supplemented with chemotherapies to combat drug-resistant
tumors.
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6.4 DIV3W-Mediated Delivery of CRISPR/Cas9
CRISPR/Cas9 is a system of single guide RNA and the Cas9 endonuclease.11
Similar to siRNA, CRISPR/Cas9 is subject to a series of degradation pathways that
prevent efficient delivery and consequent gene editing effects.12 As such, CRISPR/Cas9
requires a nanocarrier to achieve efficient levels of cell uptake and the peptide system
developed through this work could prove to be an efficient delivery vehicle. Peptide
systems have been shown to be effective vehicles for CRISPR/Cas9 delivery, specifically
using CPP-based systems.13,14 Gene editing with CRISPR/Cas9 systems, though, does
pose the risk of significant off-target effects that are more permanent than delivery of
RNAi-based therapeutics.15 Because of this our tandem system could provide significant
reduction of off-target effects due to its affinity for the LHRH-receptor in ovarian cancer
cells specifically. Also, this targeting region of the tandem peptide can be interchanged to
be specific for other overexpressed receptors that are found in cancer including EGFR,
FGFR and T7.16–19
There are many areas of exploration that can be taken on through the
establishment of the novel peptide systems presented in this dissertation. Continued
improvements in the DIV3(X), DIV3W, and LHRHDIV3W peptides can expand past the
three suggestions provided into delivery of various cargos, efficacy in different cancer
models, or even investigating the peptide system as a nanoparticle conjugation. Wherever
the directions may proceed, the system described through this work shows great promise
as a delivery vehicle and we hope that advancements will only continue to show support
for use in the clinic, helping to improve patient care and outcomes.
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CHAPTER 7 – APPENDIX
7.1 Appendix A – Observation and Analysis of Vacuole Formation in Glioblastoma
Multiforme Cells After Treatment with the Non-Apoptotic Drug, Vacquinol-1
Supplemental work investigating the chemotherapeutic drug, Vacquinol-1, was
completed alongside the studies reported in the body of this dissertation. The following
section is the complete work as it in the final stages of being submitted to Cancers for
publication review.
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After Treatment with the Non-Apoptotic Drug, Vacquinol-1
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Dr. Angela Alexander-Bryant, Ph.D. 1
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Abstract
Glioblastoma multiforme (GBM) is a highly aggressive brain cancer that does not
respond well to current treatment options, with many patients succumbing to this disease.
The current standard of care does not yield positive results with a majority of tumors being
inoperable and chemotherapeutics, such as temozolomide, failing to effectively treat these
cancerous lesions. This work aims to support the candidacy of a novel chemotherapeutic,
vacquinol-1 (V1), to treat GBM. We describe the ability of V1 to induce a type of cell
death that is not very well studied or understood, methuosis, to reduce the viability of GBM
cells in addition to their ability to recolonize after V1 treatment. V1 is confirmed to induce
catastrophic vacuolization through macropinocytosis, resulting in the destabilization of the
cell membrane and eventual destruction resulting in GBM cell death.

Figure 7.1 Graphical abstract of glioblastoma response to vacquinol-1 treatment.
Glioblastoma multiforme uses exosome production carrying genetic information to
communicate with neighboring GBM cells to encourage proliferation, invasion, and
migration. Introducing vacquinol-1 to GBM cells increases this vesicle production to
levels unsuitable for cell survival, resulting in cell membrane destabilization and
eventual breakdown.
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7.1 Introduction
Brain cancer is an increasingly common cancer diagnosis with death rates rising
over the past decade [1]. In 2021 alone, over 24,000 new brain cancer diagnoses and over
18,000 deaths will occur [2]. A primary culprit for a majority of these diagnoses and deaths
is the brain cancer subtype, glioblastoma multiforme (GBM). GBM is a highly aggressive
and fatal brain cancer that is typically diagnosed in late stages due to its rapid spread and
onset of symptoms [3]. It is these factors that contribute to one of the lowest 5-year survival
rates after GBM diagnosis as well as a significant lack of effective treatment methods that
can slow tumor progression and halt cancer recurrence [4]. While most patients undergo
an aggressive treatment regimen including tumor resection surgery and chemotherapeutic
administration, 75-90% of patients will relapse within 2 to 3 cm from the original lesion
site with less than 2% of patients surviving past 3 years when recurrence is observed [4–
6].
The current standard of care for GBM is tumor resection and chemotherapy in the
form of the apoptotic prodrug, temozolomide (TMZ) commonly prescribed as a
combination treatment supplemented with radiotherapy [3,7]. TMZ is an alkylating agent
that is stable under acidic pH conditions, allowing for oral administration but undergoes a
rapid transition to 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide (MTIC)

and

subsequently 5-aminoimidazole-4-carboxamide (AIC), the active form of TMZ when
exposed to an aqueous environment [8]. The transition to AIC contains a highly reactive
methyldiazonium cation that reacts with guanine rich DNA regions, causing methylation
and disrupted DNA sequences [8,9]. Unfortunately, TMZ does not have a lasting effect in
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GBM treatment as the release profile is incredibly fast causing a dramatic loss of
therapeutic efficacy within the tumor microenvironment, resulting in the need for highdose delivery of the drug that causes a long list of serious systemic effects [10]. With the
low efficacy and required sustained administration of the apoptotic drug, it is necessary to
explore further options for treatment of GBM that expand outside of the current breadth of
knowledge and understanding through different pathways of cell death, namely methuosis,
the process of inducing cell death through rapid formation of intracellular vacuoles causing
an unsustainable internal pressure, resulting in cell membrane rupture and loss of cell
viability [11].
Non-apoptotic cell death through methuosis is caused by high macropinocytotic
activity that causes an increasing number of intracellular vesicles over time consisting of
endosomes and lysosomes [12]. Vacquinol-1 (V1) is a new drug being investigated and has
shown significant tumor response and prolonged survival time through in vivo studies with
non-apoptotic activity [13],[14]. V1, a quinolone derivative, has been shown to induce cell
death through cell blebbing and rupture of the cell membrane, but is restricted to GBM
[14][15],. Here, we show upregulation of macropinocytotic activity in GBM models,
causing a loss in cell viability that is hypothesized to be due to methuosis. However, there
is limited literature support to determine the efficacy of V1 as a possible candidate to
disturb the status quo of GBM therapy. Vacuolization alone is a hallmark property of GBM
cell survival, communication, and proliferation [7]. Because of this natural vacuoleforming activity, GBM cells can be accustomed to trafficking high numbers of intracellular
vesicles, possibly reducing the effects of V1 in very aggressive forms of GBM.
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Examination of the therapeutic effect of V1 on GBM as well as quantifying the ability of
cells to recover can help better describe possible clinical efficacy.

7.2 Materials and Methods
Cell Culture
The human glioblastoma cell lines LN-18 and U-118 MG were obtained through
the American Type Culture Collection (ATCC, Manassas, VA). GBM cell lines were
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (ATCC, Manassas, VA),
10% fetal bovine serum (FBS) (Corning, Corning, NY), and 1% penicillin/streptomycin
(P/S) antibiotic solution (Corning, Corning, NY). Cell cultures were grown in 37°C
environment under 5% CO2.

Viability Analysis
MTS assays were completed to quantify end-point relative viability of LN-18 and
U-118 cells post-V1 treatment. Both cell lines were seeded at 10,000 cells/well density in
transparent 96-well plates for MTS assays, in complete DMEM, 10% FBS, 1% P/S
media. Plated cells were left to incubate overnight to achieve attachment to the bottom of
the plate. Treatments with increasing V1 concentrations dissolved in 2% dimethyl
sulfoxide (DMSO) were conducted for 4, 8, 12 and 24 hours in DMEM, 10% FBS media.
All experiments were performed in triplicate.
MTS assay was performed with CellTiter 96 AQueous One Solution (Promega, Madison,
WI) post-V1 treatment. Solution was added to cells in a 10% v/v ratio. MTS and cell

230

solution were incubated for 4 hours at 37°C environment under 5% CO2. MTS assays
were read using a BioTek Synergy LX plate reader at 490 nm.

Membrane Integrity Studies
Membrane permeability studies were completed to image end-point relative
viability of LN-18 and U-118 cells post-V1 treatment. Both cell lines were seeded at a
100,000 cells/well density, 500 µL volume in transparent 24-well plates (Corning,
Corning, NY) in complete DMEM, 10% FBS, 1% P/S media. Plated cells were left to
incubate overnight to achieve attachment to the bottom of the plate. Treatments with V1
were conducted for 4 hours with in DMEM, 10% FBS transfection media. All
experiments were performed in triplicate.
4 hours post-V1 treatment, plates with cell/V1 solutions were aspirated and
washed with phosphate buffered saline (PBS) three times. Following the third wash,
500uL of PBS was added to each well and one drop of each ReadyProbes Cell Viability
Imaging Blue and Green (Thermo Fisher, Waltham, MA) was added to each well. Plates
were left to incubate for 15 minutes at room temperature and were imaged at 20x using
fluorescence microscopy using the EVOS FL microscope (Thermo Fisher).

Phase Vacuole Imaging
LN-18 and U-118 cells were seeded at 100,000 cells/well in transparent 24-well
plates in complete DMEM, 10% FBS, 1% P/S media. Media was aspirated after
incubation overnight and were subsequently treated with V1 at increasing concentrations

231

in DMEM containing 10% FBS. Treated cells were placed in an EVOS FL Auto (Thermo
Fisher) stage complemented with on-stage incubation at 37°C, 5% CO2 and imaged for
24 hours as well as obtaining final 24-hour images using an EVOS FL system at 10x
magnification. Phase imaging was performed in triplicate.

CF Dextrans Vacuolization Assay
Dextran-vacuolization experiments were completed to visualize vacuole
formation as a result of V1 treatment in LN-18 and U-118 cells. Both cell lines were
seeded at a 40,000 cells/well density in transparent 96-well plates in complete DMEM,
10% FBS, 0.5% P/S media. Plated cells were left to incubate overnight to achieve
attachment to the bottom of the plate. Cells were treated with 50 µM V1 in phenol red
free DMEM with 10% FBS. Concurrently, 70 µL of 40,000 MW dextrans, 0.5 mg/mL in
PBS, (Biotium, Fremont, CA) were added to each well. After 1 hour, wells were
aspirated and cells were washed with 100 µL PBS and imaged at 20x using the EVOS
FL, GFP filter selection

Bafilomyocin-A1 Vacuole Inhibition
LN-18 and U-118 cells were seeded at 10,000 cells/well in transparent 96-well
plates in complete DMEM, 10% FBS, 1% P/S media. Plated cells were left to incubate
overnight to achieve attachment to the bottom of the plate. Treatments with increasing V1
concentrations were conducted for 4, 8, 12 and 24 hours in DMEM, 10% FBS media. All
experiments were performed in triplicate. In addition to V1 treatments, subsets of cells
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were treated with 100 nM of bafilomyocin-A1 (BA1) (Thermo Fisher), an
antivacuolization agent, in addition to a BA1-only control. Cells were imaged using an
EVOS FL Auto microscope prior to MTS viability analysis conducted as previously
described.

Clonogenic Recolonization Assay
Cells were plated in 24-well plates as described previously. After treating for 24
hours with increasing concentrations of V1, cells were harvested and counted to a total of
10,000/mL. Cells were seeded at 1,000 cells/well density in a 6-well plate for colony
growth analysis over a period of 14 days. Supplementary media was added to each group
every 3 days. After the 14 day growth period, wells were gently washed with 1x PBS.
Cells were fixed and stained with 0.1% crystal violet formed from a 1% crystal violet
solution (vendor, city, state) diluted in 100% EtOH and ddH2O for 30 minutes. All wells
were washed with ddH20 three times and imaged with a BioRad ChemiDoc XRS
Imaging System (BioRad, Hercules, CA). Bound crystal violet was dissolved in 33%
acetic acid and colonization quantified in a 96 well plate using a BioTek Synergy LX
plate reader at 490 nm with all wells normalized to a 1% crystal violet treated blank well
and untreated control.
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7.3 Results
7.3.1. Endpoint Viability Studies
LN-18 and U-118 glioblastoma multiforme cells were treated with V1 according
to protocols listed previously. Comparisons were made between each treatment group and
each treatment time to identify statistically significant reductions in relative cell viability.
Each cell line exhibited minimal statistically significant differences in viability when
comparing within treatment concentrations, with only 10 µM in LN-18 cells (Fig. 7.2A)
and 30 µM in U-118 cells (Fig. 7.2B) exhibiting time dependencies. However, comparing
within V1 treatment times in LN-18 cells (Fig. 7.2C) exhibited statistically significant
results at 10 µM, 30 µM,and 50 µM. U-118 cell viability displayed reduced viability loss,
but still contained statistically significant results at 50 µM treatments across all time
points. Although both cell lines contain their own statistically significant data,
comparisons between cell lines reveals that U-118 cells appear to be more resistant to V1
treatment at identical treatment concentrations and times, with reduced significance
across 12 hour and 24 hour treatment groups for all concentrations. Additionally,
treatment concentration viabilities remained relatively stable until the maximum
treatment of 50 µM is applied in U-118 cells in comparison to LN-18 cells.
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Figure 7.2 Viability of LN-18 and U-118 cells treated with Vacquinol-1.
(A, C) Relative viability determined through MTS assay for LN-18 and (B, D) U118treated with increasing concentrations of V1 at 4, 8, 12 ,and 24 hours. Significant
loss of viability was seen in a dose-dependent manner more so than a time-dependent
manner as evidenced by the increase in statistical significance comparing panels A and
B to C and D. Data are mean ± SEM of three independent experiments analyzed with
two-way ANOVA and multiple comparisons testing, where * p < 0.05, ** p < 0.01,
*** p < 0.001, **** p < 0.0001
7.3.2 Cell Membrane Integrity
Building on results obtained from endpoint viability studies and real-time
imaging, it was necessary to observe membrane permeability to be able to understand
what mechanism of cell death was occurring. 4 hours after treatment with V1, cells were
imaged and results are shown in figure 7.3. LN-18 cells displayed a relatively complete
color shift from magenta (NucBlue, membrane intact) to nearly all green (NucGreen,
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dead/membrane permeable) with very little colocalization of fluorescent signal, shown in
white (Fig. 7.3). However, U-118 cells show much greater colocalization of fluorescent
signal. After confirming the mechanism of fluorescent staining and the possibility of
colocalization, it was determined that this phenomenon may be occurring during the
death ‘process’. The cell membrane may be just becoming permeable, suggesting that U118 cells may be more resistant to V1 effects at similar treatment concentrations and
times in comparison to LN-18 cells, where cell membrane integrity seems to be largely
compromised.
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Figure 7.3 Live/dead viability fluorescent imaging post-V1 treatment.
(A-F) LN-18 and (G-L) U-118 cells were treated with increasing concentrations of V1
and incubated with NucBlue, shown in magenta, (live cells) and NucGreen, shown in
green, (dead cells) fluorescent viability stain for 4 hours. Following imaging, color
processing allowed for highlight of colocalized stain to be indicated as white, NucBlue
appears as magenta, and NucGreen remains green. Cell color manipulation was
performed using ImageJ software with scale bar representing 400 µm.
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7.3.3 Phase Vacuole Imaging and Bafilomyocin-A1 Vacuole Inhibition
It was imperative to evaluate inhibition of vacuole formation and delve into what
this may imply for viability in V1-treated GBM cells. BA1 is an antibiotic known to
selectively inhibit vacuolar ATPase, V-ATPase [16]. Treatment with BA1
mechanistically results in the repression of vacuolar acidity and disruption of lysosomal
fusion [16]. This disruption is a key component in vacuolar formation as mature
macropinosomes which fuse with their lysosomal counterparts for continued growth of
vesicles [17]. As a result, macropinocytosis and the formation of vacuoles is inhibited.
Results from this study are important in identifying possible mechanisms for vacquinol-1,
which is believed to upregulate macropinocytotic activity in GBM [15]. It may also
suggest the importance of vacuolization in GBM. V-ATPase has been shown to be
overexpressed in glioblastomas by means of communication [18–20]. Increased
endolysosomal acidification by V-ATPase upregulation is taken advantage of by several
signaling pathways, allowing GBM to further progress [18,21]. Specifically, we have
investigated what implications BA1 may have in vacuolization reduction and whether
vacuolization can become a hinderance rather than an advantage for GBM cells.
BA1 appeared to have different effects when observing LN-18 and U-118 cells
post-V1 treatment. Increasing concentrations of V1 also caused much higher volume and
quantity of vacuole formation in both LN-18 (Fig. 7.4) and U-118 cells (Fig. 7.5). These
results are consistent with viability data, suggesting that there is a threshold level of
vacuole formation that negatively effects GBM cells in vitro. In an attempt to block
vacuole formation, BA1 delivered to LN-18 had greater effects with increasing
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concentrations of V1. At 10 µM V1 in both LN-18 and U-118, cells appeared to rupture
as seen in V1 treatment alone, currently understood to be a result from micropinocytosis.
Differences were seen in cells treated with 30 and 50 µM V1 with BA1 supplement. LN18 cells displayed a higher binding efficiency to the well plate in this instance with
slightly reduced vacuole formation (Fig. 7.4). U-118 cells, however, continued to produce
high vacuole numbers, but were not as large in size and did not cause reduced cell
attachment (Fig. 7.5).

Figure 7.4 LN-18 vacuolization comparison between V1 and bafilomycin-A1
combination treatments.
Phase imaging of LN-18 cells. V1 was delivered to select wells at 10, 30, and 50 µM
concentrations, with comparative wells receiving identical V1 concentrations in
addition to 100 nM BA1 treatment to observe vacuolization inhibition effects. BA1
appears to increase in effectiveness with higher concentrations of V1 as the number of
vacuoles decreases and cells remain intact and adherent. Scale bar 10 µm.
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Figure 7.5 U-118 vacuolization comparison between V1 and bafilomycin-A1
combination treatments.
Phase imaging of U-118 cells. V1 was delivered to select wells at 10, 30, and 50 µM
concentrations, with comparative wells receiving identical V1 concentrations in
addition to 100 nM BA1 treatment to observe vacuolization inhibition effects. BA1
appeared to have less of an inhibitory role to vacuole formation, although cells
appeared better attached to the wells in BA1 groups at higher V1 concentrations
compared to V1 alone. Scale bar 25 µm.
7.3.4 CF Dextrans Fluorescent Vacuolization Imaging
The mechanism of action V1 induces in GBM cells is referred to as catastrophic
vacuolization, resulting from micropinocytosis, that may cause vacuolization-induced cell
death, known as methuosis. Each of these processes can be difficult to observe and
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measure, mainly because they are not yet well-studied, but supplementing real-time
imaging with a fluorescent vacuole labelling assay greatly enhances observation and
confirmation of the vacuolization process. Shown in figure 7.6, both LN-18 and U-118
cell lines were again treated with increasing V1 concentrations. Concurrently, FITClabeled fluid-phase macromolecular tracer, dextrans, were delivered at a concentration of
0.5 mg/mL for a treatment time of 1 hour. Clear increase in dextran uptake was observed
with increasing concentrations of V1. Through this, it can be determined that higher
concentrations of V1 cause an increase is vacuole formation and internalization of larger
quantities of extracellular fluid, possibly leading to methuosis, causing the loss in cell
viability seen in endpoint viability studies shown previously.
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Figure 7.6 Fluorescently labeled vacuoles in GBM cells post-V1 treatment.
(A-F) LN-18 and (G-L) U-118 cells were treated with increasing concentrations of V1
and incubated with 40kDa molecular weight fluorescent dextrans (green). Fluorescent
signal represents dextran internalization and storage within V1-induced formed
vacuoles. Scale bar 200 µm.
7.3.5 Clonogenic Analysis of Cell Recolonization
It is apparent that V1 causes a significant loss in LN-18 and U-118 viability in a
dose dependent manner but examining the long-term efficacy of this treatment is
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important in the development as a possible clinical therapeutic. Clonogenic
recolonization over a period of 14 days exhibited significant loss in cell colonization
ability for LN-18 cells treated with 30 µM and 50 µM concentrations of V1 compared to
all other groups except 10 µM V1 (Fig. 7.7A, B). U-118 cells displayed similar behavior
but colony imaging suggested a lower ability to regrow independent of nearby
neighboring cells in 100% DMSO and 0 µM V1 in 2% DMSO in comparison to LN-18
cells (Fig. 7.7A). Quantitatively, U-118 cell recolonization was significantly reduced
across all treatments, but only differed within treatments between 0 µM and 30 µM V1
(Fig. 7.7C).

Figure 7.7 Long-term cell recolonization in response to V1 treatment.
(A, B) LN-18 and (A, C) U-118 cells both exhibited loss of colonization ability after
treatment with 30 µM and 50 µM concentrations of V1 over a 2-week growth period.
Clonogenic data are presented as mean crystal violet absorbance at 490nm across three
independent experiments. Data was analyzed using a one-way ANOVA with Tukey’s
multiple comparisons post-hoc analysis. * p < 0.05, ** p < 0.01, **** p < 0.0001.
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7.4 Discussion
Treatment of LN-18 and U-118 cells with V1 in viability studies displayed some
contrasting results that can be explained by the intrinsic chemotherapeutic resistance
difference in each cell line [22]. LN-18 cells displayed a dramatic drop in cell viability
almost immediately, with all V1 concentrations having a statistically significant viability
decrease at all time points. U-118, however, displayed a more stepwise viability decrease,
with a larger viability loss as the time treatment increased. However, when comparing
recolonization ability of each cell line after V1 treatment, U-118 cells exhibited a
quantitatively lower colonization efficacy but differences in imaging observations
between the cell lines were difficult to make. These results suggest that V1 can be a
possible therapeutic drug, at least for GBM cells resembling LN-18 phenotype and
genotype in terms of rapid cell death. In contrast, U-118 cells did not display any
significant viability loss until the most concentrated dose of V1 was delivered, but also
failed to recolonize after treatment. Due to the aggressiveness of GBM, this could be a
promising result to consider V1 for additional in vivo and future clinical studies as an
inhibitor of disease recurrence and is consistent with other studies examining the efficacy
of V1 in GBM treatment [15,23].
Though much investigation into the exact mechanism behind macropinocytosis
and methuosis is needed for full understanding, it is apparent that this cell death pathway
varies among GBM cell lines treated with V1. Other cancer cell types, including
medulloblastoma, neuroblastoma, and prostate carcinoma have also shown sensitivity to
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macropinocytotic death pathways [24–26]. LN-18 cells undergo rapid vacuole formation
causing membrane destabilization and significant loss in cell viability and recolonization
ability. U-118 cells also display rapid vacuole formation and restricted recolonization
ability but lack the dramatic decrease in cell viability with low concentrations of V1
treatment. BA1, a vacuole-formation inhibitor, did not seem to have a dramatic effect on
reducing vesicle formation when supplemented with V1 at low concentrations but,
interestingly, had a greater effect on higher V1 concentrations, allowing for cells to
remain adherent. This observation speaks to the propensity of GBM to naturally produce
cellular vesicles within a range to facilitate extracellular communication but requires a
distinct balance [27,28]. When this threshold is passed, however, GBM cells succumb to
the increased internal pressures and experience methuosis.
As stated previously, GBM relies heavily on extracellular communication through
vesicular production and release of exosomes to the tumor microenvironment containing
proteins, DNA, and mRNA [29]. There have been few reports on V1 used as a
therapeutic intervention for GBM, but some recent work has described V1 and its ability
to reduce GBM viability in U87, RG2, and NS1 cells [30,31]. Both works produced
detections in viability loss across V1 treatment groups attributed to increased hydrostatic
pressures caused by the production of internal vesicles [30,31]. However, we have been
able to describe the long-term recolonization effects of V1 treatment as well as
specifically highlighting vacuole formation and the dose-dependent production of these
vesicles.
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7.5 Conclusions
Vacquinol-1 acts through a poorly understood mechanism of cell death,
methuosis. Causing increased pinocytosis, vesicle formation, and increased internal
cellular pressures, V1 results in cell membrane breakdown and cell lysis. Termed
methuosis, this mechanism of cell death advantageously upregulates the propensity of
GBM cells to communicate using vesicle formation and exosome distribution but to a
level that is unsuitable for cell survival. Due to the poor prognosis carrying by nearly
every GBM diagnosis, novel therapeutics are imminently needed and this, along with
other current studies, highlight the possibility of V1 to be a therapeutic candidate to treat
GBM.
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